



Systematic Review Multidisciplinary Neuromuscular and Endurance Interventions on Youth Basketball Players: A Systematic Review with Meta-Analysis and Meta-Regression

Arnau Sacot ^{1,2,*}, Víctor López-Ros ³, Anna Prats-Puig ^{1,4}, Jesús Escosa ^{1,2}, Jordi Barretina ^{2,5,6} and Julio Calleja-González ^{7,8}

- ¹ University School of Health and Sport (EUSES), University of Girona, 17004 Girona, Spain
- ² Basquet Girona, 17007 Girona, Spain
- ³ Research Institute of Education, Faculty of Education and Psychology, University of Girona, 17004 Girona, Spain
- ⁴ Research Group of Clinical Anatomy, Embryology and Neuroscience (NEOMA), Department of Medical Sciences, University of Girona, 17004 Girona, Spain
- ⁵ Girona Biomedical Research Institute (IDIBGI), 17190 Salt, Spain
- ⁶ Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain
- ⁷ Faculty of Education and Sport, University of Basque Country, 01007 Vitoria-Gasteiz, Spain
- ⁸ Faculty of Kinesiology, University of Zagreb, 10110 Zagreb, Croatia
- * Correspondence: asacot@euses.cat

Abstract: The main aims of this systematic review with meta-analysis and meta-regression were to describe the effect of multidisciplinary neuromuscular and endurance interventions, including plyometric training, mixed strength and conditioning, HIIT basketball programs and repeated sprint training on youth basketball players considering age, competitive level, gender and the type of the intervention performed to explore a predictive model through a meta-regression analysis. A structured search was conducted following PRISMA guidelines and PICOS model in Medline (PubMed), Web of Science (WOS) and Cochrane databases. Groups of experiments were created according to neuromuscular power (vertical; NPV and horizontal; NPH) and endurance (E). Meta-analysis and sub-groups analysis were performed using a random effect model and pooled standardized mean differences (SMD). A random effects meta-regression was performed regressing SMD for the different sub-groups against percentage change for NPV and NPH. There was a significant positive overall effect of the multidisciplinary interventions on NPV, NPH and E. Sub-groups analysis indicate differences in the effects of the interventions on NPV and NPH considering age, gender, competitive level and the type of the intervention used. Considering the current data available, the meta-regression analysis suggests a good predictability of U-16 and plyometric training on jump performance. Besides, male and elite level youth basketball players had a good predictability on multidirectional speed and agility performance.

Keywords: plyometrics; training; young; agility; basketball; sport; junior

1. Introduction

Basketball is a court-based team sport that involves high technical, tactical and physical demands performed in a very short period of time with limited time-frames for recovery [1–3]. From a conditioning standpoint, basketball is an intermittent sport involving aerobic and anaerobic capacity needs with numerous explosive accelerations, decelerations, jumps, multidirectional sprints and change of directions [4–8]. Therefore, high levels of strength and neuromuscular power together with endurance levels to repeat and recover from this high intensity actions will be required for success in this sport at a senior and junior level [1,3,9–15]. High participation is registered in basketball across all age ranges, involving numerous benefits for health such us bone mineral density, body



Citation: Sacot, A.; López-Ros, V.; Prats-Puig, A.; Escosa, J.; Barretina, J.; Calleja-González, J. Multidisciplinary Neuromuscular and Endurance Interventions on Youth Basketball Players: A Systematic Review with Meta-Analysis and Meta-Regression. *Int. J. Environ. Res. Public Health* **2022**, 19, 9642. https://doi.org/10.3390/ ijerph19159642

Academic Editor: Paul B. Tchounwou

Received: 1 July 2022 Accepted: 31 July 2022 Published: 5 August 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). mass regulation and metabolic systems development, especially in youth [16–18]. However, high levels of practice are associated with high injury risk and in fact, the overall injury rate in youth athletes is 14.4 injuries per 1000 h of practice [16,19,20]. For this reason, considering all the aforementioned, the implementation of accurate training methods to maximize the development of physical demands and avoid injury risk are of significant interest to basketball coaches for youth player's development [16].

Traditionally, short explosive-type training has been implemented to improve power and speed among athletes in different sports. In particular, plyometric training with different types of jumping actions is able to improve power and speed in different sports [21–25]. Similarly, sprint training is shown to also enhance power, speed and jump performance [24,26]. In basketball, all those explosive actions need to be performed in different movement vectors to excel by the different actions demanded during competitive conditions [1,5]. Therefore, all movement vectors should be emphasized in training periodization in order to integrally develop basketball players [3,9,27–29]. Additionally, continuous and intermittent endurance training along with high intensity interval training (HIIT) and repeated sprint ability (RSA) are claimed to be the best methods in order to improve aerobic and anaerobic fitness in basketball [9,10,30,31]. However, special adaptations should be considered in youth athletes and specially according to their development stage and sex [32–36]. There are critical and sensitive periods for physical capacity development linked to physiological changes due to maturational development with an ongoing chronological age [32,33,35–38].

Literature with respect to youth athletes, considering age, gender and competitive level of the participants provide clear information about the best training interventions [39] in order to improve endurance [40], jump performance [41] and multidirectional speed and agility [42] in team sports. Nonetheless, from the best of the author's knowledge, there is no systematic review with meta-analysis and meta-regression jointly analyzing the effectiveness of different multidisciplinary interventions on youth basketball players.

For this reason, the main aim of this systematic review with meta-analysis and metaregression were (1) to describe the effect of multidisciplinary neuromuscular and endurance interventions on performance in jump, multidirectional speed and endurance in youth basketball players (2) to analyze the magnitude of the effect considering age, competitive level, gender of the basketball players and according to the type of the intervention performed, and (3) to explore a predictive model to explain these effects considering age, gender, competitive level and training type through a meta-regression analysis.

2. Materials and Methods

2.1. Literature Search Strategies

This systematic review was carried out following the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA[®]) [43] and the PICOS model for definition of the inclusion criteria [44]. The PICOS model is shown in Table 1.

P (Population)	"youth basketball players"
I (Intervention)	"neuromuscular and endurance conditioning interventions"
C (Comparators)	"group comparison with multidisciplinary interventions and controls"
O (Outcomes)	"neuromuscular power (vertical and horizontal) and endurance"
S (Study design)	"any type of design"

 Table 1. PICOS model for inclusion criteria definition.

A structured search was conducted in Medline (PubMed), Web of Science (WOS) and Cochrane databases with no date restriction up to March 2021. Keywords were collected through expert opinion, literature review, and controlled vocabulary (e.g., Medical Subject Headings [MeSH]). Free-text words for key concepts associated with both youth and basketball were used resulting in the following unique search equation: (("basketball" [MeSH Terms]) AND (("young" [All Fields]) OR ("youth" [All Fields]))). Through this equation, all relevant articles in the field were obtained. The reference sections of all identified articles were also examined by applying the *"snowball methods"* strategy, based on examining the reference sections of the identified articles [45]. No other terms were used to explore the whole literature related to the topic and increase the power of the analysis, collecting all available data to date.

All titles and abstracts from the search were cross-referenced to identify duplicates and any potential missing studies (A.S. and J.E.). Titles and abstracts were selected for further review of the full text. The search for published studies was carried out independently by 2 authors (A.S. and J.E.) and in case of disagreements were resolved through discussion with third party group's experts (J.C.-G. and V.L.-R.).

2.2. Study Selection

One reviewer (A.S.) searched the databases and selected all studies. Four more reviewers (V.L.-R., A.P.-P., J.C.-G. and J.B.) were available to help with study eligibility. No disagreements about the appropriateness of an article were encountered.

2.3. Inclusion and Exclusion Criteria

For the articles obtained in the search, the following inclusion criteria were applied to final selected studies: (1) Studies published in peer-reviewed journals and full text available (2) controlled and uncontrolled interventions with a two group design involving more than 4 week intervention, (3) carried out only in youth basketball players from 10 to 18 years old, (4) performing on field neuromuscular and endurance interventions related to strength, power, endurance or speed/agility, (5) including neuromuscular and endurance assessments as a dependent variable, (6) performed on any number or type of basketball player regardless of category, experience, competitive level or sex and (7) published in Spanish or English. The following exclusion criteria were applied to the experimental protocols of the investigation: (1) studies involving senior basketball players 18 years old, (2) interventions performed in lab conditions; (3) the absence of reliable measurements and (4) studies conducted in participants with a pathological condition.

2.4. Data Extraction

Once the inclusion/exclusion criteria were applied to each study, experiments were clustered by the type of test used to assess the neuromuscular and endurance changes produced by intervention. Group of experiments were created according to endurance and neuromuscular power in different vectors (vertical and horizontal). Studies involving jump assessments as a dependent variable were considered as neuromuscular power vertical (NPV), whereas studies employing sprint and agility assessments as dependent variables were considered as neuromuscular power horizontal (NPH). All endurance (E) studies included Yo-yo intermittent recovery test as assessment for the dependent variable. Data on study source includes: authors, year of publication, study design, sample size, characteristics of the participants (competitive level, age and gender), intervention (type and duration), assessment test and final outcomes of the interventions. All were extracted independently by the main author (A.S.) using a spreadsheet (Microsoft Inc., Seattle, WA, USA).

Mean (M) and standard deviation (SD) data from pre and post measurements were extracted from the tables of all the included articles to compute effect sizes. Data and sub-groups formation were discussed with the research group until consensus (V.L.-R., A.P.-P., J.C.-G., J.E. and J.B.).

2.5. Risk of Bias Assessment

Methodological quality and risk of bias were assessed independently by 2 authors (A.S., J.E.) following Cochrane Collaboration Guidelines [46]. In case of disagreements, they were resolved by third-party evaluation (V.L.-R., A.P.-P., J.C.-G., J.B. and J.E.).

In the Cochrane Collaboration Guidelines, the items on the list were divided into seven different domains: random sequence generation (section bias), allocation concealment (section bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other types of bias. Then, we characterized as "low", if criteria for a low risk of bias were met (plausible bias unlikely to seriously alter the results) or "high" if criteria for a high risk of bias were met (plausible bias that seriously weakens confidence in the results). If the risk of bias was unknown, it was considered "unclear" (plausible bias that raises some doubts about the results). Figure 1, illustrate the summary of the risk of bias assessment for the included studies for qualitative analysis.



Figure 1. Risk of bias assessment summary.

2.6. Sub-Groups Analyses

Sub-groups were made according to competitive level, chronological age and gender of the basketball players and also considering the type of the intervention for both NPV and NPH. No sub-groups analysis were created in E due to the lack of studies.

Competitive level of the participants was considered elite when the basketball players were described as elite level or participated in national level competition. Conversely, basketball players from schools or regional levels were considered as amateur [47]. The chronological age categories were established according to the data from the included studies. The U-12 age category included all the participants with an age between 10 and 12 years, U-14 category included participants between 13 and 14 years, U-16 category included participants between 15 and 16 years and U-18 age group included participants between 17 and 18 years [48]. In case of studies included both (U-16 and U-18 together) without discriminating data within the study, were analyzed as U-18.

Interventions were divided among mixed strength and conditioning training, plyometric training and endurance. Mixed strength and conditioning sub-groups included all the interventions described as mixed strength and conditioning [49] and also the interventions involving bilateral and unilateral strength [50], lower body repeated power training [51] and hang clean or half squat training [52]. All the interventions involving jump protocols were included in plyometric training sub-groups. All the endurance-related protocols were included in the endurance sub-groups.

2.7. Meta-Regression

In order to explore a prediction model to explain the percentage change in the different interventions according to age, gender, competitive level and training type, a random

a minimum of 10 studies were considered in the results [46,53]. Meta-regression analyses were conducted in Statistical Package for Social Science (SPSS; V.25.0, Chicago, IL, USA) using Wilson's SPSS macros to build all regression models [54,55]. Adjusted R² was considered in the moment to quantify the proportion of variance in the model that is predicted by the independent variable. A R² between 0 and 0.4 was considered as high accountable variance, between 0.4 and 0.6 moderate, between 0.6 and 0.8 small and above 0.8 very small accountable variance in the model [56]. Additionally, sum of squares indicated the significance of the model predicting changes in percentage gain according to the different sub groups [56].

2.8. Statistical Analyses

Descriptive data of the participants are reported as the mean \pm SD. Meta-analytic statistics and figures of risk of bias were created with Review Manager© (RevMan) version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration: Copenhagen, Denmark, 2014).

Mean, SD and sample size of experimental group of each study were used to quantify changes in pre to post measures in sub-groups. Pre-measurements on each experimental group for each study were used as a control. Standardized mean differences (SMD) for each study group were calculated using Hedges's g [57], in which mean differences were weighted by the inverse of variance to calculate an overall effect and its 95% confidence interval (CI). It was decided to use a random effects model with the DerSimonian and Laird method [58] in order to reduce heterogeneity issues. Cohen's criteria were used to interpret the magnitude of SMD: <0.2, trivial; 0.2–0.5, small; 0.5–0.8, moderate; and >0.8, large [59].

To avoid problems using Q statistic to assess systematic differences (heterogeneity), it calculated the I² statistic, which indicated the percentage of observed total variation across studies that was due to real heterogeneity rather than chance [60]. An I² value between 25% and 50% represents a small amount of inconsistency, an I² value between 50% and 75% represents a medium amount of heterogeneity, and an I² value > 75% represents a large amount of heterogeneity [60].

3. Results

3.1. Main Search

A total of 22 studies [49–52,61–78] were identified for inclusion in this systematic review and meta-analysis. From the final selection, 15 studies were included in NPV [49,51,52,62,63,66,68,70–76,78], 13 in NPH [49–51,61,62,66,67,69–71,74,77,78] and 3 in E [64,65,79]. Table 2 shows the data summary from the included studies. Figure 2 illustrates the flow diagram for study selection.

Author	Participants/ Gender	Age/ Level	Duration/Type of Intervention	Outcome	Pre Test (Unit): $\mathbf{M} \pm \mathbf{SD}$	Post Test (Unit): $\mathbf{M} \pm \mathbf{SD}$	Sig
Aksović et al. 2020 [61]	33, M	U-16 amateur	10 weeks. Plyometric program	NPH	$\begin{array}{l} {\rm S5m~(s):~1.21\pm0.034}\\ {\rm S10m~(s):~2.03\pm0.048}\\ {\rm S20m~(s):~3.48\pm0.149} \end{array}$	S5m (s): $1.14 \pm 0.066 *$ S10m (s): 1.95 ± 0.084 S20m (s): $3.36 \pm 0.169 *$	* significant main effect pre and post
Arede et al. 2018 [49]	16, M	U-16 amateur	8 weeks. Mixed strength and conditioning program	NPV NPH	CMJ (cm): 30.31 ± 3.48 SJ (cm): 27.24 ± 2.91 S10m (s): 2.3 ± 0.11 505 (s): 5.54 ± 0.20	CMJ (cm): $32.34 \pm 4.94 * +$ SJ (cm): $29.37 \pm 3.72 *$ S10m (s): $1.95 \pm 0.07 * +$ 505 (s): 5.50 ± 0.17	* significant pre and post † significant EG vs. CG
Asadi et al. 2016 [62]	16, M	U-18 elite	8 weeks. Plyometric training program.	NPV NPH	VJ (cm): 44.2 ± 2.1 BJ (cm): 228 ± 4.4 <i>t</i> -Test (s): 13.34 ± 0.50 Illinois (s): 18.92 ± 0.76 1RM (kg): 183 ± 8.7 S60m (s): 8.87 ± 0.46	VJ (cm): $50.5 \pm 2.2 * +$ BJ (cm): $239 \pm 3.9 * +$ <i>t</i> -Test (s): $12.20 \pm 0.32 * +$ Illinois (s): $17.81 \pm 0.71 * +$ 1RM (kg): $200 \pm 9.8 * +$ S60m (s): $7.45 \pm 0.41 * +$	* significant pre and post † significant EG vs. CG
Aschendorf et al. 2019 [79]	25, F	U-16 elite	5 weeks. B- specific HIIT program	E	Yo-Yo (m): 1498 ± 266 S20m (s): 5.62 ± 0.30 S20m ball (s): 5.79 ± 0.31 CMJ (cm): 26.85 ± 3.73 CMJ arm (cm): 29.95 ± 4.59 SJ (cm): 25.45 ± 3.43 LJ (cm): 177 ± 10.2 Pass (m): 9.85 ± 0.79	Yo-Yo (m): 1895 \pm 42 * S20m (s): 5.53 \pm 0.22 * S20m ball (s): 5.72 \pm 0.24 * CMJ (cm): 27.05 \pm 3.63 CMJ arm (cm): 30.52 \pm 3.69 SJ (cm): 25.25 \pm 3.69 LJ (cm): 177 \pm 14.3 Pass (m): 10.24 \pm 0.58 *†	* significant pre and post † significant EG vs. CG
Attene et al. 2014_RST [65]	16, F	U-16 elite	6 weeks. Repeated Sprint training	E	$\begin{array}{c} \text{BT (s): } 6.74 \pm (0.3) \\ \text{WT (s): } 7.26 \pm (0.27) \\ \text{TT (s): } 69.91 \pm (2.73) \\ \text{BLa: } 8.45 \pm (2.41) \\ \text{FI\%: } 3.79 \pm (1.57) \\ \text{Y Dis (m): } 605 \pm (233) \\ \text{Y Speed (Km \cdot h): } 14.5 \pm (0.46) \\ \text{Y HR (bpm): } 199 \pm (8) \end{array}$	$\begin{array}{c} \textbf{BT (s): 6.53 \pm (0.19) *} \\ WT (s): 6.87 \pm (0.27) \\ TT (s): 67 \pm (2.23) \\ BLa: 7.11 \pm (2.29) \\ FI\%: 2.69 \pm (0.58) \\ Y \text{ Dis (m): } 775 \pm (242) \\ Y \text{ Speed (Km \cdot h): } 14.75 \pm (0.38) \\ Y \text{ HR (bpm): } 200 \pm (10) \end{array}$	* significant pre and post No significant main effect on training type

Table 2. Summary of the studies included in the meta-analysis. Bold numbers indicate significant changes between pre and post.

Author	Participants/ Gender	Age/ Level	Duration/Type of Intervention	Outcome	Pre Test (Unit): $\mathbf{M} \pm \mathbf{SD}$	Post Test (Unit): $M \pm SD$	Sig
Attene et al. 2014_IT [65]	16, F	U-16 elite	6 weeks. Intermittent training	Е	$\begin{array}{c} \text{BT (s): } 6.83 \pm (0.24) \\ \text{WT (s): } 7.28 \pm (0.33) \\ \text{TT (s): } 70.6 \pm (2.42) \\ \text{BLa: } 9.45 \pm (1.63) \\ \text{FI\%: } 3.34 \pm (1.34) \\ \text{Y Dis (m): } 720 \pm (291) \\ \text{Y Speed (Km \cdot h): } 14.81 \pm (0.53) \\ \text{Y HR (bpm): } 201 \pm (5) \end{array}$	BT (s): $6.41 \pm (0.1)^*$ WT (s): $6.89 \pm (0.32)^*$ TT (s): $66.37 \pm (1.83)^*$ BLa: $6.49 \pm (1.35)^*$ FI%: $3.54 \pm (1.87)$ Y Dis (m): $905 \pm (217)^*$ Y Speed (Km·h): $14.94 \pm (0.42)^*$ Y HR (bpm): $196 \pm (6)$	* significant pre and post No significant main effect on training type
Attene et al. 2015 [63]	36, F	U-16 elite	6 weeks. Plyometric training program.	NPV	CMJ Height (cm): 26.94 ± 3.62 CMJ power (w/kg): 24.52 ± 7.35 CMJ strength (n/kg): 20.22 ± 2.88 CMJ Speed (cm/s): 149 ± 31.06 SJ Height (cm): 22.71 ± 3.24 SJ power (w/kg): 29.64 ± 4.14 SJ max power (w/kg): 31.59 ± 3.87 SJ strength (n/kg): 20.76 ± 4.53 SJ Speed (cm/s): 183 ± 15.60	CMJ Height (cm): 29.99 \pm 3.65 * † CMJ power (w/kg): 27.47 \pm 7.19 * CMJ strength (n/kg): 22.29 \pm 2.60 * CMJ Speed (cm/s): 168 \pm 28.03 * SJ Height (cm): 26.21 \pm 3.55 * † SJ power (w/kg): 31.77 \pm 4.13 * SJ max power (w/kg): 32.21 \pm 4.21 SJ strength (n/kg): 22.44 \pm 2.98 SJ Speed (cm/s): 197 \pm 14.39 *	* significant pre and post † just significant main effect for SJ and CMJ height in BPT group
Attene et al. 2015b_RST [64]	18, M	U-16 elite	4 weeks. Repeated Sprint training	Е	$\begin{array}{c} \text{RSA BT (s): } 6.042 \pm 0.351 \\ \text{RSA WT (s): } 6.583 \pm 0.418 \\ \text{RSA TT (s): } 63.06 \pm 3.731 \\ \text{RSA FI (\%): } 4.4 \pm 2.3 \\ \text{IRSA BT (s): } 7.320 \pm 0.463 \\ \text{IRSA WT (s): } 7.888 \pm 0.548 \\ \text{IRSA TT (s): } 76.26 \pm 5.095 \\ \text{IRSA FI (\%): } 4.2 \pm 1.2 \\ \text{SJ (cm): } 35.0 \pm 4.0 \\ \text{CMJ (cm): } 35.3 \pm 2.8 \\ \text{Yo-Yo (m): } 1233 \pm 663 \\ \end{array}$	$\begin{array}{c} \text{RSA BT (s): } 5.940 \pm 0.307 * \\ \text{RSA WT (s): } 6.277 \pm 0.410 * \\ \text{RSA TT (s): } 61.24 \pm 3.593 \\ \text{RSA FI (\%): } 3.1 \pm 1.3 * \\ \text{IRSA BT (s): } 7.206 \pm 0.439 * \\ \text{IRSA WT (s): } 7.565 \pm 0.436 \\ \text{IRSA TT (s): } 73.92 \pm 4.527 \\ \text{IRSA FI (\%): } 2.6 \pm 0.9 \\ \text{SJ (cm): } 36.1 \pm 3.2 \\ \text{CMJ (cm): } 36.5 \pm 3.4 * \\ \text{Yo-Yo (m): } 1549 \pm 679 * \end{array}$	* significant pre and post

Author	Participants/ Gender	/ Age/ Level	Duration/Type of Intervention	Outcome	Pre Test (Unit): $M \pm SD$	Post Test (Unit): $\mathbf{M} \pm \mathbf{SD}$	Sig
Attene et al. 2015b_IRST [64]	18, M	U-16 elite	4 weeks. Intensive Repeated Sprint training	E	$\begin{array}{c} \text{RSA BT (s): } 5.676 \pm 0.198 \\ \text{RSA WT (s): } 6.121 \pm 0.280 \\ \text{RSA TT (s): } 58.89 \pm 2.040 \\ \text{RSA FI (\%): } 3.8 \pm 1.4 \\ \text{IRSA BT (s): } 6.877 \pm 0.267 \\ \text{IRSA WT (s): } 7.385 \pm 0.360 \\ \text{IRSA TT (s): } 71.25 \pm 2.943 \\ \text{IRSA FI (\%): } 3.6 \pm 1.0 \\ \text{SJ (cm): } 39.3 \pm 3.6 \\ \text{CMJ (cm): } 37.8 \pm 4.1 \\ \text{Yo-Yo (m): } 1933 \pm 560 \\ \end{array}$	$\begin{array}{c} \text{RSA BT (s): } 5.595 \pm 0.180\\ \text{RSA WT (s): } 5.975 \pm 0.342\\ \text{RSA TT (s): } 57.57 \pm 2.163\\ \textbf{RSA FI (\%): } 2.9 \pm 1.2 *\\ \textbf{IRSA BT (s): } 6.665 \pm 0.245 *\\ \textbf{IRSA WT (s): } 7.011 \pm 0.327 *\\ \text{IRSA TT (s): } 68.54 \pm 2.986\\ \text{IRSA FI (\%): } 2.8 \pm 1.5\\ \textbf{SJ (cm): } 41.3 \pm 3.5 *\\ \textbf{CMJ (cm): } 40.7 \pm 4.5 * \texttt{H}\\ \text{Yo-Yo (m): } 2244 \pm 638\\ \end{array}$	* significant pre and post † just significant main effect for CMJ in IRSAG
Bouteraa et al. 2020 [66]	22, F	U-18, amateur	8 weeks. Plyometric training program.	NPV NPH	SJ (cm): 20.4 ± 3.9 CMJ (cm): 26.8 ± 3.8 DJ (cm): 24.7 ± 2.9 DJ (w/kg): 26.5 ± 4.0 S5m (s): 0.95 ± 0.08 S10m (s): 1.82 ± 0.14 S20m (s): 3.39 ± 0.25 SBT (cm): 17.3 ± 9.6 YBT (cm): 104.3 ± 9.7 Illiniois (s): 11.3 ± 0.6	SJ (cm): 22.5 ± 3.5 CMJ (cm): 28.8 ± 3.3 DJ (cm): $28.4 \pm 3.0 * +$ DJ (w/kg): 27.8 ± 5.0 S5m (s): 0.91 ± 0.05 S10m (s): 1.72 ± 0.09 S20m (s): 3.27 ± 0.16 SBT (cm): $39.2 \pm 13.3 * +$ YBT (cm): $114.4 \pm 10.4 * +$ Illiniois (s): $10.6 \pm 0.4 * +$	* significant pre and post † just significant main effect for EG compared to CG
Figueira et al. 2020_FLAT [67]	31, M	U-14 elite	4 weeks. Plyometric training program flat	NPV NPH	Standing height jump (cm): 48.20 ± 5.29 Drop Jump (cm): 42.00 ± 7.44 Contact time (ms): 200.20 ± 26.62 Jump Power (W): 1171.20 ± 256.01 Jump power (W/kg): 20.95 ± 2.90 AnAl Power (W): 859.33 ± 160.16 AnAl Power (Wkg): 15.36 ± 1.33 Hexagon agility (s): 13.21 ± 1.88	$\begin{array}{c} \mbox{Standing height jump (cm):} \\ 52.27 \pm 4.13 \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	† just significant main effect for standing height jump in FLAT No look at pre to post changes

Author	Participants/ Gender	Age/ Level	Duration/Type of Intervention	Outcome	Pre Test (Unit): $\mathbf{M} \pm \mathbf{SD}$	Post Test (Unit): $M \pm SD$	Sig
Figueira et al. 2020_SLOPE [67]	31, M	U-14 elite	4 weeks. Plyometric training program slope	NPV NPH	Standing height jump (cm): 47.20 ± 5.72 Drop Jump (cm): 42.20 ± 6.17 Contact time (ms): 238.20 ± 35.22 Jump Power (W): 923.07 ± 250.73 Jump power (Wkg): 17.56 ± 2.61 AnAl Power (W): 714.27 ± 195.70 AnAl power (Wkg): 13.50 ± 1.39 Hexagon agility (s): 14.37 ± 0.80	$\begin{array}{l} \mbox{Standing height jump (cm): } 46.13 \\ \pm 6.01 \\ \mbox{Drop Jump (cm): } 43.53 \pm 9.01 \\ \mbox{Contact time (ms): } 216.80 \pm 41.85 \\ \mbox{Jump Power (W): } 1011.47 \pm 225.18 \\ \mbox{Jump power (wKg): } 19.30 \pm 3.22 \\ \mbox{AnAl Power (W): } 750.80 \pm 204.46 \\ \mbox{AnAl power (Wkg): } 14.16 \pm 1.37 \\ \mbox{Hexagon agility (s): } 13.11 \pm 0.74 \end{array}$	No look at pre to post changes
Gonzalo-Skok et al. 2017_BIL [50]	22, M	U-16 to U-18 elite	6 weeks. Mixed strength and conditioning program bilateral	NPV NPH	$\begin{array}{c} \text{V-cut test (s): } 6.63 \pm 0.24 \\ 180^{\circ} \text{ RCOD (s): } 3.50 \pm 0.12 \\ 180^{\circ} \text{ LCOD (s): } 3.48 \pm 0.12 \\ \text{MP BIL (W): } 407.5 \pm 56.2 \\ \text{MP UNI R (W): } 270.1 \pm 32.8 \\ \text{MP UNI I (W): } 270.9 \pm 51.3 \\ \text{BL Imb (\%): } 6.9 \pm 5.0 \\ \text{BL Def (\%): } 23.1 \pm 8.4 \\ \text{S5m (s): } 1.10 \pm 0.05 \\ \text{S15m (s): } 2.52 \pm 0.09 \\ \text{S25m (s): } 3.80 \pm 0.15 \\ \text{CMJ (cm): } 38.9 \pm 5.3 \\ \end{array}$	V-cut test (s): 6.56 ± 0.20 180° RCOD (s): 3.45 ± 0.09 180° LCOD (s): 3.48 ± 0.11 MP BIL (W): 470.2 ± 75.8 ** MP UNI R (W): 330.1 ± 61.2 * MP UNI L (W): 330.4 ± 73.8 * BL Imb (%): 4.4 ± 2.5 BL Def (%): 27.0 ± 6.4 S5m (s): 1.06 ± 0.02 * S15m (s): 2.46 ± 0.07 * S25m (s): 3.69 ± 0.15 * CMJ (cm): 40.6 ± 5.5	* Very likely changes pre and post ** almost certainly changes pre to post
Gonzalo-Skok et al. 2017_UNI [50]	22, M	U-16 to U-18 elite	6 weeks. Mixed strength and conditioning program unilateral	NPV NPH	$\begin{array}{c} \text{V-cut test (s): } 6.57 \pm 0.23 \\ 180^{\circ} \text{ RCOD (s): } 3.54 \pm 0.15 \\ 180^{\circ} \text{ LCOD (s): } 3.55 \pm 0.17 \\ \text{MP BIL (W): } 406.9 \pm 48.5 \\ \text{MP UNI R (W): } 273.7 \pm 40.0 \\ \text{MP UNI L (W): } 271.2 \pm 36.8 \\ \text{BLImb (\%): } 9.6 \pm 3.8 \\ \text{BLDef (\%): } 24.8 \pm 8.9 \\ \text{S5m (s): } 1.13 \pm 0.05 \\ \text{S15m (s): } 2.54 \pm 0.08 \\ \text{S25m (s): } 3.84 \pm 0.12 \\ \text{CMJ (cm): } 37.4 \pm 4.2 \\ \end{array}$	$\begin{array}{c} \mbox{V-cut test (s): } 6.50 \pm 0.18 \\ 180^\circ \mbox{ RCOD (s): } 3.47 \pm 0.10 * \\ 180^\circ \mbox{ LCOD (s): } 3.46 \pm 0.15 + \\ \mbox{ MP BIL (W): } 466.3 \pm 72.8 ** \\ \mbox{ MP UNI R (W): } 372.2 \pm 57.3 ** + \\ \mbox{ MP UNI L (W): } 370.4 \pm 50.4 ** + \\ \mbox{ BLImb (\%): } 4.8 \pm 1.3 * + \\ \mbox{ BLDef (\%): } 36.8 \pm 7.7 \\ \mbox{ S5m (s): } 1.07 \pm 0.06 ** \\ \mbox{ S15m (s): } 2.48 \pm 0.1 ** \\ \mbox{ S25m (s): } 3.75 \pm 0.15 ** \\ \mbox{ CMJ (cm): } 39.8 \pm 5.1 * \\ \end{array}$	* Very likely changes pre and post ** almost certainly changes pre to post † likely changes between UNI and BIL

Author	Participants/ Gender	Age/ Level	Duration/Type of Intervention	Outcome	Pre Test (Unit): $M \pm SD$	Post Test (Unit): $\mathbf{M} \pm \mathbf{SD}$	Sig
Gonzalo-Skok et al. 2016 [51]	22, M	U-16 to U-18 elite	6 weeks. Mixed strength and conditioning program repeated power training	NPH	$\begin{array}{c} \text{RSA BT (s): } 7.16 \pm 0.23 \\ \text{RSA ST (s): } 7.86 \pm 0.29 \\ \text{RSA M (s): } 7.52 \pm 0.2 \\ \% \text{DEC RSA(\%): } 5.1 \pm 1.8 \\ \text{RCOD BT (s): } 6.58 \pm 0.21 \\ \text{RCOD ST (s): } 6.77 \pm 0.20 \\ \text{RCOD MT (s): } 6.86 \pm 0.25 \\ \% \text{DEC RCOD(\%): } 2.0 \pm 0.7 \\ \text{UNIR (cm): } 169.1 \pm 16.8 \\ \text{UNIL (cm): } 170.4 \pm 16.6 \\ \text{LSIuni (\%): } 94.3 \pm 3.6 \\ \text{DJR (cm): } 402.2 \pm 35.2 \\ \text{DJL (cm): } 410.8 \pm 24.5 \\ \text{LSIdj (\%): } 94.5 \pm 4.4 \\ \text{LSIuni (\%): } 94.5 \pm 24.4 \\ \text{DJR (cm): } 394.5 \pm 24.4 \\ \text{DJL (cm): } 412.6 \pm 17.8 \\ \text{LSIdj (\%): } 95.2 \pm 3.4 \\ \end{array}$	$\begin{array}{c} \text{RSA BT (s): } 7.10 \pm 0.18 \\ \text{RSA ST (s): } 7.67 \pm 0.29 \texttt{+} \\ \text{RSA M (s): } 7.40 \pm 0.2 ** \texttt{+} \\ \% \text{DEC RSA(\%): } 4.3 \pm 1.7 \\ \text{RCOD BT (s): } 6.41 \pm 0.20 ** \texttt{+} \texttt{+} \\ \text{RCOD ST (s): } 6.61 \pm 0.21 * \texttt{+} \texttt{+} \\ \text{RCOD ST (s): } 6.72 \pm 0.23 * \texttt{+} \texttt{+} \\ \% \text{DEC RCOD(\%): } 2.6 \pm 1.5 \\ \text{UNIR (cm): } 180.9 \pm 14.4 * \texttt{+} \\ \text{UNIL (cm): } 182.7 \pm 12.8 ** \texttt{+} \\ \text{LSIuni (\%): } 95.9 \pm 2.3 \\ \text{DJR (cm): } 411.1 \pm 30.8 \\ \text{DJL (cm): } 419 \pm 28.9 \\ \text{LSIdj (\%): } 95.5 \pm 4.3 \\ \text{DJR (cm): } 393.4 \pm 24.2 \\ \text{DJL (cm): } 410.4 \pm 14.3 \\ \text{LSIdj (\%): } 95.5 \pm 4.6 \\ \end{array}$	 * Very likely changes pre and post ** almost certainly changes pre to post + likely changes between RPA and CG + very likely changes between RPA and CG
Gonzalo-Skok et al. 2019_UH [68]	20, M	U-14 elite	6 weeks. Plyometric training program unilateral horizontal	NPV NPH	$\begin{array}{c} {\rm S5m} \ ({\rm s}): \ 1.13 \pm 0.07 \\ {\rm S10m} \ ({\rm s}): \ 1.92 \pm 0.08 \\ {\rm S25m} \ ({\rm s}): \ 4.02 \pm 0.20 \\ {\rm CMJ} \ ({\rm cm}): \ 31.6 \pm 4.2 \\ {\rm CMJ} \ {\rm L} \ ({\rm cm}): \ 12.9 \pm 3.1 \\ {\rm CMJ} \ {\rm R} \ ({\rm cm}): \ 12.5 \pm 3.0 \\ {\rm HJ} \ {\rm L} \ ({\rm cm}): \ 147.0 \pm 22.5 \\ {\rm HJ} \ {\rm R} \ ({\rm cm}): \ 147.0 \pm 22.5 \\ {\rm HJ} \ {\rm R} \ ({\rm cm}): \ 147.0 \pm 22.5 \\ {\rm COD} \ 180 \ ({\rm s}): \ 2.72 \pm 0.05 \\ {\rm DORS} \ {\rm L} \ ({\rm cm}): \ 10.5 \pm 2.4 \\ {\rm DORS} \ {\rm R} \ ({\rm cm}): \ 10.0 \pm 2.9 \\ {\rm SEBT} \ {\rm AL} \ ({\rm cm}): \ 55.9 \pm 6.4 \\ {\rm SEBT} \ {\rm AR} \ ({\rm cm}): \ 53.7 \pm 5.7 \\ {\rm SEBT} \ {\rm PLL} \ ({\rm cm}): \ 72.8 \pm 8.4 \\ {\rm SEBT} \ {\rm PLR} \ ({\rm cm}): \ 72.3 \pm 11.9 \end{array}$	$\begin{array}{c} {\rm S5m} \ {\rm (s):} \ {\rm 1.07} \pm 0.05 \ ^{**} \\ {\rm S10m} \ {\rm (s):} \ {\rm 1.86} \pm 0.06 \ ^{**} \ {\rm t} \\ {\rm S25m} \ {\rm (s):} \ {\rm 3.95} \pm 0.19 \\ {\rm CMJ} \ {\rm (cm):} \ {\rm 33.0} \pm 2.8 \\ {\rm CMJ} \ {\rm L} \ {\rm (cm):} \ {\rm 14.9} \pm 1.9 \ ^{*} \\ {\rm CMJ} \ {\rm R} \ {\rm (cm):} \ {\rm 14.1} \pm 2.9 \ ^{*} \\ {\rm HJ} \ {\rm L} \ {\rm (cm):} \ {\rm 159.0} \pm 21.1 \ ^{*} \\ {\rm HJ} \ {\rm R} \ {\rm (cm):} \ {\rm 153.2} \pm 16.6 \\ {\rm V-cut} \ {\rm (s):} \ {\rm 7.01} \pm 0.19 \ ^{**} \\ {\rm COD} \ {\rm 180} \ {\rm (s):} \ {\rm 2.72} \pm 0.07 \\ {\rm DORS} \ {\rm L} \ {\rm (cm):} \ {\rm 10.4} \pm 4.2 \\ {\rm DORS} \ {\rm R} \ {\rm (cm):} \ {\rm 10.6} \pm 3.9 \\ \\ {\rm SEBT} \ {\rm AL} \ {\rm (cm):} \ {\rm 56.2} \pm 6.8 \ ^{*} \\ {\rm SEBT} \ {\rm AR} \ {\rm (cm):} \ {\rm 54.5} \pm 7.3 \\ {\rm SEBT} \ {\rm PLL} \ {\rm (cm):} \ {\rm 74.9} \pm 7.4 \\ \\ {\rm SEBT} \ {\rm PLR} \ {\rm (cm):} \ {\rm 78.2} \pm 11.6 \end{array}$	 * Very likely changes pre and post ** almost certainly changes pre to post † likely changes between BV and UH, more in UH

Table	2.	Cont.
Iuvic	<u> </u>	Conn.

Author	Participants/ Gender	/ Age/ Level	Duration/Type of Intervention	Outcome	Pre Test (Unit): $M \pm SD$	Post Test (Unit): $M \pm SD$	Sig
Gonzalo-Skok et al. 2019_BV [68]	20, M	U-14 elite	6 weeks. Plyometric training program bilateral vertical	NPV NPH	$\begin{array}{c} {\rm S5m} \ ({\rm s}): \ 1.14 \pm 0.08\\ {\rm S10m} \ ({\rm s}): \ 1.91 \pm 0.10\\ {\rm S25m} \ ({\rm s}): \ 3.99 \pm 0.22\\ {\rm CMJ} \ ({\rm cm}): \ 32.5 \pm 5.1\\ {\rm CMJ} \ {\rm L} \ ({\rm cm}): \ 12.4 \pm 3.6\\ {\rm CMJ} \ {\rm R} \ ({\rm cm}): \ 12.3 \pm 2.4\\ {\rm HJ} \ {\rm L} \ ({\rm cm}): \ 141.0 \pm 24.9\\ {\rm HJ} \ {\rm R} \ ({\rm cm}): \ 143.2 \pm 21.7\\ {\rm V-cut} \ ({\rm s}): \ 7.37 \pm 0.41\\ {\rm COD} \ 180 \ ({\rm s}): \ 2.79 \pm 0.17\\ {\rm DORS} \ {\rm L} \ ({\rm cm}): \ 9.1 \pm 2.7\\ {\rm DORS} \ {\rm R} \ ({\rm cm}): \ 10.1 \pm 2.4\\ {\rm SEBT} \ {\rm AL} \ ({\rm cm}): \ 53.4 \pm 6.3\\ {\rm SEBT} \ {\rm AL} \ ({\rm cm}): \ 53.4 \pm 5.2\\ {\rm SEBT} \ {\rm PLL} \ ({\rm cm}): \ 69.3 \pm 7.6\\ {\rm SEBT} \ {\rm PLR} \ ({\rm cm}): \ 68.0 \pm 7.8\\ \end{array}$	$\begin{array}{c} {\rm S5m} \ ({\rm s}): \ 1.11 \pm 0.06\\ {\rm S10m} \ ({\rm s}): \ 1.90 \pm 0.10\\ {\rm S25m} \ ({\rm s}): \ 3.96 \pm 0.21\\ {\rm CMJ} \ ({\rm cm}): \ 33.4 \pm 4.3\\ {\rm CMJ} \ {\rm L} \ ({\rm cm}): \ 14.1 \pm 3.4\\ {\rm CMJ} \ {\rm R} \ ({\rm cm}): \ 14.6 \pm 3.1 \ ^{**}\\ {\rm HJ} \ {\rm L} \ ({\rm cm}): \ 152.8 \pm 16.5\\ {\rm HJ} \ {\rm R} \ ({\rm cm}): \ 152.6 \pm 17.9 \ ^{*}\\ {\rm V-cut} \ ({\rm s}): \ 7.21 \pm 0.40\\ {\rm COD} \ 180 \ ({\rm s}): \ 2.77 \pm 0.16\\ {\rm DORS} \ {\rm L} \ ({\rm cm}): \ 10.0 \pm 1.7\\ {\rm SEBT} \ {\rm AL} \ ({\rm cm}): \ 55.6 \pm 6.8\\ {\rm SEBT} \ {\rm PLL} \ ({\rm cm}): \ 71.8 \pm 7.3\\ {\rm SEBT} \ {\rm PLR} \ ({\rm cm}): \ 72.9 \pm 9.7\\ \end{array}$	* Very likely changes pre and post ** almost certainly changes pre to post
Gottlieb et al. 2014_PT [70]	9,M	U-16 elite	6 weeks Plyometric training program	NPV NPH	CMJ (cm): 41.32 ± 3.87 S20m (s): 3.03 ± 0.12	CMJ (cm): 42.51 ± 2.72 S20m (s): 3.01 ± 0.13	
Gottlieb et al. 2014_ST [70]	10,M	U-16 elite	6 weeks Repeated sprint training program	NPV NPH	CMJ (cm): 40.60 ± 4.80 S20m (s): 3.07 ± 0.11	CMJ (cm): 42.36 ± 5.75 S20m (s): 2.99 \pm 0.07 *	* significant pre and post
Matavulj et al. 2001 [72]	33, M	U-16 elite	6 weeks. Plyometric training program drop jumps	NPV	CMJ (cm): $40,4 \pm 6.3$	CMJ (cm): 46± 6 * †	* significant pre and post † more than control
McCormick et al. 2016_SP [73]	14, F	U-16 amateur	6 weeks. Plyometric training program sagittal plane	NPV	CMJ (cm): 47.72 ± 7.07 SLJ (cm): 177.89 ± 30.07 LHr (cm): 135.89 ± 22.36 LHl (cm): 140.06 ± 25.81 LSHr: 23.86 ± 3.13 LSHI: 24.00 ± 3.06	CMJ (cm): $52.61 \pm 9.36 * +$ SLJ (cm): $191.95 \pm 29.06 *$ LHr (cm): $143.87 \pm 25.34 *$ LHl (cm): $142.60 \pm 32.33 *$ LSHr: $24.57 \pm 2.99 *$ LSHI: $24.14 \pm 2.55 *$	* significant pre and post † more than FPP

Author	Participants Gender	s/ Age/ Level	Duration/Type of Intervention	Outcome	Pre Test (Unit): $\mathbf{M} \pm \mathbf{SD}$	Post Test (Unit): $M \pm SD$	Sig
McCormick et al. 2016_FP [73]	14, F	U-16 amateur	6 weeks. Plyometric training program frontal plane	NPV	CMJ (cm): 48.26 ± 5.39 SLJ (cm): 176.89 ± 18.47 LHr (cm): 141.06 ± 7.47 LHl (cm): 137.16 ± 12.97 LSHr: 23.00 ± 2.31 LSHI: 22.71 ± 2.22	CMJ (cm): 50.07 ± 5.33 * SLJ (cm): 187.05 ± 14.19 * LHr (cm): 154.94 ± 13.03 * LHI (cm): 153.49 ± 6.02 * Y LSHr: 24.57 ± 1.90 * LSHI: 24.71 ± 2.36 * Y	* significant pre and post Ѱ more than SPP
Meszler & Váczi (2019) [74]	16, F	U-18 amateur	7 weeks. Plyometric training program	NPV NPH	IAT (s): 16.21 ± 0.81 <i>t</i> -Test (s): 10.96 ± 0.48 CMJ (cm): 33.52 ± 3.89 B: 74.82 ± 2.22 MVC60ext (Nm): 165.64 ± 22.53 MVC60flex (Nm): 94.54 ± 14.05 MVC180ext (Nm): 120.25 ± 25.89 MVC180flex (Nm): 94.82 ± 24.99 H:Q60 ratio (%): 60.42 ± 9.99 H:Q180 ratio (%): 78.52 ± 10.32	$\begin{array}{c} \textbf{IAT (s): 16.95 \pm 1.07 }^{*} \\ t\text{-Test (s): 11.13 \pm 0.63} \\ \textbf{CMJ (cm): 31.96 \pm 3.48 }^{*} \\ \text{B: 75.62 \pm 4.31} \\ \text{MVC60ext (Nm): 175.16 \pm 21.61} \\ \text{MVC60flex (Nm): 99.11 \pm 17.96} \\ \text{MVC180ext (Nm): 130.01 \pm 19.06} \\ \textbf{MVC180ext (Nm): 130.01 \pm 19.06} \\ \textbf{MVC180flex (Nm): 113.01 \pm 26.80 }^{*} \\ \text{H:Q60 ratio (\%): 58.79 \pm 7.72} \\ \text{H:Q180 ratio (\%): 86.38 \pm 10.51} \end{array}$	* significant pre and post
Hernández et al. 2018_R [71]	19, M	U-12 amateur	7 weeks. Plyometric training program randomized	NPV NPH	CMJ (cm): 28.4 ± 8.3 DJ (cm): 20.6 ± 5.1 S30m (s): 5.71 ± 0.46 S30m ball (s): 7.18 ± 1.1 <i>t</i> -Test (s): 12.1 ± 1.1	CMJ (cm): $33.5 \pm 8.1 * +$ DJ (cm): $25.4 \pm 5.9 * +$ S30m (s): $5.06 \pm 0.52 * +$ S30m ball (s): $6.52 \pm 1.0 * +$ t-Test (s): $10.3 \pm 0.7 * +$	* significant pre and post † more RG group than the others
Hernández et al. 2018_NR [71]	19, M	U-12 amateur	7 weeks. Plyometric training program non randomized	NPV NPH	CMJ (cm): 24.1 ± 5.9 DJ (cm): 19.6 ± 6.5 S30m (s): 5.87 ± 0.51 S30m ball (s): 7.57 ± 1.7 <i>t</i> -Test (s): 12.3 ± 1.1	CMJ (cm): $26.9 \pm 5.8 *$ DJ (cm): $22.0 \pm 6.0 *$ S30m (s): $5.48 \pm 0.56 *$ S30m ball (s): $6.92 \pm 1.6 *$ <i>t</i> -Test (s): $11.0 \pm 1.1 *$	* significant pre and post
Santos & Janeira (2008) [75]	25, M	U-16 amateur	10 weeks. Plyometric training program	NPV	SJ (cm): 24.79 ± 4.2 CMJ (cm): 29.88 ± 5.9 ABA (cm): 34.77 ± 6.3 DJ (cm): 34.71 ± 7.4 MP (W·Kg): 23.69 ± 4.0 MBT (m): 3.47 ± 0.6	SJ (cm): $28.01 \pm 4.6 * +$ CMJ (cm): $33.02 \pm 6.2 * +$ ABA (cm): $38.43 \pm 7.1 *$ DJ (cm): $36.64 \pm 8.1 +$ MP (W·Kg): 24.48 ± 3.9 MBT (m): $4.15 \pm 0.5 * +$	* significant pre and post † significant different post training EG group than the CG

Author	Participants/ Gender	Age/ Level	Duration/Type of Intervention	Outcome	Pre Test (Unit): $\mathbf{M} \pm \mathbf{SD}$	Post Test (Unit): $M \pm SD$	Sig
Santos & Janeira (2012) [76]	25, M	U-16 amateur	10 weeks. Plyometric training program	NPV	SJ (cm): 24.81 ± 3.3 CMJ (cm): 33.30 ± 4.3 ABA (cm): 38.73 ± 4.9 DJ (cm): 34.80 ± 4.1 MBT (m): 3.42 ± 0.38	SJ (cm): 27.92 ± 4.0 * † CMJ (cm): 36.68 ± 4.2 * † ABA (cm): 42.62 ± 4.4 * † DJ (cm): 38.10 ± 4.3 * † MBT (m): 3.68 ± 0.42 *	* significant pre and post † significant different post training EG group than the CG
Ciacci & Bartolomei (2017)_U-16HS [52]	36, M	U-16 elite	16 weeks. Mixed strength and conditioning program half squat	NPV	$\begin{array}{c} \text{U-16 SJ (cm): } 34.19 \pm 3.32 \\ \text{U-16 CMJ (cm): } 35.56 \pm 3.41 \\ \text{U-16 CMJarm (cm): } 43.33 \pm 5.47 \\ \text{U-16 TCMJstep (cm): } 40.83 \pm 4.98 \\ \text{U-16 Power Balance (\%): } 84.91 \pm 9.62 \end{array}$	U-16 SJ (cm): $36.66 \pm 3.34 * +$ U-16 CMJ (cm): 37.43 ± 4.94 U-16 CMJarm (cm): 43.02 ± 4.46 U-16 TCMJstep (cm): $43.94 \pm 4.54 * +$ U-16 Power Balance (%): 82.92 ± 7.01	* significant pre and post † significant different post training HSQ group than the HCL
Ciacci & Bartolomei (2017)_U-16HC [52]	36, M	U-16 elite	16 weeks. Mixed strength and conditioning program hang clean	NPV	$\begin{array}{c} \text{U-16 SJ (cm): } 37.32 \pm 3.99 \\ \text{U-16 CMJ (cm): } 39.01 \pm 4.72 \\ \text{U-16 CMJarm (cm): } 43.37 \pm 5.82 \\ \text{U-16 TCMJstep (cm): } 48.86 \pm 4.24 \\ \text{U-16 Power Balance (\%): } 91.31 \pm 8.37 \end{array}$	U-16 SJ (cm): 37.16 ± 4.32 U-16 CMJ (cm): 39.98 ± 5.94 U-16 CMJarm (cm): 43.79 ± 6.82 U-16 TCMJstep (cm): 48.81 ± 6.75 U-16 Power Balance (%): 80.42 ± 14.63	post training HSQ group than the HCL
Ciacci & Bartolomei (2017)_U-18HS [52]	36, M	U-18 elite	16 weeks. Mixed strength and conditioning program half squat	NPV	$\begin{array}{c} \text{U-18 SJ (cm): } 38.44 \pm 5.98 \\ \text{U-18 CMJ (cm): } 40.11 \pm 6.91 \\ \text{U-18 CMJarm (cm): } 43.13 \pm 7.14 \\ \text{U-18 TCMJstep (cm): } 47.45 \pm 7.86 \\ \text{U-18 Power Balance (\%): } 86.46 \pm 7.98 \end{array}$	U-18 SJ (cm): 40.79 \pm 4.97 * U-18 CMJ (cm): 40.23 \pm 4.86 U-18 CMJarm (cm): 46.71 \pm 5.68 U-18 TCMJstep (cm): 48.90 \pm 5.5 * U-18 Power Balance (%): 78.47 \pm 9.05	* significant pre and post
Ciacci & Bartolomei (2017)_U-18HC [52]	36, M	U-18 elite	16 weeks. Mixed strength and conditioning program hang clean	NPV	$\begin{array}{c} U\text{-}18 \mbox{ SJ (cm): } 38.78 \pm 5.87 \\ U\text{-}18 \mbox{ CMJ (cm): } 39.46 \pm 5.78 \\ U\text{-}18 \mbox{ CMJarm (cm): } 45.72 \pm 6.58 \\ U\text{-}18 \mbox{ TCMJstep (cm): } 47.84 \pm 7.71 \\ U\text{-}18 \mbox{ Power Balance (\%): } 76.68 \pm 7.62 \end{array}$	U-18 SJ (cm): $40.71 \pm 5.17 *$ U-18 CMJ (cm): $40.80 \pm 5.71 *$ U-18 CMJarm (cm): $47.33 \pm 6.16 *$ U-18 TCMJstep (cm): $50.02 \pm 6.96 *$ U-18 Power Balance (%): 72.62 ± 10.30	* significant pre and post
Tsimachidis et al. 2010 [77]	26, M	U-18 amateur	10 weeks. Plyometric training program	NPV NPH	S30m (s): 5.29 ± 0.70 CMJ (cm): 32.7 ± 12.3	S30m (s): 5.02 \pm 0.23 * † CMJ (cm): 36.8 \pm 9.7 * †	* significant pre and post † significant different post training CTG than the CG

Author	Participants/ Gender	Age/ Level	Duration/Type of Intervention	Outcome	Pre Test (Unit): $M \pm SD$	Post Test (Unit): $M \pm SD$	Sig
Yañez-García et al. 2019_U-14 [78]	11,M	U-14 elite	6 weeks Mixed strength and conditioning program	NPV NPH	S10m (s): 1.96 ± 0.12 S20m (s): 3.46 ± 0.19 CMJ (cm): 27.0 ± 6.2	S10m (s): 1.88 \pm 0.09 * S20m (s): 3.34 \pm 0.18 * CMJ (cm): 30.2 \pm 6.2 *	* significant intra groups
Yañez-García et al. 2019_U-16 [78]	11,M	U-16 elite	6 weeks Mixed strength and conditioning program	NPV NPH	S10m (s): 1.83 ± 0.06 S20m (s): 3.18 ± 0.11 CMJ (cm): 32.5 ± 3.7	S10m (s): 1.82 \pm 0.06 * S20m (s): 3.14 \pm 0.10 * CMJ (cm): 35.9 \pm 3.4 *	* significant intra groups
Yañez-García et al. 2019_U-18 [78]	11,M	U-18 elite	6 weeks Mixed strength and conditioning program	NPV NPH	S10m (s): 1.78 ± 0.07 S20m (s): 3.11 ± 0.11 CMJ (cm): 33.9 ± 6.1	S10m (s): 1.78 \pm 0.05 * S20m (s): 3.09 \pm 0.11 * CMJ (cm): 36.2 \pm 6.1	* significant intra groups

% = percentage; 1RM = 1 repetition maximum; A = Anterior; ABA = abalakov; AnAl = Anaerobic Alactic; B = Balance; BJ = broad jump; BLa = Blood lactate; BLDef = bilateral deficit; BPT = basketball plyometric training group; BT = best time; BV = bilateral vertical group; CG = control group; cm = centimeters; CMJ = counter movement jump; CMJarm = counter movement jump arm use; COD = change of direction; CTG = combined training program group; Def = Deficit; DJ = drop jump; DORS = dorsiflexion test; EG = experimental group; F = female; FFP = frontal plane plyometric group; FI = fatigue index; FLAT = flat surface group; H:Q = hamstrings to quadriceps ratio; HCL = hang clean group; HJ = horizontal jump; HSQ = half squat group; IAT = Illinois agility test; Imb = Imbalance; IRSA = intermittent repeated sprint ability; IRSAG = Intermittent repeated sprint ability group; L = left; LH = lateral hop; LJ = long jump; LS = lateral shuffle; LSI = Limb symetry index; LSI = limb symmetry index; M = male; m = meters; MBT = medicine ball throw; min = minutes; MP = mechanical power; MPBIL = maximal power bilateral; MPUNI = maximal power unilateral; ms = miliseconds; MT = mean time; MVC = maximal voluntary contraction; NPH = neuromuscular power horizontal; NPV = neuromuscular power vertical; P = Posterior; PL = postero lateral; R = Right; RCOD = Repeated change of direction; RCODA = repeated change of direction ability; RG = randomized exercises group; RPA = repeated power ability group; RSA = repeated sprint ability; s = seconds; S10m = Sprint 10 m; S15m = Sprint 15 m; S20m = Sprint 20 m; S25m = Sprint 25 m; S30m = Sprint 30 m; S5m = Sprint 5 m; S60m = Sprint 60 m; SBT = stock balance test; SEBT = star excursion balance test; SJ = squat jump; SLJ = standing long jump; SLJ = single leg jump; TCMJ = counter movement jump with step approach; TCMJstep = Counter movement jump arm use with 1 step approach ;TT = total time; UH = unilateral horizontal group; UNI = Unilateral hop test; VJ = vertical jump; w/kg = wattage per weight in kilogra



Figure 2. Flow diagram of study selection in PRISMA[®] 35.

3.2. Risk of Bias Assessment

Results for risk of bias assessment are illustrated in Figure 1. Low risk of bias was evident in the analysis following the Cochrane Collaboration Guidelines assessment. The primary source of bias detected was found in selection bias and other bias domains.

3.3. Neuromuscular Interventions in Youth Basketball Players

All the included studies were randomized controlled designs with pre and post measurements investigating the effect of multidisciplinary neuromuscular interventions on endurance and neuromuscular power (vertical and horizontal) in youth basketball players. A total of 528 participants including 399 males and 129 females participated in the selected studies. The description of the participants and interventions is described in Table 3.

3.3.1. Age

Figure 4A shows the forest plot for the age sub-groups analysis on NPV. Low level of heterogeneity was found in all the analysis except from the U-18 group with moderate level (I², 43%; p = 0.08). No significant effect was found in the U-12 sub-groups (SMD, 0.51; 95% CI: -0.28 to 1.29; I², 0%; Z, 1.26; p = 0.21) and also in the U-14 sub-groups (SMD, 0.34; 95% CI: -0.02 to 0.70; I², 1%; Z, 1.85; p = 0.06). A significant positive moderate effect was found in the U-16 group (SMD, 0.56; 95% CI: 0.33 to 0.80; I², 0%; Z, 4.71; p < 0.0001). Significant positive small effect was found in the U-18 group (SMD, 0.40; 95% CI: 0.11 to 0.69; I², 43%; Z, 2.67; p = 0.008).

3.4. Effect on Neuromuscular Power Vertical

Figure 3 illustrates the forest plot for NPV. Thirty trials [49,50,52,62–64,66–68,71–78] involving 320 participants were included for the analysis. There was a significant small to

moderate positive effect of the multidisciplinary interventions on NPV with no heterogeneity (SMD, 0.47; 95% CI: 0.31 to 0.63; I^2 , 0%; Z, 5.74; p < 0.0001).

Competitive level of	Amateur	9 [49,61,66,71,73–77]
participants	Elite	13 [50–52,62–65,67,68,70,72,78,79]
	U-12	1 [71]
Age	U-14	3 [50,67,78]
	U-16	13 [49,52,61,63–65,70,72,73,75,76,78,79]
	U-18	7 [51,52,62,66,74,77,78]
Candar	Male	16 [49–52,61,62,64,67,68,70–72,75–78]
Gender	Female	6 [63,65,66,73,74,79]
	Mixed Strength and conditioning program	7 [49–52,76,78,80]
	Plyometric training program	12 [61–63,66–68,70,71,73–75,77]
Interventions	HIIT B program	1 [79]
	Repeated sprint training	3 [64,65,70]
	Neuromuscular power vertical (NPV)	30 [49,51,52,62,63,66,68,70–76,78]
Outcomes	Neuromuscular power horizontal (NPH)	24 [49–51,61,62,66–68,70,71,74,77,78]
	Endurance (E)	3 [64,65,79]

 Table 3. Number studies included in the meta-analysis per sub-group and references.

		Post Pre			S	td. Mean Difference	Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Arede et al. 2018	32.35	4.94	9	30.31	3.48	9	2.9%	0.45 [-0.48, 1.39]	-+
Asadi et al. 2016	50.5	2.2	8	44.2	2.1	8	1.2%	2.77 [1.29, 4.25]	
Attene et al. 2015	29.99	3.65	18	26.94	3.62	18	5.4%	0.82 [0.14, 1.50]	
Attene et al. 2015b_IRST	40.7	4.5	9	37.8	4.1	9	2.8%	0.64 [-0.31, 1.60]	—
Attene et al. 2015b_RST	36.5	3.4	9	35.3	2.8	9	2.9%	0.37 [-0.57, 1.30]	-
Bouteraa et al. 2020	28.8	3.3	16	26.28	3.9	16	5.0%	0.68 [-0.04, 1.40]	
Ciacci & Bartolomei 2017_U16HC	39.98	5.94	9	39.01	4.72	9	3.0%	0.17 [-0.75, 1.10]	
Ciacci & Bartolomei 2017_U16HS	37.43	4.94	9	35.56	3.41	9	2.9%	0.42 [-0.52, 1.36]	
Ciacci & Bartolomei 2017_U18HC	40.8	5.71	10	39.46	5.78	10	3.3%	0.22 [-0.66, 1.10]	
Ciacci & Bartolomei 2017_U18HS	40.23	4.86	8	40.11	6.91	8	2.6%	0.02 [-0.96, 1.00]	
Figueira et al. 2020_FLAT	52.27	4.13	16	48.2	5.29	16	4.8%	0.84 [0.11, 1.56]	
Figueira et al. 2020_SLOPE	46.13	6.01	15	47.2	5.72	15	4.9%	-0.18 [-0.89, 0.54]	
Gonzalo-Skok et al. 2017_BIL	40.6	5.5	11	38.9	5.3	11	3.6%	0.30 [-0.54, 1.14]	
Gonzalo-Skok et al. 2017_UNI	39.8	5.1	11	37.4	4.2	11	3.5%	0.49 [-0.36, 1.35]	
Gonzalo-Skok et al. 2019_BV	33.4	4.3	10	32.5	5.1	10	3.3%	0.18 [-0.70, 1.06]	
Gonzalo-Skok et al. 2019_UH	33	2.8	10	31.6	4.2	10	3.2%	0.38 [-0.51, 1.26]	
Gottlieb et al. 2014_PT	42.51	2.72	9	41.32	3.87	9	2.9%	0.34 [-0.59, 1.27]	
Gottlieb et al. 2014_ST	42.36	5.75	10	40.6	4.8	10	3.3%	0.32 [-0.57, 1.20]	_ _
Hernández et al. 2018_NR	26.9	5.8	7	24.1	5.9	7	2.2%	0.45 [-0.62, 1.51]	
Hernández et al. 2018_R	33.5	8.1	6	28.4	8.3	6	1.9%	0.57 [-0.59, 1.74]	
Matavulj et al. 2001	46	6	11	40.4	6.3	11	3.3%	0.88 [-0.01, 1.76]	
McCormick et al. 2016_FP	50.07	5.33	7	48.26	5.39	7	2.3%	0.32 [-0.74, 1.37]	
McCormick et al. 2016_SP	52.61	9.36	7	47.72	7.07	7	2.2%	0.55 [-0.52, 1.63]	
Meszler & Váczi 2019	31.96	3.48	9	33.52	3.89	9	2.9%	-0.40 [-1.34, 0.53]	
Santos & Janeira 2008	33.02	6.2	15	29.88	5.9	15	4.8%	0.50 [-0.22, 1.23]	<u>+</u>
Santos & Janeira 2012	36.68	4.2	15	33.3	4.3	15	4.6%	0.77 [0.03, 1.52]	
Tsimachidis et al. 2010	36.8	9.7	13	32.7	12.3	13	4.2%	0.36 [-0.42, 1.13]	
Yañez-García et al. 2019_U14	30.2	6.2	11	27	6.2	11	3.5%	0.50 [-0.35, 1.35]	+
Yañez-García et al. 2019_U16	35.9	3.4	11	32.5	3.7	11	3.2%	0.92 [0.03, 1.81]	└──
Yañez-García et al. 2019_U18	36.2	6.1	11	33.9	6.1	11	3.6%	0.36 [-0.48, 1.21]	+
Total (95% CI)			320			320	100.0%	0.47 [0.31, 0.63]	◆
Heterogeneity: $Chi^2 = 23.31$. df = 29	(P = 0.76)	$ ^2 =$	0%						
Test for overall effect: $Z = 5.74$ (P < 0	.00001)								-4 -2 0 2 4
									Negative effect Positive effect



Study of Subgroup	Post	Total		Pre	Tatal	y Waisht	Std. Mean Difference	Std. Mean Difference
1.1.1 U-12	Mean S	JIOTAI	Mean	30	Total	weight	IV, Fixed, 95% CI	
Hernández et al. 2018_NR Hernández et al. 2018 R	26.9 5. 33.5 8.	87 16	24.1 28.4	5.9 8.3	7	2.2% 1.9%	0.45 [-0.62, 1.51] 0.57 [-0.59, 1.74]	
Subtotal (95% CI)	0.00) 12 0	13			13	4.1%	0.51 [-0.28, 1.29]	◆
Test for overall effect: $Z = 1.26$ (P = 0.	21)	76						
1.1.2 U-14								
Figueira et al. 2020_FLAT	52.27 4.1	3 16	48.2	5.29	16	4.8%	0.84 [0.11, 1.56]	
Gonzalo-Skok et al. 2019_BV	33.4 4.	1 15 3 10	32.5	5.72	15	4.9%	0.18 [-0.70, 1.06]	
Gonzalo-Skok et al. 2019_UH	33 2. 30 2 6	8 10 2 11	31.6	4.2	10	3.2%	0.38 [-0.51, 1.26]	
Subtotal (95% Cl)	50.2 0.	62	27	0.2	62	19.8%	0.34 [-0.02, 0.70]	◆
Heterogeneity: $Chi^{*} = 4.05$, $df = 4$ (P = Test for overall effect: Z = 1.85 (P = 0.	0.40); l* = 1 06)	%						
1.1.3 U-16								
Arede et al. 2018	32.35 4.9	4 9	30.31	3.48	9	2.9%	0.45 [-0.48, 1.39]	+
Attene et al. 2015 Attene et al. 2015b_IRST	29.99 3.6 40.7 4.	5 18 5 9	26.94 37.8	3.62 4.1	18 9	5.4% 2.8%	0.82 [0.14, 1.50] 0.64 [-0.31, 1.60]	
Attene et al. 2015b_RST	36.5 3.	4 9	35.3	2.8	9	2.9%	0.37 [-0.57, 1.30]	
Ciacci & Bartolomei 2017_U16HS	37.43 4.9	4 9	35.56	3.41	9	2.9%	0.42 [-0.52, 1.36]	_
Gottlieb et al. 2014_PT Gottlieb et al. 2014 ST	42.51 2.7 42.36 5.7	29 510	41.32 40.6	3.87 4.8	9 10	2.9% 3.3%	0.34 [-0.59, 1.27] 0.32 [-0.57, 1.20]	
Matavulj et al. 2001	46	6 11	40.4	6.3	11	3.3%	0.88 [-0.01, 1.76]	
McCormick et al. 2016_FP McCormick et al. 2016_SP	52.61 9.3	37 67	48.26 47.72	5.39 7.07	7	2.3%	0.32 [-0.74, 1.37] 0.55 [-0.52, 1.63]	
Santos & Janeira 2008 Santos & Janeira 2012	33.02 6. 36.68 4	2 15 2 15	29.88	5.9 4.3	15 15	4.8% 4.6%	0.50 [-0.22, 1.23]	<u> </u>
Yañez-García et al. 2019_U16	35.9 3.	4 11	32.5	3.7	11	3.2%	0.92 [0.03, 1.81]	
Heterogeneity: $Chi^2 = 3.73$, $df = 13$ (P	= 0.99); I ² =	148 0%			148	46.3%	0.56 [0.33, 0.80]	•
Test for overall effect: $Z = 4.71$ (P < 0.	00001)							
1.1.4 U-18	505 0					1.20/	2 77 (1 20 4 25)	
Asadi et al. 2016 Bouteraa et al. 2020	28.8 3.	2 8 3 16	44.2 26.28	2.1 3.9	8 16	1.2%	0.68 [-0.04, 1.40]	
Ciacci & Bartolomei 2017_U18HC	40.8 5.7	1 10	39.46	5.78	10	3.3%	0.22 [-0.66, 1.10]	
Gonzalo-Skok et al. 2017_BIL	40.23 4.8	5 11	38.9	5.3	11	3.6%	0.30 [-0.54, 1.14]	
Gonzalo-Skok et al. 2017_UNI Meszler & Váczi 2019	39.8 5. 31.96 3.4	1 11 8 9	37.4	4.2	11 9	3.5%	0.49 [-0.36, 1.35]	
Tsimachidis et al. 2010	36.8 9.	7 13	32.7	12.3	13	4.2%	0.36 [-0.42, 1.13]	+
Yanez-Garcia et al. 2019_018 Subtotal (95% Cl)	36.2 6.	1 11 97	33.9	6.1	97	3.6% 29.8%	0.36 [-0.48, 1.21] 0.40 [0.11, 0.69]	•
Heterogeneity: $Chi^2 = 14.15$, $df = 8$ (P Test for overall effect: Z = 2.67 (P = 0.	= 0.08); I ² = 008)	43%						
Total (95% CI)		320			320	100.0%	0.47 [0.31, 0.63]	•
Heterogeneity: $Chi^2 = 23.31$, $df = 29$ (I	$P = 0.76$; $I^2 = 0.0001$	= 0%						-4 -2 0 2 4
Test for subgroup differences: $Chi^2 = 1$.36, df = 3 (P = 0.71), $I^2 = 0$	%				Negative effect Positive effect
					(4	A)		
	Post			Pre		S	td. Mean Difference	Std. Mean Difference
1.1.1 FEMALE	Mean SI	D Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Attene et al. 2015 Bouteraa et al. 2020	29.99 3.6 28.8 3	5 18 3 16	26.94	3.62	18 16	5.4%	0.82 [0.14, 1.50]	
McCormick et al. 2016_FP	50.07 5.3	3 7	48.26	5.39	7	2.3%	0.32 [-0.74, 1.37]	
Meszler & Váczi 2019	31.96 3.4	8 9	33.52	3.89	9	2.2%	-0.40 [-1.34, 0.53]	
Subtotal (95% CI) Heterogeneity: $Chi^2 = 4.78$, $df = 4$ (P =	(0.31) : $l^2 = 1$	57 6%			57	17.8%	0.48 [0.11, 0.86]	•
Test for overall effect: $Z = 2.51$ (P = 0.	01)							
1.1.2 MALE	22.25.4.5		20.25	2		2.000	0.451.0.10.1.2-1	
Arede et al. 2018 Asadi et al. 2016	32.35 4.9 50.5 2.	4 9 2 8	44.2	3.48	9	2.9%	0.45 [-0.48, 1.39] 2.77 [1.29, 4.25]	
Attene et al. 2015b_IRST	40.7 4.	5 9 4 9	37.8	4.1	9	2.8%	0.64 [-0.31, 1.60]	
Ciacci & Bartolomei 2017_U16HC	39.98 5.9	4 9	39.01	4.72	9	3.0%	0.17 [-0.75, 1.10]	
Ciacci & Bartolomei 2017_U16HS Ciacci & Bartolomei 2017 U18HC	37.43 4.9 40.8 5.7	49 110	35.56 39.46	3.41 5.78	9 10	2.9% 3.3%	0.42 [-0.52, 1.36] 0.22 [-0.66, 1.10]	
Ciacci & Bartolomei 2017_U18HS	40.23 4.8	6 8	40.11	6.91	8	2.6%	0.02 [-0.96, 1.00]	
Figueira et al. 2020_SLOPE	46.13 6.0	1 15	48.2	5.72	15	4.8%	-0.18 [-0.89, 0.54]	
Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017 UNI	40.6 5.	5 11 1 11	38.9	5.3	11	3.6%	0.30 [-0.54, 1.14]	
Gonzalo-Skok et al. 2019_BV	33.4 4.	3 10	32.5	5.1	10	3.3%	0.18 [-0.70, 1.06]	
Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT	33 2. 42.51 2.7	8 10 2 9	31.6 41.32	4.2 3.87	10 9	3.2%	0.38 [-0.51, 1.26] 0.34 [-0.59, 1.27]	
Gottlieb et al. 2014_ST	42.36 5.7	5 10	40.6	4.8	10	3.3%	0.32 [-0.57, 1.20]	<u> </u>
Hernández et al. 2018_R	33.5 8.	1 6	28.4	8.3	6	1.9%	0.57 [-0.59, 1.74]	
Matavulj et al. 2001 Santos & Janeira 2008	46 33.02 6	6 11 2 15	40.4	6.3 5.9	11	3.3%	0.88 [-0.01, 1.76]	
Santos & Janeira 2012	36.68 4.	2 15	33.3	4.3	15	4.6%	0.77 [0.03, 1.52]	
Yañez-García et al. 2010 Yañez-García et al. 2019_U14	30.8 9. 30.2 6.	/ 13 2 11	32.7	6.2	13	4.2%	0.50 [-0.42, 1.13]	
Yañez-García et al. 2019_U16 Yañez-García et al. 2019_U18	35.9 3.	4 11	32.5	3.7	11	3.2%	0.92 [0.03, 1.81]	
Subtotal (95% CI)	50.2 0.	263	55.5	0.1	263	82.2%	0.46 [0.29, 0.64]	۲

Heterogeneity: $Chi^2 = 18.52$, df = 24 (P = 0.78); $I^2 = 0\%$ Test for overall effect: Z = 5.16 (P < 0.00001)

 $\label{eq:2.1} \begin{array}{l} \textbf{Total (95\% Cl)} & \textbf{320} \\ \text{Heterogeneity: Chi^2 = 23.3.1, df = 29 (P = 0.76); l^2 = 0\% \\ \text{Test for overall effect: Z = 5.74 (P < 0.00001)} \\ \text{Test for subgroup differences: Chi^2 = 0.0.1, df = 1 (P = 0.92), l^2 = 0\% \\ \end{array}$

320 100.0%

0.47 [0.31, 0.63]

-4

4

-2 0 2 Negative effect Positive effect

	P	ost			Pre			Std. Mean Difference	Std. Mean Difference
Study or Subgroup 1.1.1 ELITE	Mean	SD T	otal	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
Asadi et al. 2016	50.5	2.2	8	44.2	2.1	8	1.2%	2.77 [1.29, 4.25]	
Attene et al. 2015 Attene et al. 2015b IRST	29.99	3.65	18	26.94	3.62	18	5.4%	0.82 [0.14, 1.50]	
Attene et al. 2015b_RST	36.5	3.4	9	35.3	2.8	9	2.9%	0.37 [-0.57, 1.30]	
Ciacci & Bartolomei 2017_U16HC	39.98	5.94	9	39.01	4.72	9	3.0%	0.17 [-0.75, 1.10]	
Ciacci & Bartolomei 2017_010HS Ciacci & Bartolomei 2017_018HC	40.8	5.71	10	39.46	5.78	10	3.3%	0.22 [-0.66, 1.10]	
Ciacci & Bartolomei 2017_U18HS	40.23	4.86	8	40.11	6.91	8	2.6%	0.02 [-0.96, 1.00]	
Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE	46.13	4.13 6.01	16	48.2	5.29	16	4.8%	-0.18 [-0.89, 0.54]	
Gonzalo-Skok et al. 2017_BIL	40.6	5.5	11	38.9	5.3	11	3.6%	0.30 [-0.54, 1.14]	
Gonzalo-Skok et al. 2017_UNI Gonzalo-Skok et al. 2019 BV	39.8 33.4	5.1 4.3	11	37.4	4.2	11	3.5%	0.49 [-0.36, 1.35] 0.18 [-0.70, 1.06]	
Gonzalo-Skok et al. 2019_UH	33	2.8	10	31.6	4.2	10	3.2%	0.38 [-0.51, 1.26]	
Gottlieb et al. 2014_PT Gottlieb et al. 2014_ST	42.51	2.72	9 10	41.32	3.87	9	2.9%	0.34 [-0.59, 1.27]	
Matavulj et al. 2001	46	6	11	40.4	6.3	11	3.3%	0.88 [-0.01, 1.76]	
Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U16	30.2	6.2	11	27	6.2	11	3.5%	0.50 [-0.35, 1.35]	
Yañez-García et al. 2019_010	36.2	6.1	11	33.9	6.1	11	3.6%	0.36 [-0.48, 1.21]	
Subtotal (95% CI)	(P - 0.47)	12 - 09	216			216	67.1%	0.47 [0.28, 0.67]	•
Test for overall effect: $Z = 4.76$ (P < 0	(P = 0.47), 0.00001)	1 = 0%	0						
1.1.2 AMATEUR						220	<u>0 - 50</u> 00		
Arede et al. 2018 Bouteraa et al. 2020	32.35	4.94	9	30.31	3.48	9	2.9%	0.45 [-0.48, 1.39]	
Hernández et al. 2018_NR	26.9	5.8	7	24.1	5.9	7	2.2%	0.45 [-0.62, 1.51]	
Hernández et al. 2018_R	33.5	8.1	6	28.4	8.3	6	1.9%	0.57 [-0.59, 1.74]	
McCormick et al. 2016_FP McCormick et al. 2016_SP	52.61	9.36	7	48.26	5.39	7	2.3%	0.32 [-0.74, 1.37] 0.55 [-0.52, 1.63]	
Meszler & Váczi 2019	31.96	3.48	9	33.52	3.89	9	2.9%	-0.40 [-1.34, 0.53]	
Santos & Janeira 2008 Santos & Janeira 2012	33.02	6.2	15	29.88	5.9	15	4.8%	0.50 [-0.22, 1.23]	
Tsimachidis et al. 2010	36.8	9.7	13	32.7	12.3	13	4.2%	0.36 [-0.42, 1.13]	
Subtotal (95% CI)	0.87), 12	09/	104			104	32.9%	0.46 [0.18, 0.73]	•
Test for overall effect: $Z = 3.21$ (P = 0	= 0.87); 1-	= 0%							
Total (95% CI)			320			320	100.0%	0.47 [0.31, 0.63]	•
Heterogeneity: $Chi^2 = 23.31$, $df = 29$ Test for overall effect: $Z = 5.74$ ($P < 0$	(P = 0.76);	$1^2 = 0\%$	6					1.5	-4 -2 0 2 4
Test for subgroup differences: $Chi^2 =$	0.01, df =	1 (P =	0.92),	$I^2 = 09$	6				Negative effect Positive effect
						(2)		
	Po	ost			Pre		Ś	itd. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD T	otal	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1 1 1 PLYOMETRIC TRAINING									1
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016	50.5	2.2	8	44.2	2.1	8	1.2%	2.77 [1.29, 4.25]	<u> </u>
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015	50.5 29.99 3	2.2	8 18	44.2 26.94	2.1 3.62	8 18	1.2% 5.4%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50]	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020_FLAT	50.5 29.99 3 28.8 52.27 4	2.2 3.65 3.3	8 18 16 16	44.2 26.94 26.28 48.2	2.1 3.62 3.9 5.29	8 18 16 16	1.2% 5.4% 5.0% 4.8%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04, 1.40] 0.84 [0.11, 1.56]	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_FLAT	50.5 29.99 3 28.8 52.27 4 46.13 6	2.2 3.65 3.3 4.13 5.01	8 18 16 16 15	44.2 26.94 26.28 48.2 47.2	2.1 3.62 3.9 5.29 5.72	8 18 16 16 15	1.2% 5.4% 5.0% 4.8% 4.9%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04, 1.40] 0.84 [0.11, 1.56] -0.18 [-0.89, 0.54]	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueria et al. 2020_FLAT Figueria et al. 2020_SLOPE Gonzalo-Skok et al. 2019_UH	50.5 29.99 3 28.8 52.27 4 46.13 6 33.4 33	2.2 3.65 3.3 4.13 5.01 4.3 2.8	8 18 16 16 15 10 10	44.2 26.94 26.28 48.2 47.2 32.5 31.6	2.1 3.62 3.9 5.29 5.72 5.1 4.2	8 18 16 16 15 10 10	1.2% 5.4% 5.0% 4.8% 4.9% 3.3% 3.2%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04, 1.40] 0.84 [0.11, 1.56] -0.18 [-0.89, 0.54] 0.18 [-0.70, 1.06] 0.38 [-0.51, 1.26]	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020 FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT	50.5 29.99 3 28.8 52.27 4 46.13 6 33.4 33 42.51 2	2.2 3.65 3.3 5.01 4.3 2.8 2.72	8 18 16 16 15 10 10 9	44.2 26.94 26.28 48.2 47.2 32.5 31.6 41.32	2.1 3.62 3.9 5.29 5.72 5.1 4.2 3.87	8 18 16 15 10 10 9	1.2% 5.4% 5.0% 4.8% 4.9% 3.3% 3.2% 2.9%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04, 1.40] 0.84 [0.11, 1.56] -0.18 [-0.89, 0.54] 0.18 [-0.70, 1.06] 0.38 [-0.51, 1.26] 0.34 [-0.59, 1.27]	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020 FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_R	50.5 29.99 3 28.8 52.27 4 46.13 6 33.4 33 42.51 2 26.9 33.5	2.2 3.65 3.3 4.13 5.01 4.3 2.8 2.72 5.8 8.1	8 18 16 15 10 10 9 7 6	44.2 26.94 26.28 48.2 47.2 32.5 31.6 41.32 24.1 28.4	2.1 3.62 3.9 5.29 5.72 5.1 4.2 3.87 5.9 8.3	8 16 16 15 10 10 9 7 6	1.2% 5.4% 5.0% 4.8% 4.9% 3.3% 3.2% 2.9% 2.2% 1.9%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.84 [-0.04, 1.40] 0.84 [0.11, 1.56] -0.18 [-0.89, 0.54] 0.18 [-0.70, 1.06] 0.38 [-0.51, 1.26] 0.34 [-0.59, 1.27] 0.45 [-0.62, 1.51] 0.57 [-0.59, 1.74]	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Flgueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottileb et al. 2014_PT Hernández et al. 2018_R Hernández et al. 2018_R Matavulj et al. 2001	50.5 29.99 3 28.8 52.27 4 46.13 6 33.4 33 42.51 2 26.9 33.5 46	2.2 3.65 3.3 4.13 5.01 4.3 2.8 2.72 5.8 8.1 6	8 16 16 15 10 10 9 7 6 11	44.2 26.94 26.28 48.2 47.2 32.5 31.6 41.32 24.1 28.4 40.4	2.1 3.62 3.9 5.29 5.72 5.1 4.2 3.87 5.9 8.3 6.3	8 18 16 15 10 10 9 7 6 11	1.2% 5.4% 5.0% 4.8% 3.3% 3.2% 2.9% 2.2% 1.9% 3.3%	$\begin{array}{c} 2.77 \; [1.29,\; 4.25] \\ 0.82 \; [0.14,\; 1.50] \\ 0.68 \; [-0.04,\; 1.40] \\ 0.84 \; [0.11,\; 1.56] \\ -0.18 \; [-0.89,\; 0.54] \\ 0.18 \; [-0.70,\; 1.06] \\ 0.38 \; [-0.51,\; 1.26] \\ 0.34 \; [-0.59,\; 1.27] \\ 0.45 \; [-0.62,\; 1.51] \\ 0.57 \; [-0.59,\; 1.74] \\ 0.88 \; [-0.01,\; 1.76] \end{array}$	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_R Matavulj et al. 2001 McCormick et al. 2016_FP	50.5 29.99 3 28.8 52.27 4 46.13 6 33.4 33 42.51 2 26.9 33.5 46 50.07 5 52 61 9	2.2 3.65 3.3 4.13 5.01 4.3 2.8 2.72 5.8 8.1 6 5.33 0.36	8 18 16 15 10 10 9 7 6 11 7 7	44.2 26.94 26.28 48.2 47.2 32.5 31.6 41.32 24.1 28.4 40.4 48.26 47.72	2.1 3.62 3.9 5.29 5.72 5.1 4.2 3.87 5.9 8.3 6.3 5.39 7.07	8 18 16 15 10 10 9 7 6 11 7 7	1.2% 5.4% 5.0% 4.8% 3.3% 2.9% 2.2% 1.9% 3.3% 2.3% 2.3%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04, 1.40] 0.84 [0.11, 1.56] 0.18 [-0.89, 0.54] 0.18 [-0.70, 1.06] 0.38 [-0.51, 1.26] 0.34 [-0.59, 1.27] 0.45 [-0.62, 1.51] 0.57 [-0.59, 1.74] 0.88 [-0.01, 1.76] 0.32 [-0.74, 1.37] 0.55 [-0.52, 1.63]	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020_ELAT Figueira et al. 2020_ELAT Gonzalo-Skok et al. 2019_EV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_R Matavulj et al. 2016 McCormick et al. 2016_FP McCormick et al. 2019	50.5 29.99 3 28.8 52.27 4 46.13 6 33.4 33 42.51 2 26.9 33.5 46 50.07 5 52.61 9 31.96 3	2.2 3.65 3.3 4.13 5.01 4.3 2.8 2.72 5.8 8.1 6 5.33 0.36 3.48	8 18 16 15 10 10 9 7 6 11 7 7 9	44.2 26.94 26.28 48.2 47.2 32.5 31.6 41.32 24.1 28.4 40.4 48.26 47.72 33.52	2.1 3.62 3.9 5.29 5.72 5.1 4.2 3.87 5.9 8.3 6.3 5.39 7.07 3.89	8 18 16 15 10 10 9 7 6 11 7 7 9	1.2% 5.4% 5.0% 4.8% 4.9% 3.3% 2.9% 2.2% 3.3% 2.2% 2.3% 2.2% 2.9%	$\begin{array}{c} 2.77 \; [1.29, 4.25] \\ 0.82 \; [0.14, 1.50] \\ 0.68 \; [-0.04, 1.40] \\ 0.84 \; [0.11, 1.56] \\ 0.18 \; [-0.89, 0.54] \\ 0.18 \; [-0.70, 1.06] \\ 0.38 \; [-0.51, 1.26] \\ 0.34 \; [-0.59, 1.27] \\ 0.45 \; [-0.62, 1.51] \\ 0.57 \; [-0.59, 1.74] \\ 0.88 \; [-0.01, 1.76] \\ 0.32 \; [-0.74, 1.37] \\ 0.55 \; [-0.52, 1.63] \\ -0.40 \; [-1.34, 0.53] \end{array}$	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020_ELAT Figueira et al. 2020_ELAT Gonzalo-Skok et al. 2019_EV Gonzalo-Skok et al. 2019_EV Gonzalo-Skok et al. 2019_EV Hernández et al. 2018_NR Hernández et al. 2018_NR Hernández et al. 2018_R Matavulj et al. 2001 McCormick et al. 2016_FP McCormick et al. 2016_FP McSormick et al. 2016_SP Meszler & Váczi 2019 Santos & Janeira 2008 Santos & Janeira 2008	50.5 29.99 3 28.8 52.27 4 46.13 6 33.4 33 42.51 2 26.9 33.5 46 50.07 5 52.61 9 31.96 3 33.02 26 68	2.2 3.65 3.3 5.01 4.3 2.8 2.72 5.8 8.1 6.33 0.36 6.2 4.2	8 18 16 15 10 10 9 7 6 11 7 9 15	44.2 26.94 26.28 48.2 47.2 32.5 31.6 41.32 24.1 28.4 40.4 48.26 47.72 33.52 29.88 23.2	2.1 3.62 3.9 5.29 5.72 5.1 4.2 3.87 5.9 8.3 6.3 5.39 7.07 3.89 5.9 4.2	8 16 16 15 10 10 9 7 6 11 7 7 9 15	1.2% 5.4% 5.0% 4.8% 4.9% 3.3% 2.9% 2.2% 2.3% 2.3% 2.2% 2.9% 4.8%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04, 1.40] 0.84 [0.11, 1.56] 0.18 [-0.89, 0.54] 0.18 [-0.70, 1.06] 0.38 [-0.51, 1.26] 0.45 [-0.62, 1.51] 0.57 [-0.59, 1.74] 0.88 [-0.01, 1.76] 0.32 [-0.74, 1.37] 0.55 [-0.52, 1.63] 0.50 [-0.22, 1.23] 0.77 [0.03, 1.53]	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_FLAT Gonzalo-Skok et al. 2019_UH Gonzalo-Skok et al. 2019_UH Gonzalo-Skok et al. 2019_UH Hernández et al. 2018_NR Hernández et al. 2018_R Matavulj et al. 2001 McCormick et al. 2016_FP McCormick et al. 2016_FP McCormick et al. 2016_FP Mszler & Váczi 2019 Santos & Janeira 2008 Santos & Janeira 2012 Tsimachidis et al. 2010	$\begin{array}{c} 50.5\\ 29.99\\ 32.8\\ 52.27\\ 4\\ 6.13\\ 6\\ 33.4\\ 33\\ 42.51\\ 26.9\\ 33.5\\ 46\\ 50.07\\ 5\\ 52.61\\ 9\\ 31.96\\ 3\\ 3.62\\ 36.68\\ 36.8 \end{array}$	2.2 3.65 3.3 4.13 5.01 4.3 2.8 2.72 5.8 8.1 6 3.33 6.2 4.2 9.7	8 18 16 15 10 10 9 7 6 11 7 9 15 15 13	44.2 26.94 48.2 47.2 32.5 31.6 41.32 24.1 28.4 40.4 48.26 47.72 33.52 29.88 33.3 32.7	2.1 3.62 3.9 5.29 5.72 5.1 4.2 3.87 5.9 8.3 6.3 5.39 7.07 3.89 5.9 4.3 12.3	8 18 16 15 10 9 7 6 11 7 7 9 15 15 13	1.2% 5.4% 5.0% 4.8% 4.9% 2.2% 2.9% 3.3% 2.2% 2.3% 2.2% 2.9% 4.8% 4.6%	$\begin{array}{c} 2.77 \; [1.29, 4.25] \\ 0.82 \; [0.14, 1.50] \\ 0.68 \; [-0.04, 1.40] \\ 0.84 \; [0.11, 1.56] \\ 0.18 \; [-0.89, 0.54] \\ 0.18 \; [-0.70, 1.06] \\ 0.38 \; [-0.51, 1.26] \\ 0.34 \; [-0.59, 1.27] \\ 0.45 \; [-0.62, 1.51] \\ 0.57 \; [-0.59, 1.74] \\ 0.88 \; [-0.01, 1.76] \\ 0.32 \; [-0.74, 1.37] \\ 0.55 \; [-0.52, 1.63] \\ -0.40 \; [-1.34, 0.53] \\ 0.50 \; [-0.22, 1.23] \\ 0.77 \; [0.03, 1.52] \\ 0.36 \; [-0.42, 1.13] \end{array}$	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_FLAT Gonzalo-Skok et al. 2019_UH Gonzalo-Skok et al. 2019_UH Gonzalo-Skok et al. 2019_UH Hernández et al. 2018_NR Hernández et al. 2018_R Matavulj et al. 2001 McCormick et al. 2016_FP McCormick et al. 2016_FP McCormick et al. 2016_FP McCormick et al. 2016_FP McSartos & Janeira 2008 Santos & Janeira 2012 Tsimachidis et al. 2010 Subtotal (95% CI)	50.5 29.99 3 28.8 52.27 4 46.13 6 33.4 33.4 26.9 33.5 46 50.07 5 52.61 9 31.96 3 33.02 36.68 8 6.8 P = 0.21 4	2.2 3.3 3.3 3.13 3.01 4.3 2.8 2.72 5.8 8.11 6 3.33 3.36 3.48 6.2 4.2 9.7 9.7	8 18 16 16 15 10 10 9 7 6 11 7 9 15 15 13 192	44.2 26.94 48.2 47.2 32.5 31.6 41.32 24.1 28.4 40.4 48.26 47.72 33.52 29.88 33.3 32.7	2.1 3.62 3.9 5.29 5.72 5.1 4.2 3.87 5.9 8.3 6.3 5.39 7.07 3.89 5.9 4.3 12.3	8 18 16 15 10 9 7 6 11 7 7 9 15 15 13 192	1.2% 5.4% 5.0% 4.8% 4.9% 2.9% 2.2% 1.9% 3.3% 2.3% 2.3% 2.2% 4.8% 4.6% 4.2% 59.0%	$\begin{array}{c} 2.77 \; [1.29, 4.25] \\ 0.82 \; [0.14, 1.50] \\ 0.68 \; [-0.04, 1.40] \\ 0.84 \; [0.11, 1.56] \\ 0.18 \; [-0.89, 0.54] \\ 0.18 \; [-0.70, 1.06] \\ 0.38 \; [-0.51, 1.26] \\ 0.34 \; [-0.59, 1.27] \\ 0.45 \; [-0.62, 1.51] \\ 0.57 \; [-0.59, 1.74] \\ 0.88 \; [-0.01, 1.76] \\ 0.32 \; [-0.74, 1.37] \\ 0.55 \; [-0.52, 1.63] \\ -0.40 \; [-1.34, 0.53] \\ 0.50 \; [-0.22, 1.23] \\ 0.77 \; [0.03, 1.52] \\ 0.35 \; [0.30, 0.72] \end{array}$	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020_ELAT Figueira et al. 2020_ELAT Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Hernández et al. 2018_R Hernández et al. 2018_R Matavulj et al. 2016_FP McCormick et al. 2016_FP McCormick et al. 2016_SP McSormick et al. 2017_Santos & Janeira 2008 Santos & Janeira 2008 Santos & Janeira 2012 Tsimachidis et al. 2010 Subtotal (95% CI) Heterogenety: Chi ² = 20.15, df = 16 (Test for overall effect: Z = 4.83 (P < 0.	50.5 29.99 3 28.8 52.27 4 46.13 6 33.4 33 42.51 2 26.9 33.5 52.61 9 31.96 3 33.02 36.68 9 9 0.21); 1 00001)	2.2 3.65 3.3 3.13 5.01 4.3 2.8 2.72 5.8 8.1 6 3.3 3.3 6.2 4.2 9.7 $l^2 = 215$	8 18 16 15 10 9 7 6 11 7 9 15 15 13 192 %	44.2 26.94 48.2 47.2 32.5 31.6 41.32 24.1 28.4 40.4 48.26 47.72 33.52 29.88 33.3 32.7	2.1 3.62 3.9 5.29 5.72 5.1 4.2 3.87 5.9 8.3 6.3 9 5.39 7.07 3.89 5.9 4.3 12.3	8 18 16 15 10 10 7 6 11 7 7 9 15 15 13 192	1.2% 5.4% 5.0% 4.8% 3.3% 3.2% 2.2% 2.2% 2.2% 2.3% 2.2% 2.9% 4.8% 4.6% 4.2% 59.0%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04, 1.40] 0.84 [0.11, 1.56] 0.18 [-0.89, 0.54] 0.18 [-0.70, 1.06] 0.38 [-0.51, 1.26] 0.34 [-0.59, 1.27] 0.45 [-0.62, 1.51] 0.57 [-0.59, 1.74] 0.88 [-0.01, 1.76] 0.32 [-0.74, 1.37] 0.55 [-0.52, 1.63] -0.40 [-1.34, 0.53] 0.50 [-0.22, 1.23] 0.77 [0.03, 1.52] 0.36 [-0.42, 1.13] 0.51 [0.30, 0.72]	
 1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Asten et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020_ELAT Figueira et al. 2020_ELAT Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_RR Hernández et al. 2018_RR Matavulj et al. 2016_FP McCormick et al. 2016_FP McCormick et al. 2016_FP McCormick et al. 2016_FP McCormick et al. 2016_TP Santos & Janeira 2008 Santos & Janeira 2008 Santos & Janeira 2002 Tsimachidis et al. 2010 Subtotal (95%C) Heterogenety: Chi² = 20.15, df = 16 (Test for overall effect: Z = 4.83 (P < 0. 	50.5 29.99 3 28.8 52.27 4 46.13 6 33.4 33 42.51 2 26.9 33.5 52.61 9 31.96 3 33.02 36.68 36.8 P = 0.21); 1 00001)	2.2 3.3 3.3 3.3 3.3 3.3 5.01 4.3 2.8 8.1 6 5.8 8.1 6.33 3.36 6.48 6.2 4.2 9.7 $2^2 = 215^2$	8 18 16 15 10 10 9 7 6 11 7 7 9 15 15 13 192 %	44.2 26.94 26.28 48.2 47.2 32.5 31.6 41.32 24.1 28.4 40.4 48.26 47.72 33.52 29.88 33.3 32.7	2.1 3.62 3.9 5.29 5.72 5.1 4.2 5.9 8.3 6.3 5.39 8.3 6.3 5.39 7.07 3.89 5.9 4.3 12.3	8 18 16 16 15 10 9 7 6 11 7 7 9 15 15 13 192	1.2% 5.4% 5.0% 4.8% 4.9% 3.3% 2.9% 2.2% 1.9% 2.3% 2.3% 2.3% 2.3% 2.3% 4.8% 4.6% 4.2% 59.0%	$\begin{array}{c} 2.77 \ [1.29, 4.25] \\ 0.82 \ [0.14, 1.50] \\ 0.68 \ [-0.04, 1.40] \\ 0.84 \ [0.11, 1.56] \\ 0.18 \ [-0.70, 1.06] \\ 0.38 \ [-0.70, 1.06] \\ 0.38 \ [-0.70, 1.06] \\ 0.38 \ [-0.51, 1.26] \\ 0.34 \ [-0.59, 1.27] \\ 0.45 \ [-0.62, 1.51] \\ 0.57 \ [-0.59, 1.74] \\ 0.88 \ [-0.01, 1.76] \\ 0.32 \ [-0.74, 1.37] \\ 0.55 \ [-0.52, 1.63] \\ -0.40 \ [-1.34, 0.53] \\ 0.50 \ [-0.22, 1.23] \\ 0.77 \ [0.03, 1.52] \\ 0.36 \ [-0.42, 1.13] \\ 0.51 \ [0.30, 0.72] \end{array}$	
 1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020 Figueira et al. 2020_ELAT Figueira et al. 2020_ELAT Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_R Matavulj et al. 2001 McCormick et al. 2016_FP McCormick et al. 2016_FP McCormick et al. 2016_FP McCormick et al. 2016_FP McCormick et al. 2010 Subtotal (95% CI) Heterogenety: Chi² = 20.15, df = 16 (Test for overall effect: Z = 4.83 (P < 0. 1.1.2 MIXED STRENGTH AND CONDIT Arede et al. 2018 Care at al. 2017 Care	50.5 29.99 3 28.8 52.27 4 46.13 6 33.4 33.4 26.9 33.5 42.51 2 26.9 33.5 42.51 2 26.9 33.5 42.51 2 33.0 33.0 33.0 33.0 33.0 33.0 2 36.68 36.8 36.8 36.8 36.8 36.8 36.8 36.	2.2 3.35 3.3 3.13 3.01 4.3 2.8 3.72 5.8 8.1 6 3.33 3.36 6.2 4.2 9.7 1000 1000 1000 1000 1000 1000 1000 1000 1000 100	8 18 16 15 10 10 9 7 6 11 7 7 9 15 15 13 192 %	44.2 26.94 26.28 48.2 47.2 32.5 31.6 41.32 24.1 28.4 40.4 48.26 47.72 33.52 29.88 33.3 32.7 30.31 39.01	2.1 3.62 3.9 5.29 5.71 4.2 3.87 5.9 8.3 6.3 5.39 4.3 12.3 3.48 4.72	8 18 16 16 10 10 9 7 6 11 17 7 9 9 15 13 192 9 9 9	1.2% 5.4% 5.0% 4.8% 4.9% 3.3% 2.9% 2.2% 2.9% 2.3% 2.3% 2.3% 2.3% 4.8% 4.6% 4.2% 59.0%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04, 1.40] 0.84 [0.11, 1.56] -0.18 [-0.89, 0.54] 0.38 [-0.51, 1.26] 0.38 [-0.59, 1.27] 0.45 [-0.62, 1.51] 0.57 [-0.59, 1.74] 0.88 [-0.01, 1.76] 0.32 [-0.74, 1.37] 0.55 [-0.52, 1.63] 0.50 [-0.22, 1.23] 0.57 [0.03, 1.52] 0.36 [-0.42, 1.13] 0.51 [0.30, 0.72] 0.45 [-0.48, 1.39] 0.17 [-0.75, 1.10]	
 1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Flayeria et al. 2020_FLAT Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottileb et al. 2014_PT Hernández et al. 2018_R Metarduig et al. 2018_R Metarduig et al. 2010_FP McCormick et al. 2016_SP McCormick et al. 2016_SP Meszler & Váczi 2019 Santos & Janeira 2008 Santos & Janeira 2008 Santos & Janeira 2018 Tsimachidis et al. 2010 Heterogeneity: Chi² = 20.15, df = 16 (Test for overall effect: Z = 4.83 (P < 0. 1.1.2 MIXED STRENGTH AND CONDIT Arede et al. 2018 Ciacci & Bartoiomei 2017_U16HC Ciaci & Bartoiomei 2017_U16HC	50.5 29.99 3 28.8 52.27 4 46.13 6 33.4 33.4 33.5 42.51 2 26.9 33.5 52.61 9 31.96 3 33.02 36.68 36.8 36.8 36.8 36.8 36.8 36.8 36.	2.2 3.3 3.3 5.1 3.3 5.1 4.3 2.2 5.8 8.1 6 5.8 8.1 6 6.3 3.3 6.6 2.4 4.2 9.7 $(2^2 = 21)^2$ 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9	8 18 16 16 15 10 9 7 6 11 7 9 15 15 15 15 192 %	44.2 26.94 48.2 47.2 32.5 31.6 41.32 24.1 24.1 24.1 24.1 40.4 48.26 47.72 33.52 29.88 33.3 32.7 30.31 39.01 35.56	2.1 3.62 3.9 5.29 5.72 4.2 3.87 5.9 8.3 6.3 5.39 7.07 3.89 5.9 4.3 12.3 3.48 4.72 3.41	8 18 16 16 10 10 9 7 6 11 7 7 9 9 15 13 192 9 9 9 9 9 9	1.2% 5.4% 5.0% 4.8% 4.9% 3.2% 2.9% 2.9% 2.9% 4.9% 59.0% 2.2% 59.0%	$\begin{array}{c} 2.77 \ [1.29, 4.25]\\ 0.82 \ [0.14, 1.50]\\ 0.68 \ [-0.04, 1.40]\\ 0.84 \ [0.11, 1.56]\\ -0.18 \ [-0.70, 1.06]\\ 0.18 \ [-0.70, 1.06]\\ 0.38 \ [-0.51, 1.26]\\ 0.34 \ [-0.59, 1.27]\\ 0.45 \ [-0.59, 1.27]\\ 0.45 \ [-0.59, 1.27]\\ 0.45 \ [-0.52, 1.63]\\ 0.52 \ [-0.52, 1.63]\\ 0.52 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.63]\\ 0.55 \ [-0.52, 1.51]\\ 0.55 \ [-0.52, 1.36]\\ 0.45 \ [-0.52, 1.36]\\ 0.45 \ [-0.52, 1.36]\\ 0.42 \ [-0.52, 1.36]\\ 0.42 \ [-0.52, 1.36]\\ 0.42 \ [-0.52, 1.36]\\ 0.51 \ [-0.52, 1.$	
 1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gonzalo-Skok et al. 2019_UH Gonzalo-Skok et al. 2019_UH Hernández et al. 2018_R Metandig et al. 2014_PT Hernández et al. 2018_R Metandig et al. 2016_FP McCormick et al. 2016_SP Meszler & Váczi 2019 Santos & Janeira 2012 Tsimachidis et al. 2010 Subtotal (95% CI) Heterogeneity: Chi² = 20.15, df = 16 (Test for overall effect: Z = 4.83 (P < 0. 1.12 MIXED STRENGTH AND CONDIT Ared et al. 2017_U16HC Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U18HC 	50.5 29.99 3 28.8 52.27 4 46.13 6 33.4 42.51 2 26.9 33.5 46 50.07 5 52.61 9 33.06 33.05 46 36.08 75 52.61 9 33.05 46 36.08 75 52.61 9 33.05 46 36.08 75 52.61 9 33.05 46 36.08 75 52.61 9 33.05 46 36.08 75 52.61 9 33.05 46 36.08 75 52.61 9 33.05 46 36.08 75 52.61 9 33.05 46 36.08 37.09 52.51 40 50 50 50 50 50 50 50 50 50 5	2.2 5.5 3.3 1.3 5.01 4.3 2.8 8.1 6 3.33 3.36 6.48 6.2 4.2 9.7 $2^2 = 215^2$ 1.94	8 18 16 16 15 10 9 7 6 11 7 7 9 15 15 13 192 % 9 9 9 10 8 8 9 9 10 8 10 10 10 10 10 10 10 10 10 10	44.2 26.94 48.2 47.2 32.5 31.6 41.32 24.1 28.4 40.4 48.26 47.72 33.52 29.88 33.3 32.7 30.31 39.01 35.56 39.46	2.1 3.62 3.9 5.29 5.72 5.1 4.2 3.87 5.9 6.3 5.39 7.07 3.89 4.3 12.3 3.48 4.72 3.41 5.78	8 18 16 16 10 9 7 7 10 9 7 6 11 7 7 9 15 13 192 9 9 9 9 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0	1.2% 5.4% 5.0% 4.8% 4.9% 3.2% 2.9% 2.9% 3.3% 2.2% 2.9% 4.6% 4.2% 59.0% 2.9% 3.0% 2.9% 3.0% 2.9%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04 , 1.40] 0.84 [0.11, 1.56] -0.18 [-0.38 , 0.54] 0.18 [-0.59 , 1.27] 0.45 [-0.59 , 1.27] 0.45 [-0.59 , 1.27] 0.45 [-0.59 , 1.27] 0.45 [-0.22 , 1.51] 0.55 [-0.52 , 1.63] 0.52 [-0.74 , 1.37] 0.55 [-0.52 , 1.63] 0.55 [-0.22 , 1.23] 0.55 [-0.22 , 1.23] 0.55 [-0.22 , 1.23] 0.55 [-0.36 , [-0.42 , 1.13] 0.51 [0.30 , 0.72] 0.45 [-0.48 , 1.39] 0.45 [-0.48 , 1.39] 0.45 [-0.52 , 1.63] 0.42 [-0.52 , 1.10] 0.42 [-0.52 , 1.10] 0.42 [-0.66 , 1.10] 0.42 [-0.66 , 1.00]	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020_ELAT Figueira et al. 2020_ELAT Figueira et al. 2020_ELAT Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_R Matavulj et al. 2014 McCormick et al. 2016.FP McCormick et al. 2016.FP McCormick et al. 2016_SP Meszler & Váczi 2019 Santos & Janeira 2008 Santos & Janeira 2008 Santos & Janeira 2008 Subtotal (95% CI) Heterogeneity: Chi ² = 20.15, df = 16 (Test for overall effect: Z = 4.83 (P < 0. 1.1.2 MIXED STRENGTH AND CONDIT Arede et al. 2018 Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U18HC Ciacci & Bartolomei 2017_U18HS Gonzalo-Skok et al. 2017_EBL	50.5 29.99 3 52.27 4 46.13 6 33.4 42.51 2 26.9 33.5 46 50.07 5 52.61 9 31.96 3 33.02 36.68 9 31.96 3 36.8 P = 0.21); 1 000010 7 100NING 32.35 4 39.98 5 37.43 4 40.8 5	2.2 (.65) (.33) (.13) (.14)	8 18 16 16 15 10 9 7 6 11 7 7 9 15 15 13 192 % 9 9 9 10 8 11	44.2 26.94 48.2 32.5 31.6 41.32 24.1 28.4 44.32 24.1 28.4 44.32 24.1 33.5 33.3 32.7 30.31 33.01 35.56 39.46 40.11 38.9	2.1 3.62 3.9 5.29 5.72 5.1 4.2 3.87 5.9 4.3 5.39 7.07 3.89 4.3 12.3 3.48 4.72 3.41 5.78 5.9 4.3 12.3	8 18 16 15 10 10 9 7 6 11 7 7 9 15 15 13 192 9 9 9 9 9 10 8 11 15 15 15 15 15 10 10 15 15 15 15 15 15 15 15 15 15	1.2% 5.4% 5.0% 4.8% 4.9% 3.3% 2.2% 2.3% 2.2% 2.3% 2.2% 4.6% 4.6% 59.0% 2.9% 3.3% 2.9% 3.3% 2.9% 3.6%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04, 1.40] 0.84 [0.11, 1.56] -0.18 [-0.89, 0.54] 0.18 [-0.59, 1.27] 0.45 [-0.62, 1.51] 0.57 [-0.59, 1.27] 0.45 [-0.62, 1.51] 0.57 [-0.52, 1.63] -0.40 [-1.34, 0.53] 0.50 [-0.22, 1.23] 0.55 [-0.42, 1.13] 0.51 [0.30, 0.72] 0.45 [-0.48, 1.39] 0.77 [-0.75, 1.10] 0.45 [-0.48, 1.39] 0.77 [-0.75, 1.10] 0.42 [-0.52, 1.36] 0.22 [-0.66, 1.10] 0.02 [-0.95, 1.10] 0.42 [-0.54, 1.14]	
 1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Asadi et al. 2016 Attene et al. 2017 Bouteraa et al. 2020 Figueira et al. 2020_ELAT Figueira et al. 2020_ELAT Figueira et al. 2020_SLOPE Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_R Matavulj et al. 2016_FP McCormick et al. 2016_FP McCormick et al. 2016_FP McCormick et al. 2016_SP Meszler & Váczi 2019 Santos & Janeira 2008 Santos & Janeira 2008 Santos & Janeira 2008 Subtotal (95% CI) Heterogeneity: Chi² = 20.15, df = 16 (Test for overall effect: Z = 4.83 (P < 0. 1.1.2 MIXED STRENGTH AND CONDIT Arede et al. 2018 Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U18HS Conzalo-Skok et al. 2017_BIL Conzalo-Skok et al. 2017_BIL Conzalo-Skok et al. 2017_UNI Váñoz_Grufo et al. 2017_UNI 	50.5 29.99 3 52.27 4 46.13 6 33.4 42.51 2 26.9 33.5 46 50.07 5 52.61 9 31.96 3 33.02 36.68 9 = 0.21); 1 00001) CONING 43.25 4 39.98 5 37.43 4 40.8 5 40.23 4 40.2 40.2 40.2 40.2 40.2 40.2 40.2 40.2	2.2 (.65) (.13) (.13) (.14) (.13) (.13) (.14) (.13) (.14)	8 18 16 16 10 9 7 6 11 7 7 9 15 15 15 13 192 % 9 9 10 8 11 11 19 10 10 10 10 10 10 10 10 10 10	44.2 26.94 48.2 32.5 31.6 44.32 24.1 28.4 44.32 24.1 28.4 44.32 24.1 33.5 33.3 32.7 30.31 35.56 39.46 40.11 35.56 39.46 40.11	2.1 3.62 3.9 5.29 5.72 5.7 4.2 3.87 5.9 8.3 6.3 9 7.07 3.89 5.9 4.3 12.3 3.48 4.72 3.41 5.78 4.2 5.74 6.91 5.79 5.9 5.9 5.9 5.9 5.9 5.9 5.9 5.9 5.9 5.	8 18 16 16 15 10 10 9 7 6 11 7 7 9 15 13 192 9 9 9 9 9 9 10 8 11 12 13 13 13 13 13 13 13 13 13 14 15 15 15 15 15 15 15 15 15 15	1.2% 5.4% 5.0% 4.8% 4.8% 3.2% 2.2% 2.2% 2.2% 2.2% 2.2% 2.3% 2.2% 2.3% 2.2% 59.0% 4.8% 4.6% 59.0%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04, 1.40] 0.84 [0.11, 1.56] 0.18 [-0.89, 0.54] 0.18 [-0.70, 1.06] 0.33 [-0.51, 1.26] 0.34 [-0.59, 1.27] 0.45 [-0.62, 1.51] 0.57 [-0.52, 1.63] 0.50 [-0.52, 1.63] 0.50 [-0.52, 1.63] 0.50 [-0.52, 1.63] 0.55 [-0.63, 1.37] 0.55 [-0.63, 1.52] 0.36 [-0.42, 1.13] 0.51 [0.30, 0.72] 0.45 [-0.48, 1.39] 0.17 [-0.75, 1.10] 0.42 [-0.52, 1.36] 0.22 [-0.66, 1.10] 0.22 [-0.66, 1.10] 0.23 [-0.54, 1.14] 0.49 [-0.36, 1.35]	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020_ELAT Figueira et al. 2020_ELAT Gonzalo-Skok et al. 2019_EV Gonzalo-Skok et al. 2019_UH Gottileb et al. 2014_PT Hernández et al. 2018_R Hernández et al. 2018_R Matavulj et al. 2016_FP McCormick et al. 2016_SP Meszler & Váczi 2019 Santos & Janeira 2008 Santos & Janeira 2008 Santos & Janeira 2008 UE Santos & Janeira 2012 Tsimachidis et al. 2010 UE Stro overall effect: Z = 4.83 (P < 0. 1.1.2 MIXED STRENGTH AND CONDIT Arede et al. 2018 Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U16HS Ciacci & Bartolomei 2017_U18HS Gonzalo-Skok et al. 2017_UNI Yańez-Garcia et al. 2019_U16	50.5 29.99 3 52.27 4 46.13 6 33.4 42.51 2 26.9 33.5 46 50.07 5 52.61 9 33.02 36.68 9 9.1.96 3 33.02 36.68 P = 0.21); 1 00001) TONING 32.35 4 40.8 39.98 5 37.43 4 40.8 40.23 40.25 4	2.2 (.65) (.13) (.13) (.14) (.13) (.13) (.14) (.13) (.14)	8 18 16 16 10 9 7 6 11 7 9 15 15 15 13 192 % 9 9 9 10 8 11 11 11 11 12 13 14 15 15 15 15 15 15 15 15 15 15	44.2 26.94 48.2 47.2 32.5 31.6 41.32 24.1 40.4 48.26 40.4 48.26 40.4 48.26 33.3 32.7 33.3 32.7 30.31 39.01 39.01 39.01 39.55 39.46 40.11 38.9 37.4 42,2 32.5	2.1 3.62 3.9 5.29 5.72 5.7 3.87 5.9 8.3 6.3 5.9 7.07 3.89 5.9 7.07 3.89 5.9 7.07 3.89 5.9 4.3 12.3 3.48 4.72 3.41 5.78 4.2 3.41 5.78 4.2 3.41 5.78 5.79 5.9 5.9 5.9 5.9 5.9 5.9 5.9 5.9 5.9 5.	8 18 16 15 10 9 7 7 7 7 15 13 192 9 9 9 9 9 9 10 8 11 11 12 13 192 192 192 192 192 192 193 192 193 193 193 193 193 193 193 193	1.2% 5.4% 4.8% 4.9% 2.2% 1.9% 2.3% 2.2% 4.8% 4.2% 59.0%	$\begin{array}{c} 2.77 \ [1.29, 4.25]\\ 0.82 \ [0.14, 1.50]\\ 0.68 \ [-0.04, 1.40]\\ 0.84 \ [0.11, 1.56]\\ 0.18 \ [-0.89, 0.54]\\ 0.18 \ [-0.70, 1.06]\\ 0.38 \ [-0.70, 1.06]\\ 0.38 \ [-0.51, 1.26]\\ 0.34 \ [-0.59, 1.27]\\ 0.45 \ [-0.62, 1.51]\\ 0.57 \ [-0.59, 1.74]\\ 0.88 \ [-0.01, 1.76]\\ 0.32 \ [-0.72, 1.37]\\ 0.55 \ [-0.52, 1.63]\\ 0.50 \ [-0.22, 1.23]\\ 0.50 \ [-0.22, 1.23]\\ 0.50 \ [-0.22, 1.23]\\ 0.51 \ [-0.30, 0.72]\\ 0.36 \ [-0.48, 1.39]\\ 0.17 \ [-0.75, 1.10]\\ 0.42 \ [-0.52, 1.36]\\ 0.22 \ [-0.66, 1.10]\\ 0.42 \ [-0.54, 1.13]\\ 0.51 \ [0.30, 0.72]\\ 0.36 \ [-0.54, 1.14]\\ 0.49 \ [-0.36, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.36, 1.35$	
 1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020_ELAT Figueira et al. 2020_ELAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottileb et al. 2014_PT Hernández et al. 2018_R Metarvulj et al. 2016_FP McCormick et al. 2016_SP Meszler & Váczi 2019 Santos & Janeira 2008 Santos & Janeira 2008 Santos & Janeira 2008 Santos & Janeira 2008 Santos & Janeira 2012 Tsimachidis et al. 2010 Subtotal (95% CI) Heterogeneity: Chi² = 20.15, df = 16 (J Test for overall effect: Z = 4.83 (P < 0. L.2 MIXED STRENGTH AND CONDIT Arede et al. 2018 Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U16HS Ciacci & Bartolomei 2017_U18HS Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_U1NHY Yañez-Carcía et al. 2019_U16 Yañez-García et al. 2019_U16 	$\begin{array}{c} 50.5\\ 29.99\\ 28.8\\ 52.27\\ 46.13\\ 6\\ 33.4\\ 4.51\\ 26.9\\ 33.5\\ 46\\ 50.07\\ 52.61\\ 9\\ 33.5\\ 46\\ 50.07\\ 52.61\\ 9\\ 33.02\\ 36.68\\ 36.8\\ 7\\ 9\\ 9\\ 00001\\ 1\\ 0\\ 00001\\ 1\\ 0\\ 0\\ 0\\ 0\\ 1\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\$	2.2 3.3 3.3 3.01 4.3 2.8 2.8 3.72 5.8 8.1 6.33 3.36 6.48 6.2 9.7 $2^2 = 215^2$ 3.94 3.94 3.94 3.94 3.94 3.94 3.94 3.94 6.2 3.4 6.1 6.2 3.4 6.1 3.4 6.1 3.4 6.2 3.4 7.2 7.	8 18 16 16 15 10 10 9 7 6 11 7 7 9 15 13 192 % 9 9 9 9 10 8 11 11 11 11 12 13 192 %	44.2 26.94 48.2 47.2 32.5 31.6 41.32 24.1 40.4 48.26 40.4 48.26 40.4 48.26 33.3 32.7 33.3 32.7 30.31 39.01 39.01 39.05 39.46 40.11 27 38.9 37.4 27 33.5 38.9	2.1 3.62 3.9 5.29 5.72 5.1 4.2 5.3 8.3 5.39 7.07 4.3 12.3 3.48 4.72 3.41 5.78 4.72 3.41 5.78 5.3 4.2 5.3 4.2 3.41 5.73 5.3 4.2 3.41 5.3 5.3 7.1 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3	8 18 16 16 15 10 9 9 7 7 7 7 7 15 13 192 9 9 9 9 9 9 9 9 10 8 11 11 12 13 19 10 10 10 10 10 10 10 10 10 10	1.2% 5.4% 4.8% 4.9% 3.3% 3.2% 2.2% 2.2% 2.2% 2.2% 4.8% 4.2% 59.0% 59.0%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.86 [-0.04, 1.40] 0.84 [0.11, 1.56] -0.18 [-0.89, 0.54] 0.38 [-0.51, 1.26] 0.38 [-0.59, 1.27] 0.45 [-0.62, 1.51] 0.57 [-0.59, 1.74] 0.55 [-0.59, 1.74] 0.55 [-0.52, 1.63] 0.50 [-0.22, 1.23] 0.51 [0.30, 0.72] 0.36 [-0.48, 1.39] 0.77 [-0.75, 1.10] 0.42 [-0.52, 1.36] 0.22 [-0.96, 1.00] 0.42 [-0.54, 1.14] 0.50 [-0.35, 1.35] 0.50 [-0.	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020_ELAT Figueira et al. 2020_ELAT Gonzalo-Skok et al. 2019_EV Gonzalo-Skok et al. 2019_EV Gonzalo-Skok et al. 2019_UH Gottileb et al. 2014_PT Hernández et al. 2018_R Metarández et al. 2018_R Matavulj et al. 2016_FP McCormick et al. 2010_T Santos & Janeira 2008 Santos & Janeira 2008 Santos & Janeira 2008 Gonzalo-Skok et al. 2012 Tsimachidis et al. 2010 Subtotal (95% CI) Heterogeneity: Chi ² = 20.15, df = 16 (Test for overall effect: Z = 4.83 (P < 0. LI.2 MIXED STRENGTH AND CONDIT Arede et al. 2018 Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U16HS Ciacci & Bartolomei 2017_U18HS Gonzalo-Skok et al. 2017_U14 Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U16 Yañez-García et al. 2019_U18 Subtotal (95% CI)	$\begin{array}{c} 50.5\\ 29.99\\ 28.8\\ 52.27\\ 46.13\\ 6\\ 33.4\\ 42.51\\ 26.9\\ 33.5\\ 46\\ 50.07\\ 52.61\\ 9\\ 33.5\\ 46\\ 50.07\\ 52.61\\ 9\\ 33.02\\ 36.68\\ 9\\ 9\\ 0.21); 1\\ 00001)\\ \hline 00001)\\ \hline 00001\\ \hline 00001\\ \hline 00001\\ \hline 00001\\ 32.35\\ 40.23\\ 40.8\\ 39.8\\ 540.23\\ 40.8\\ 39.8\\ 30.2\\ 39.8\\ 30.2\\ 35.9\\ 36.2\\ \hline 0008); 1^2 = \\ 0.98); 1^2 = \\ \end{array}$	2.2 3.5 3.3 5.01 4.3 2.8 2.72 5.8 3.33 3.36 6.2 4.2 9.7 $2^2 = 215$ 3.34 6.2 4.2 9.7 $2^2 = 215$ 3.94 4.34 3.94 4.34 5.55 5.5 7.4 7	8 18 16 16 15 10 10 9 7 6 11 7 7 9 15 13 192 % 9 9 9 9 10 8 11 11 11 11 10 8 10 10 10 15 15 10 10 15 15 10 15 15 15 15 15 15 15 15 15 15	44.2 26.94 47.2 32.5 31.6 41.32 24.1 28.4 40.4 48.26 47.72 33.52 99.88 33.3 32.7 30.31 39.01 39.01 39.46 40.11 29.88 33.3 32.7 30.31 39.01 39.46 40.11 27 39.46 39	2.1 3.62 3.9 5.29 5.72 5.1 4.2 3.87 5.9 4.3 5.39 7.07 4.3 12.3 3.48 4.72 3.41 5.78 6.91 5.73 4.2 5.3 4.2 5.3 4.2 5.3 4.2 5.3 4.2 5.3 4.2 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3	8 18 16 16 15 10 9 9 7 7 7 7 9 13 192 9 9 9 9 9 9 9 9 9 10 11 11 12 13 192 10 10 10 10 10 10 10 10 10 10	1.2% 5.4% 4.8% 4.9% 3.3% 3.2% 2.2% 2.3% 2.2% 2.3% 2.2% 2.3% 59.0% 59.0% 2.9% 3.3% 59.0% 2.9% 3.3% 59.0% 3.3% 3.6% 3.2% 3.2% 3.2% 3.2% 3.2% 3.2% 3.2% 3.2	$\begin{array}{c} 2.77 \ [1.29, 4.25]\\ 0.82 \ [0.14, 1.50]\\ 0.68 \ [-0.04, 1.40]\\ 0.84 \ [0.11, 1.56]\\ 0.18 \ [-0.70, 1.06]\\ 0.38 \ [-0.59, 1.27]\\ 0.45 \ [-0.59, 1.27]\\ 0.45 \ [-0.59, 1.27]\\ 0.45 \ [-0.59, 1.74]\\ 0.57 \ [-0.59, 1.74]\\ 0.57 \ [-0.59, 1.74]\\ 0.55 \ [-0.52, 1.63]\\ 0.50 \ [-0.22, 1.23]\\ 0.57 \ [-0.22, 1.23]\\ 0.55 \ [-0.22, 1.23]\\ 0.51 \ [0.30, 0.72]\\ 0.55 \ [-0.48, 1.39]\\ 0.17 \ [-0.75, 1.10]\\ 0.42 \ [-0.52, 1.36]\\ 0.22 \ [-0.52, 1.36]\\ 0.22 \ [-0.52, 1.36]\\ 0.22 \ [-0.52, 1.36]\\ 0.50 \ [-0.52, 1.36]\\ 0.50 \ [-0.52, 1.36]\\ 0.50 \ [-0.52, 1.36]\\ 0.50 \ [-0.54, 1.14]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.21]\\ 0.36 \ [-0.48, 1.21]\\ 0.36 \ [-0.48, 1.21]\\ 0.39 \ [0.11, 0.68]\\ \end{array}$	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 Figueira et al. 2020_ELAT Figueira et al. 2020_ELAT Gonzalo-Skok et al. 2019_UH Gortlieb et al. 2014_PT Hernández et al. 2018_R Hernández et al. 2018_R Matavulj et al. 2016_FP McCormick et al. 2010 Santos & Janeira 2008 Santos & Janeira 2008 Gonzalo-Skok et al. 2017_U16HC Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U16HS Ciacci & Bartolomei 2017_U18HS Gonzalo-Skok et al. 2017_U18 Gonzalo-Skok et al. 2017_U14 Yañez-García et al. 2017_U14 Yañez-García et al. 2017_U16 Subtotal (95% CI) Heterogeneity: Chi ² = 2.46, df = 9 (P = Test for overall effect: Z = 2.74 (P = 0.	$\begin{array}{c} 50.5\\ 29.99\\ 28.8\\ 52.27\\ 46.13\\ 6\\ 33.4\\ 42.51\\ 26.9\\ 33.5\\ 46\\ 50.07\\ 52.61\\ 9\\ 33.02\\ 36.68\\ 9\\ 9\\ 0.21); 1\\ 00001)\\ \hline 00001)\\ \hline 00001\\ 32.35\\ 40.23\\ 37.43\\ 40.8\\ 39.98\\ 52.40,23\\ 40.23\\ 40.8\\ 39.8\\ 30.2\\ 35.9\\ 36.2\\ 20.98; 1^2\\ =0.98); 1^2\\ =006) \end{array}$	2.2 3.3 3.3 3.13 3.01 4.3 2.8 72 2.8 3.33 3.36 6.2 4.2 9.7 $2^2 = 215$ 3.94 3.9	8 18 16 15 10 9 7 6 11 7 7 15 13 192 % 9 9 9 9 10 8 11 11 11 11 11 10 10 10 10 10	44.2 26.94 47.2 32.5 31.6 41.32 24.1 28.4 40.4 40.4 40.4 29.88 33.3 32.7 30.31 39.01 39.01 39.04 40.11 39.05 39.46 40.11 38.9 37.4 27 33.9	2.1 3.62 3.9 5.29 5.72 5.1 4.2 3.87 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.3 12.3 3.48 4.3 12.3 3.48 4.72 3.41 5.78 5.79 5.3 4.2 4.2 5.1 5.9 5.9 5.9 5.9 5.29 5.29 5.29 5.29 5.2	8 18 16 15 10 9 7 7 9 15 13 192 9 9 9 9 9 9 9 10 8 11 11 11 11 11 11 11 10 8 10 10 10 10 10 10 10 10 10 10	1.2% 5.4% 4.8% 4.9% 3.3% 3.2% 2.2% 1.3% 2.2% 2.2% 2.2% 2.2% 3.3% 59.0% 59.0% 2.2% 3.3% 59.0% 2.2% 3.3% 59.0% 3.3% 3.6% 3.2% 3.2% 3.2% 3.2% 3.2% 3.2% 3.2% 3.2	$\begin{array}{c} 2.77 \ [1.29, 4.25]\\ 0.82 \ [0.14, 1.50]\\ 0.68 \ [-0.04, 1.40]\\ 0.84 \ [0.11, 1.56]\\ 0.38 \ [-0.59, 0.54]\\ 0.18 \ [-0.70, 1.06]\\ 0.38 \ [-0.59, 1.27]\\ 0.45 \ [-0.62, 1.51]\\ 0.57 \ [-0.59, 1.74]\\ 0.55 \ [-0.59, 1.74]\\ 0.55 \ [-0.52, 1.63]\\ 0.50 \ [-0.22, 1.23]\\ 0.55 \ [-0.22, 1.63]\\ 0.50 \ [-0.22, 1.23]\\ 0.55 \ [-0.48, 1.37]\\ 0.55 \ [-0.48, 1.39]\\ 0.17 \ [-0.75, 1.10]\\ 0.42 \ [-0.54, 1.13]\\ 0.52 \ [-0.54, 1.13]\\ 0.52 \ [-0.54, 1.13]\\ 0.52 \ [-0.54, 1.14]\\ 0.52 \ [-0.48, 1.25]\\ 0.50 \ [-0.54, 1.14]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.21]\\ 0.36 \ [-0.48, 1.21]\\ 0.36 \ [-0.48, 1.21]\\ 0.39 \ [0.11, 0.68]\\ \end{array}$	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 FLAT Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_R Matavulj et al. 2018_R Matavulj et al. 2010_FP McCormick et al. 2016_FP McCormick et al. 2016_FP McCormick et al. 2016_SP McCormick et al. 2016_SP McCormick et al. 2016_SP McCormick et al. 2016_SP Meszler & Váczi 2019 Santos & Janeira 2008 Santos & Janeira 2008 Santos & Janeira 2018 Gottlieb et al. 2010 Subtotal (95% CI) Heterogeneity: Chi ² = 20.15, df = 16 (Test for overall effect: Z = 4.83 (P < 0. 1.1.2 MIXED STRENCTH AND CONDIT Arede et al. 2018 Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U18HS Gonzalo-Skok et al. 2017_U18 Subtotal (95% CI) Heterogeneity: Chi ² = 2.46, df = 9 (P = Test for overall effect: Z = 2.74 (P = 0. 1.1.3 ENDURANCE	$\begin{array}{c} 50.5\\ 29.99\\ 28.8\\ 52.27\\ 46.13\\ 6\\ 33.4\\ 45.13\\ 26.9\\ 33.4\\ 25.12\\ 26.9\\ 33.6\\ 50.07\\ 5\\ 5.61\\ 9\\ 31.96\\ 33.02\\ 36.68\\ 36.8\\$	2.2 3.3 3.3 3.13 3.01 4.3 2.8 722 8.8.1 6 2.8 3.33 3.36 6.2 4.2 9.7 $2^2 = 215$ 3.94 3.4 6.1 3.4 6.1 3.4 5.5	8 18 16 15 10 9 7 6 11 7 7 15 15 13 192 % 9 9 9 9 9 9 9 10 8 11 11 11 10 10 10 10 10 10 10	44.2 26.94 48.2 47.2 32.5 31.6 41.32 24.1 28.4 40.4 48.26 40.4 48.26 33.5 29.88 33.3 32.7 30.31 39.46 40.11 38.99 40.11 38.9 37.4 22.5 33.9	2.1 3.62 3.9 5.29 5.29 5.72 5.3 8.3 6.3 5.39 4.2 3.87 5.39 4.2 3.87 5.39 4.2 3.87 5.39 4.3 12.3 3.48 4.72 3.41 5.73 4.2 3.41 5.73 4.2 5.74 5.9 5.9 5.9 5.9 5.9 5.9 5.9 5.9 5.9 5.9	8 18 16 16 15 10 9 7 7 7 9 9 9 9 9 9 9 10 8 11 11 11 11 11 10 0 8 10 10 10 10 10 10 10 10 10 10	1.2% 5.4% 4.8% 4.9% 3.3% 2.2% 2.2% 2.2% 2.2% 2.2% 2.2% 5.9% 5.9% 5.9% 5.9% 5.9% 5.9% 5.9% 5.9	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04 , 1.40] 0.84 [0.11, 1.56] 0.38 [-0.70 , 1.06] 0.38 [-0.53 , 1.26] 0.38 [-0.53 , 1.26] 0.34 [-0.53 , 1.26] 0.35 [-0.59 , 1.74] 0.55 [-0.52 , 1.63] 0.55 [-0.52 , 1.63] 0.52 [-0.74 , 1.37] 0.55 [-0.22 , 1.23] 0.55 [-0.22 , 1.23] 0.55 [-0.48 , 1.39] 0.17 [-0.75 , 1.10] 0.42 [-0.52 , 1.63] 0.51 [0.30 , 0.72] 0.45 [-0.48 , 1.39] 0.17 [-0.75 , 1.10] 0.22 [-0.66 , 1.10] 0.22 [-0.66 , 1.10] 0.20 [-0.96 , 1.00] 0.30 [-0.54 , 1.14] 0.49 [-0.36 , 1.35] 0.50 [-0.35 , 1.35] 0.92 [0.3 , 1.81] 0.36 [-0.48 , 1.21] 0.39 [0.11 , 0.68]	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 FLAT Figueira et al. 2020_FLAT Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_UH Cottlieb et al. 2014_PT Hernández et al. 2018_R Matavulj et al. 2018_R Matavulj et al. 2010_FP McCormick et al. 2016_SP McCormick et al. 2017 Suntos & Janeira 2008 Santos & Janeira 2008 Santos & Janeira 2018 Subtotal (95% CI) Heterogeneity: Chi ² = 20.15, df = 16 (Test for overall effect: Z = 4.83 ($P < 0$. 1.1.2 MIXED STRENCTH AND CONDIT Arede et al. 2018 Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U18HS Conzalo-Skok et al. 2017_U18 Subtotal (95% CI) Heterogeneity: Chi ² = 2.46, df = 9 ($P =$ Test for overall effect: Z = 2.74 ($P = 0$. 1.1.3 ENDURANCE Attene et al. 2015b_IRST	$\begin{array}{c} 50.5\\ 29.99\\ 28.8\\ 52.27\\ 46.13\\ 6\\ 33.4\\ 45.12\\ 26.9\\ 33.5\\ 46\\ 50.07\\ 5\\ 26.19\\ 33.9\\ 33.5\\ 46\\ 50.07\\ 5\\ 26.19\\ 33.06\\ 33.68\\ 36.8\\ 36$	2.2 3.65 3.3 3.1 3.1 3.1 4.3 2.8 8.1 4.3 2.8 8.1 6.3 3.3 6.2 9.7 $2^2 = 215^2$ 4.94 4.94 5.5 5.1 6.2 5.1 6.2 5.1 6.2 5.1 6.2 5.1 6.2 5.1 6.2 5.1 6.2 5.1 6.2 5.1 6.2 5.1 6.2 5.1 6.2 5.1 6.2 5.1 6.2 5.2 5.2 5.2 5.2 5.2 5.2 5.2 5	8 18 16 16 15 10 9 7 6 11 7 7 9 15 13 192 % 9 9 9 9 9 10 8 11 11 11 12 9 9 9 9 9 9 9 9 9 9 9 9 9	44.2 26.94 48.2 47.2 31.6 41.32 24.1 28.4 40.4 48.26 40.7 33.52 33.53 32.7 30.31 33.52 33.3 32.7 30.31 33.54 40.41 40.4 40.4 48.26 33.3 32.7 33.9 46 40.11 38.96 40.11 38.96 40.11 38.96 37.4 35.5 33.9	2.1 3.62 3.9 5.29 5.72 5.1 4.2 3.87 5.9 8.3 5.39 7.07 3.89 5.3 4.3 12.3 3.41 5.78 6.91 5.78 6.91 5.78 6.91 5.78 6.91 5.72 5.3 4.2 3.41 2.8	8 18 16 16 15 10 9 7 6 11 7 7 9 9 9 9 10 8 11 11 11 11 10 9 9 9 9 9 9 9 9 9 9 9 9 9	1.2% 5.4% 4.8% 4.9% 3.3% 3.2% 2.2% 3.3% 2.2% 3.3% 2.2% 2.2	$\begin{array}{c} 2.77 \ [1.29, 4.25]\\ 0.82 \ [0.14, 1.50]\\ 0.68 \ [-0.04, 1.40]\\ 0.84 \ [0.11, 1.56]\\ 0.18 \ [-0.08, 0.54]\\ 0.18 \ [-0.59, 1.27]\\ 0.45 \ [-0.59, 1.27]\\ 0.45 \ [-0.59, 1.27]\\ 0.45 \ [-0.59, 1.27]\\ 0.45 \ [-0.52, 1.63]\\ 0.57 \ [-0.59, 1.74]\\ 0.52 \ [-0.52, 1.63]\\ 0.50 \ [-0.22, 1.23]\\ 0.51 \ [-0.22, 1.23]\\ 0.51 \ [-0.30, 0.72]\\ 0.51 \ [-0.30, 0.72]\\ 0.51 \ [-0.30, 0.72]\\ 0.51 \ [-0.30, 0.72]\\ 0.51 \ [-0.30, 0.72]\\ 0.51 \ [-0.30, 0.73]\\ 0.52 \ [-0.48, 1.39]\\ 0.17 \ [-0.75, 1.10]\\ 0.42 \ [-0.52, 1.63]\\ 0.22 \ [-0.64, 1.14]\\ 0.49 \ [-0.36, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.92 \ [0.03, 1.81]\\ 0.36 \ [-0.48, 1.21]\\ 0.36 \ [-0.48, 1.21]\\ 0.36 \ [-0.48, 1.21]\\ 0.36 \ [-0.48, 1.21]\\ 0.36 \ [-0.48, 1.21]\\ 0.37 \ [-0.57, 1.30]\\ 0.54 \ [-0.57, 1.30]\\ 0.55 \ [-0.57, 1.30]\\ 0.55 \ [-0.57, 1.30]\\ 0.55 \ [-0.57, 1.30]\\ 0.55 \ [-0.57, 1.30]\\ 0.55 \ [-0.57, 1.30]\\ 0.55 \ [-0.57, 1.30]\\ 0.55 \ [-0.57, 1.30]\\ 0.55 \ [-0.57, 1.30]\\ 0.55 \ [-0.57, 1.30$	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 FLAT Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_FT Hernández et al. 2018_R Matavulj et al. 2014_FT Matavulj et al. 2016_FP McCormick et al. 2016_SP McCormick et al. 2016_SP McCormick et al. 2016_SP McCormick et al. 2016_SP McCormick et al. 2016_SP Meszler & Váczi 2019 Santos & Janeira 2012 Tsimachidis et al. 2010 Subtotal (95% CI) Heterogeneity: Chi ² = 20.15, df = 16 (Test for overall effect: Z = 4.83 (P < 0. 1.12 MIXED STRENGTH AND CONDIT Arede et al. 2018 Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U18HS Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2019_U14 Yañez_García et al. 2019_U14 Yañez_García et al. 2019_U16 Yañez_García et al. 2019_U16 Yañez_García et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Chi ² = 2.46, df = 9 (P = Test for overall effect: Z = 2.74 (P = 0. 1.13 ENDURANCE Attene et al. 2015b_JRST Gottlieb et al. 2014_ST	$\begin{array}{c} 50.5\\ 29.99\\ 28.8\\ 52.27\\ 46.13\\ 6\\ 33.4\\ 42.51\\ 26.9\\ 33.5\\ 46\\ 50.07\\ 5\\ 26.19\\ 33.35\\ 46\\ 50.07\\ 5\\ 26.19\\ 33.02\\ 33.0$	2.2 3.3 3.3 3.1 3.0 4.3 2.8 8.1 5.8 8.1 5.8 8.1 6.2 9.7 $^2 = 215$ 3.94 4.95 5.51 6.1 5.75	8 18 16 16 15 10 9 7 6 11 7 7 9 15 15 15 15 15 15 15 15 15 15	44.2 26.94 48.2 47.2 24.1 28.4 40.4 48.26 24.1 28.4 40.4 48.26 33.5 33.3 32.7 30.31 39.01 38.9 37.4 39.9 37.8 35.3 32.9 37.8 35.3 40.6	2.1 3.62 3.29 5.72 5.1 4.2 3.87 6.3 5.9 4.3 12.3 3.41 5.78 6.91 5.78 6.91 5.78 6.91 5.78 6.91 5.78 6.91 5.78 6.91 5.78 6.91 5.78 6.9 5.72 5.72 5.9 5.9 5.9 5.9 5.9 5.9 5.9 5.9 5.9 5.9	8 18 16 16 10 10 9 7 7 7 7 7 13 192 9 9 9 9 9 9 10 8 11 11 11 11 10 8 9 9 9 9 9 9 9 9 9 9 9 9 9	1.2% 5.4% 4.8% 4.9% 3.3% 3.2% 2.2% 1.9% 2.2% 2.3% 59.0% 2.2% 59.0% 2.9% 3.3% 3.5% 3.5% 3.5% 3.5% 3.5% 3.2% 3.5% 3.5% 3.2% 4.6% 59.0% 50.0% 59.0% 50.0%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04, 1.40] 0.84 [0.11, 1.56] -0.18 [-0.89, 0.54] 0.18 [-0.59, 1.27] 0.45 [-0.59, 1.27] 0.45 [-0.62, 1.51] 0.57 [-0.59, 1.27] 0.45 [-0.21, 1.76] 0.52 [-0.52, 1.63] 0.50 [-0.22, 1.23] 0.55 [-0.52, 1.63] 0.55 [-0.22, 1.23] 0.55 [-0.22, 1.23] 0.55 [-0.22, 1.23] 0.55 [-0.22, 1.23] 0.55 [-0.22, 1.23] 0.55 [-0.22, 1.23] 0.55 [-0.22, 1.23] 0.51 [0.30, 0.72] 0.45 [-0.48, 1.39] 0.17 [-0.75, 1.10] 0.42 [-0.52, 1.36] 0.22 [-0.66, 1.10] 0.22 [-0.66, 1.10] 0.22 [-0.66, 1.35] 0.50 [-0.35, 1.35] 0.59 [0.13, 1.66] 0.39 [0.11, 0.68]	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 FIGUERI et al. 2020 FIGUERI et al. 2020_FLAT Figueria et al. 2020_SLOPE Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_FT Hernández et al. 2018_R Matavulj et al. 2014_FT Matavulj et al. 2016_FP McCormick et al. 2016_FP McCormick et al. 2016_SP McCormick et al. 2016_SP McCormick et al. 2016_SP McCormick et al. 2016_SP Meszler & Váczi 2019 Santos & Janeira 2008 Santos & Janeira 2012 Tsimachidis et al. 2010 Subtotal (95% CI) Heterogeneity: Chi ² = 20.15, df = 16 (Test for overall effect: Z = 4.83 ($P < 0$. 1.1.2 MIXED STRENGTH AND CONDIT Arede et al. 2017_U16HC Ciacci & Bartolomei 2017_U18HS Gonzalo-Skok et al. 2019_U14 Yańez-Garcia et al. 2019_U14 Yańez-Garcia et al. 2019_U16 Yańez-Garcia et	$\begin{array}{c} 50.5\\ 29.99\\ 28.8\\ 52.27\\ 46.13\\ 6\\ 33.4\\ 45.12\\ 26.9\\ 33.5\\ 46\\ 50.07\\ 5\\ 26.19\\ 33.5\\ 46\\ 50.07\\ 5\\ 26.19\\ 33.02$	2.2 1.65 1.3 1.3 1.3 1.3 1.3 1.3 1.3 2.8 1.72 5.8 8.1 6 1.33 1.3 6 1.33 6 1.33 1.3 6 1.33 1.3 6 1.33 1.3 1.3 1.3 1.3 1.3 1.3 1.	8 18 16 16 15 10 9 7 6 11 7 9 9 15 13 192 % 9 9 9 9 9 9 10 8 11 11 12 8 10 10 9 7 7 8 10 10 9 9 15 15 15 15 15 15 15 15 15 15	44.2 26.94 48.2 47.2 23.1 6 41.32 24.1 28.4 40.4 48.26 33.3 32.7 33.5 33.3 32.7 30.31 38.0 33.3 32.7 33.5 33.4 0.1 38.9 37.8 37.8 35.3 40.6	2.1 3.62 5.29 5.72 3.87 5.9 8.3 5.9 8.3 5.9 5.9 4.3 12.3 3.48 4.72 3.41 5.3 4.2 6.9 1 5.78 6.9 1 5.78 6.9 1 5.78 6.1 1 5.3 8 4.2 6.1 1 5.78 4.2 6.1 1 5.79 5.79 5.79 5.99 5.99 5.99 5.99 5.99	8 18 16 16 10 10 9 9 7 7 7 7 7 13 192 9 9 9 9 9 9 9 9 9 9 9 9 9	1.2% 5.4% 4.8% 4.9% 3.3% 2.2% 2.2% 2.2% 2.2% 2.2% 59.0% 59.0% 3.3% 3.3% 3.2% 3.3% 3.5% 3.5% 3.2% 3.5% 3.2% 3.5% 3.2% 3.5% 3.2% 4.2% 59.0%	$\begin{array}{c} 2.77 \ [1.29, 4.25]\\ 0.82 \ [0.14, 1.50]\\ 0.68 \ [-0.04, 1.40]\\ 0.84 \ [0.11, 1.56]\\ -0.18 \ [-0.08, 0.54]\\ 0.18 \ [-0.59, 1.27]\\ 0.45 \ [-0.59, 1.27]\\ 0.45 \ [-0.59, 1.27]\\ 0.45 \ [-0.59, 1.27]\\ 0.45 \ [-0.52, 1.63]\\ 0.57 \ [-0.59, 1.74]\\ 0.55 \ [-0.52, 1.63]\\ 0.50 \ [-0.22, 1.23]\\ 0.55 \ [-0.52, 1.63]\\ 0.51 \ [-0.22, 1.23]\\ 0.55 \ [-0.52, 1.63]\\ 0.51 \ [-0.22, 1.23]\\ 0.55 \ [-0.52, 1.63]\\ 0.51 \ [-0.30, 0.72]\\ 0.45 \ [-0.48, 1.39]\\ 0.17 \ [-0.75, 1.10]\\ 0.42 \ [-0.52, 1.35]\\ 0.22 \ [-0.66, 1.10]\\ 0.22 \ [-0.52, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.38, 1.23]\\ 0.36 \ [-0.48, 1.21]\\ 0.36 \ [-0.48, 1.21]\\ 0.36 \ [-0.48, 1.21]\\ 0.36 \ [-0.48, 1.21]\\ 0.36 \ [-0.57, 1.20]\\ 0.43 \ [-0.57, 1.20]\\ 0.43 \ [-0.10, 0.97]\\ \end{array}$	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 FLAT Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_R Matavulj et al. 2018_R Matavulj et al. 2016_FP McCornick et al. 2016_SP McCornick et al. 2017_S Subtotal (95% CI) Heterogeneity: Chi ² = 20.15, df = 16 (Tast for overall effect: Z = 4.83 ($P < 0$. 1.1.2 MIXED STRENGTH AND CONDIT Arede et al. 2018 Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U18HS Gonzalo-Skok et al. 2017_U18 Subtotal (95% CI) Heterogeneity: Chi ² = 2.46, df = 9 ($P =$ Test for overall effect: Z = 2.74 ($P = 0$. 1.1.3 ENDURANCE Attene et al. 2015b_IRST Attene et al. 2015b_IRST Gottlieb et al. 2014_ST Subtotal (95% CI) Heterogeneity: Chi ² = 0.27, df = 2 ($P = 0$.	$\begin{array}{c} 50.5\\ 29.99\\ 28.8\\ 52.27\\ 46.13\\ 6\\ 33.4\\ 45.12\\ 26.9\\ 33.5\\ 46\\ 50.07\\ 5\\ 26.19\\ 33.02\\ 33.02\\ 33.02\\ 33.02\\ 33.02\\ 33.02\\ 33.02\\ 36.68\\ 36.8\\$	2.2 1.65 3.3 3.13 1.01 4.3 2.8 1.72 5.8 8.1 6 3.33 6 4.8 8.1 6 2 2 2 2 2 2 2 2 2 3.4 4.3 3.3 6 6 2 4.2 8.1 6 6 2 4.2 8.1 6 2 4.2 8.1 6 2 4.2 8.1 6 2 4.2 8.1 6 6 2 4.2 8.1 6 6 2 4.2 8.1 6 6 2 4.2 8.1 6 6 2 4.2 8.1 6 2 4.2 8.1 6 6 2 4.2 8.1 6 2 4.2 8.1 6 2 4.2 8.1 6 2 2 2 2 2 2 2 2 2 3.3 4 8 8 1 6 2 4 8 1 6 2 4 8 1 6 2 4 8 1 6 2 4 8 1 6 2 4 8 1 6 2 4 8 1 6 2 4 8 1 6 2 3 3 4 8 1 6 2 3 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5	8 18 16 16 15 10 9 7 7 15 15 13 192 % 9 9 9 9 9 10 8 11 11 11 11 11 10 9 9 9 9 9 9 9 9 10 8 11 10 10 10 10 10 10 10 10 10	44.2 26.94 48.2 47.2 23.1 31.6 41.32 24.1 28.4 40.4 48.26 33.3 32.7 30.31 39.01 39.01 39.55 39.46 (0.11 38.9 37.4 32.5 33.9 37.8 35.3 40.6	2.1 3.62 5.29 5.72 8.3 5.9 8.3 5.9 8.3 5.9 8.3 5.9 8.3 5.9 4.3 12.3 3.48 4.72 3.41 5.78 6.9 4.3 12.3 3.48 4.72 3.41 5.78 6.1 5.78 6.1 5.78 6.3 5.70 7.07 5.70 7.07 5.70 7.07 5.70 7.07 5.70 7.07 5.70 7.07 7.07	8 18 16 16 10 9 7 7 9 9 9 9 9 9 9 9 9 9 10 8 11 11 11 10 9 9 9 9 9 9 9 9 9 9 9 9 9	1.2% 5.4% 4.8% 4.9% 3.3% 3.2% 2.2% 3.3% 2.2% 3.3% 2.2% 3.3% 2.2% 59.0% 2.2% 3.3% 59.0% 2.2% 3.3% 3.3% 3.5% 3.2% 3.2% 3.3% 3.2% 3.3% 3.2% 3.3% 3.2% 3.3% 3.2% 3.3% 3.3	$\begin{array}{c} 2.77 \ [1.29, 4.25]\\ 0.82 \ [0.14, 1.50]\\ 0.68 \ [-0.04, 1.40]\\ 0.84 \ [0.11, 1.56]\\ 0.18 \ [-0.08, 0.54]\\ 0.18 \ [-0.59, 1.27]\\ 0.45 \ [-0.59, 1.27]\\ 0.45 \ [-0.59, 1.27]\\ 0.45 \ [-0.59, 1.27]\\ 0.45 \ [-0.52, 1.63]\\ 0.57 \ [-0.59, 1.74]\\ 0.55 \ [-0.52, 1.63]\\ 0.50 \ [-0.22, 1.23]\\ 0.55 \ [-0.52, 1.63]\\ 0.50 \ [-0.22, 1.23]\\ 0.51 \ [0.30, 0.72]\\ 0.51 \ [0.30, 0.72]\\ 0.51 \ [0.30, 0.72]\\ 0.45 \ [-0.48, 1.39]\\ 0.17 \ [-0.75, 1.10]\\ 0.42 \ [-0.52, 1.63]\\ 0.22 \ [-0.64, 1.14]\\ 0.49 \ [-0.36, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.50 \ [-0.35, 1.35]\\ 0.36 \ [-0.48, 1.21]\\ 0.36 \ [-0.48, 1.21]\\ 0.36 \ [-0.48, 1.21]\\ 0.37 \ [-0.57, 1.30]\\ 0.32 \ [-0.57, 1.20]\\ 0.43 \ [-0.10, 0.97]\\ \end{array}$	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 FLAT Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_UH Gottieb et al. 2014_PT Hernández et al. 2018_R Matavulj et al. 2014_PT McCormick et al. 2016_FP McCormick et al. 2016_SP McCormick et al. 2010_S Subtoal (95% CI) Heterogeneity: Chi ² = 20.15, df = 16 (Test for overall effect: Z = 4.83 ($P < 0$. 1.1.2 MIXED STRENGTH AND CONDIT Arede et al. 2017_U16HC Ciacci & Bartolomei 2017_U18HC Gonzalo-Skok et al. 2019_U14 Yañez-Garcia et al. 2019_U14 Yañez-Garcia et al. 2019_U16 Heterogeneity: Chi ² = 2.46, df = 9 ($P =$ Test for overall effect: Z = 2.74 ($P = 0$. 1.1.3 ENDURANCE Attene et al. 2015b_JRST Gottlieb et al. 2014_ST Subtoal (95% CI) Heterogeneity: Chi ² = 0.27, df = 2 ($P =$ Test for overall effect: Z = 1.60 ($P = 0$. Total (95% CI)	$\begin{array}{c} 50.5\\ 29.99\\ 28.8\\ 52.27\\ 46.13\\ 6\\ 33.4\\ 45.12\\ 26.9\\ 33.5\\ 46\\ 50.07\\ 5\\ 26.9\\ 33.5\\ 46\\ 50.07\\ 5\\ 26.19\\ 33.02\\$	2.2 1.65 1.3 1.3 1.3 1.3 1.3 1.4 2.8 1.3 2.8 1.3 3.3 6 1.3 3.3 6 1.3 3.3 6 1.3 3.3 6 1.4 8.1 6 1.3 3.3 6 1.3 3.3 6 1.4 8.1 6 1.3 3.3 1.4 8.1 6 1.4 8.5 5.5 1.5 1.4 8.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1	8 18 16 16 15 10 9 7 7 15 15 13 192 % 9 9 9 9 9 9 10 8 11 11 11 11 11 10 8 10 28 320	44.2 26.94 48.2 47.2 31.6 41.32 24.1 28.4 40.4 48.26 33.3 32.7 30.31 39.01 39.06 39.46 0.11 38.9 37.4 32.5 33.9 37.8 35.3 40.6	2.1 3.62 5.29 5.72 5.3 6.3 5.39 5.39 6.3 5.39 4.3 12.3 3.48 4.72 5.70 7.07 3.89 4.3 12.3 3.41 5.73 4.2 3.7 6.1 5.3 4.2 8.3 4.2 8.3 4.4 8.3 4.4 8.3 4.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 8.3 9.4 8.3 9.4 8.3 9.4 8.3 9.4 8.3 8.4 8.3 8.4 8.4 8.4 8.4 8.4 8.4 8.4 8.4 8.4 8.4	8 18 16 16 10 10 9 7 7 7 9 9 9 9 9 9 9 9 9 9 9 10 8 11 11 11 7 7 9 9 9 9 9 9 9 9 9 9 9 9 9	1.2% 5.4% 4.8% 4.9% 3.3% 2.2% 2.2% 2.9% 2.2% 2.2% 2.2% 2.2% 2.2	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04, 1.40] 0.84 [0.11, 1.56] -0.18 [-0.89, 0.54] 0.18 [-0.59, 1.27] 0.45 [-0.59, 1.27] 0.45 [-0.59, 1.27] 0.45 [-0.52, 1.63] 0.57 [-0.59, 1.74] 0.55 [-0.52, 1.63] 0.50 [-0.22, 1.23] 0.51 [0.30, 0.72] 0.45 [-0.48, 1.39] 0.17 [-0.75, 1.10] 0.42 [-0.52, 1.36] 0.22 [-0.66, 1.10] 0.22 [-0.66, 1.10] 0.22 [-0.66, 1.35] 0.50 [-0.35, 1.35] 0.52 [-0.57, 1.20] 0.43 [-0.10, 0.97] 0.47 [0.31, 0.63]	
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 FLAT Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_FT Hernández et al. 2018_R Matavulj et al. 2014_PT Hernández et al. 2016_FP McCormick et al. 2016_SP McCormick et al. 2016_SP McCormick et al. 2016_SP McCormick et al. 2016_SP McCormick et al. 2016_SP Meszler & Váczi 2019 Santos & Janeira 2012 Tsimachidis et al. 2010 Subtotal (95% CI) Heterogeneity: Chi ² = 20.15, df = 16 (Test for overall effect: Z = 4.83 (P < 0. 1.12 MIXED STRENGTH AND CONDIT Arede et al. 2018 Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U18HS Gonzalo-Skok et al. 2019_U14 Yañez_García et al. 2019_U14 Yañez_García et al. 2019_U16 Yañez_García et al. 2019_U16 Yañez_García et al. 2019_U16 Yañez_García et al. 2019_U16 Yañez_García et al. 2019_U17 Heterogeneity: Chi ² = 2.46, df = 9 (P = 7 Est for overall effect: Z = 2.74 (P = 0. 1.13 ENDURANCE Attene et al. 2015b_JRST Gottileb et al. 2014_ST Subtotal (95% CI) Heterogeneity: Chi ² = 0.27, df = 2 (P = 7 Est for overall effect: Z = 2.33.1, df = 29 (D Test for overall effect: Z = 2.33.1, df = 29 (D Test for overall effect: Z = 5.74 (P < 0.	$\begin{array}{c} 50.5 \\ 29.99 \\ 28.8 \\ 52.27 \\ 46.13 \\ 63.4 \\ 33.4 \\ 45.12 \\ 26.9 \\ 33.5 \\ 46 \\ 50.07 \\ 52.61 \\ 93.196 \\ 33.02 \\$	2.2 1.65 1.3 1.3 1.3 1.3 1.3 1.4 2.8 1.72 5.8 8.1 6 1.33 1.3 6 1.33 1.3 6 1.33 1.3 1.3 1.3 1.3 1.3 1.3 1.	8 18 16 16 16 10 9 7 6 11 7 7 15 15 15 15 15 15 15 15 15 15	44.2 26.94 48.2 47.2 24.1 28.4 40.4 48.26 24.1 28.4 40.4 48.26 33.5 33.3 32.7 30.31 39.01 33.3 33.3 32.7 30.31 39.01 38.9 37.4 35.5 33.9 37.8 35.3 40.6	2.1 3.62 5.29 5.72 5.1 4.2 5.3 8.3 6.3 5.39 8.3 6.3 5.39 4.3 12.3 3.48 4.72 5.70 7 3.89 4.3 12.3 3.41 5.78 6.91 5.73 4.2 3.7 6.1	8 18 16 16 10 10 9 7 7 7 9 9 9 9 9 9 9 9 9 9 9 9 9	1.2% 5.4% 4.8% 4.9% 3.3% 3.2% 2.2% 2.3% 2.2% 2.2% 2.2% 59.0% 2.2% 59.0% 2.9% 3.3% 3.5% 3.5% 3.5% 3.5% 3.5% 3.2% 3.5% 3.2% 4.6% 59.0% 2.9% 3.3% 2.9% 3.3% 3.5% 3.2% 4.2% 59.0% 50.0%	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04, 1.40] 0.84 [0.11, 1.56] -0.18 [-0.89, 0.54] 0.18 [-0.59, 1.27] 0.45 [-0.59, 1.27] 0.45 [-0.59, 1.27] 0.45 [-0.52, 1.63] 0.50 [-0.52, 1.63] 0.50 [-0.52, 1.63] 0.51 [0.30, 0.72] 0.45 [-0.48, 1.39] 0.51 [0.30, 0.72] 0.45 [-0.48, 1.39] 0.77 [0.03, 1.52] 0.36 [-0.42, 1.13] 0.51 [0.30, 0.72] 0.45 [-0.48, 1.39] 0.17 [-0.75, 1.10] 0.42 [-0.52, 1.36] 0.22 [-0.66, 1.10] 0.22 [-0.66, 1.10] 0.30 [-0.35, 1.35] 0.39 [0.11, 0.68] 0.43 [-0.48, 1.21] 0.36 [-0.48, 1.21] 0.36 [-0.48, 1.21] 0.37 [-0.57, 1.30] 0.32 [-0.57, 1.20] 0.43 [-0.10, 0.97] 0.47 [0.31, 0.63]	• • • • • • • • • • • • • • • • • • •
1.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Attene et al. 2015 Bouteraa et al. 2020 FLAT Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_BV Conzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_R Matavulj et al. 2018_R Matavulj et al. 2016_FP McCormick et al. 2016_SP McCormick et al. 2016_SP McCormick et al. 2016_SP McCormick et al. 2016_SP McCormick et al. 2016_SP Meszler & Váczi 2019 Santos & Janeira 2008 Santos & Janeira 2008 Subtotal (95% CI) Heterogeneity: Chi ² = 20.15, df = 16 (Test for overall effect: Z = 4.83 (P < 0. 1.1.2 MIXED STRENGTH AND CONDIT Arede et al. 2018 Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U16HC Ciacci & Bartolomei 2017_U18HS Conzalo-Skok et al. 2019_U14 Yańez-Garcia et al. 2019_U14 Yańez-Garcia et al. 2019_U14 Yańez-Garcia et al. 2019_U16 Heterogeneity: Chi ² = 2.46, df = 9 (P = Test for overall effect: Z = 2.74 (P = 0. 1.1.3 ENDURANCE Attene et al. 2015b_JRST Gottlieb et al. 2014_ST Subtotal (95% CI) Heterogeneity: Chi ² = 2.3.31, df = 29 (T Test for overall effect: Z = 2.74 (P = 0. Total (95% CI) Heterogeneity: Chi ² = 2.3.31, df = 29 (T Test for overall effect: Z = 2.74 (P = 0. Total (95% CI)	$\begin{array}{c} 50.5\\ 29.99\\ 28.8\\ 52.27\\ 46.13\\ 6\\ 33.4\\ 45.13\\ 26.9\\ 33.5\\ 46\\ 50.07\\ 5\\ 26.19\\ 33.5\\ 46\\ 50.07\\ 5\\ 26.19\\ 33.02$	2.2 1.65 1.3 1.3 1.3 1.3 1.4 2.8 1.72 5.8 8.1 6 1.33 1.3 6 1.33 1.33 6 1.48 6.2 2.48 1.48 6.2 2.49 9.7 2 ² = 215 1.94 1.9	8 18 16 16 16 10 9 7 6 11 7 7 15 15 15 15 15 15 15 15 15 15	44.2 26.94 48.2 47.2 24.1 28.4 40.4 48.26 24.1 28.4 40.4 48.26 33.3 32.7 30.31 39.01 38.9 37.4 35.3 35.3 40.6 1 ² = 0%	2.1 3.62 5.29 5.72 5.1 4.2 5.3 8.3 6.3 5.39 8.3 6.3 5.39 4.3 12.3 3.48 4.72 5.79 4.3 12.3 3.48 4.72 5.79 6.1 5.3 4.2 3.7 6.1 5.79 4.3 12.3 3.48 4.42 5.70 4.3 5.70 5.70 5.70 5.70 5.70 5.70 5.70 5.70	8 18 16 16 10 10 9 7 7 7 9 9 9 9 9 9 9 9 9 9 9 9 9	1.2% 5.4% 4.8% 4.9% 3.3% 3.2% 2.2% 2.3% 2.2% 2.3% 59.0% 2.2% 59.0% 2.9% 3.3% 3.5% 3.5% 3.5% 3.5% 3.5% 3.2% 3.5% 3.2% 3.5% 3.2% 4.6% 59.0% 2.9% 3.3% 2.9% 3.3% 3.5% 3.2% 4.2% 59.0% 50.0% 5	2.77 [1.29, 4.25] 0.82 [0.14, 1.50] 0.68 [-0.04, 1.40] 0.84 [0.11, 1.56] -0.18 [-0.89, 0.54] 0.18 [-0.59, 1.27] 0.45 [-0.59, 1.27] 0.45 [-0.59, 1.27] 0.45 [-0.52, 1.51] 0.55 [-0.52, 1.63] 0.50 [-0.52, 1.63] 0.50 [-0.22, 1.23] 0.55 [-0.52, 1.63] 0.51 [0.30, 0.72] 0.45 [-0.48, 1.39] 0.17 [-0.75, 1.10] 0.42 [-0.52, 1.36] 0.22 [-0.66, 1.10] 0.22 [-0.66, 1.10] 0.22 [-0.66, 1.10] 0.22 [-0.66, 1.35] 0.50 [-0.35, 1.35] 0.50 [-0.35, 1.35] 0.50 [-0.35, 1.35] 0.50 [-0.38, 1.31] 0.51 [0.30, 0.77] 0.43 [-0.14, 1.24] 0.45 [-0.48, 1.21] 0.50 [-0.35, 1.35] 0.50 [-0.35, 1.35] 0.50 [-0.35, 1.35] 0.52 [-0.57, 1.20] 0.43 [-0.10, 0.97] 0.47 [0.31, 0.63]	• • • • • • • • • • • • • • • • • • •

Figure 4. Forest Plot comparing the effect of multidisciplinary interventions on neuromuscular power vertical (NPV) considering sub-groups analysis for age (**A**), gender (**B**), level (**C**) and type of intervention (**D**) [49,50,52,62–64,66–68,70–78].

3.4.1. Gender

Figure 4B displays the forest plot for gender sub-groups analysis on NPV. A significant positive small effect was found with low levels of heterogeneity both in female (SMD, 0.48; 95% CI: 0.11 to 0.86; I^2 , 16%; Z, 2.51; p = 0.01) and male (SMD, 0.46; 95% CI: 0.29 to 0.64; I^2 , 0%; Z, 5.16; p < 0.0001) sub-groups.

3.4.2. Competitive Level

Figure 4C shows the forest plot for the competitive level analysis on NPV. A significant positive small effect was evident in both elite (SMD, 0.47; 95% CI: 0.28 to 0.67; I^2 , 0%; *Z*, 4.76; *p* < 0.00001) and amateur (SMD, 0.47; 95% CI: 0.18 to 0.73; I^2 , 0%; *Z*, 3.21; *p* = 0.001) competitive level with low heterogeneity in the two sub-groups.

3.4.3. Training Type

Figure 4D displays the forest plot for training type analysis on NPV. All the sub-groups showed low levels of heterogeneity (I², >21%). Both plyometric training (SMD, 0.51; 95% CI: 0.30 to 0.72; I², 21%; Z, 4.83; p < 0.0001) and mixed strength and conditioning interventions (SMD, 0.39; 95% CI: 0.11 to 0.68; I², 0%; Z, 2.74; p = 0.006) reached a significant positive effect in comparison to endurance training (SMD, 0.43; 95% CI: -0.10 to 0.97; I², 0%; Z, 1.60; p = 0.08) with moderate and small effects, respectively.

3.5. Effect on Neuromuscular Power Horizontal

Figure 5 displays the forest plot for NPH. Twenty-four trials were included for analysis [49–51,61,62,64–68,70,71,74,77,78] with a total of 254 participants. A significant overall moderate positive effect was found in NPH; however, moderate levels of heterogeneity were evident (SMD, -0.55; 95% CI: -0.88 to -0.22; I², 68%; Z, 3.23; p = 0.001).

	Post			Pre			9	Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
Aksović et al. 2020	3.36	0.169	16	3.48	0.149	16	4.9%	-0.73 [-1.45, -0.02]		
Arede et al. 2018	5.5	0.32	9	5.54	0.2	9	4.2%	-0.14 [-1.07, 0.78]		
Asadi et al. 2016	7.45	0.41	8	8.87	0.46	8	2.6%	-3.08 [-4.65, -1.51]		
Attene et al. 2014_IT	6.41	0.1	8	6.83	0.24	8	3.2%	-2.16 [-3.47, -0.85]		
Attene et al. 2014_RST	6.53	0.19	8	6.74	0.3	8	3.9%	-0.79 [-1.82, 0.24]		
Attene et al. 2015b_IRST	5.959	0.18	9	5.68	0.198	9	3.8%	1.40 [0.34, 2.46]	—	
Attene et al. 2015b_RST	5.94	0.31	9	6.04	0.35	9	4.2%	-0.29 [-1.22, 0.64]		
Bouteraa et al. 2020	10.6	0.4	16	11.3	0.6	16	4.7%	-1.34 [-2.11, -0.56]		
Figueira et al. 2020_FLAT	13.21	1.88	15	11.62	0.77	15	4.7%	1.08 [0.30, 1.85]		
Figueira et al. 2020_SLOPE	13.11	0.74	16	14.37	0.8	16	4.6%	-1.59 [-2.40, -0.79]		
Gonzalo-Skok et al. 2016	7.4	0.2	11	7.52	0.2	11	4.4%	-0.58 [-1.43, 0.28]	+	
Gonzalo-Skok et al. 2017_BIL	6.56	0.2	11	6.63	0.24	11	4.5%	-0.30 [-1.15, 0.54]		
Gonzalo-Skok et al. 2017_UNI	6.57	0.23	11	6.5	0.18	11	4.5%	0.33 [-0.52, 1.17]	- -	
Gonzalo-Skok et al. 2019_BV	7.21	0.4	10	7.37	0.41	10	4.3%	-0.38 [-1.26, 0.51]		
Gonzalo-Skok et al. 2019_UH	7.01	0.19	10	7.25	0.22	10	4.1%	-1.12 [-2.08, -0.16]		
Gottlieb et al. 2014_PT	3.01	0.13	9	3.03	0.12	9	4.2%	-0.15 [-1.08, 0.77]		
Gottlieb et al. 2014_ST	2.99	0.07	10	3.07	0.11	10	4.2%	-0.83 [-1.75, 0.09]		
Hernández et al. 2018_NR	11	1.1	7	12.3	1.1	7	3.6%	-1.11 [-2.26, 0.05]		
Hernández et al. 2018_R	10.3	0.7	6	12.1	1.1	6	2.9%	-1.80 [-3.24, -0.37]		
Meszler & Váczi 2019	11.13	0.63	9	10.96	0.48	9	4.2%	0.29 [-0.64, 1.22]	_ 	
Tsimachidis et al. 2010	5.02	0.23	13	5.29	0.7	13	4.7%	-0.50 [-1.28, 0.28]	+	
Yañez-García et al. 2019_U14	3.34	0.18	11	3.46	0.19	11	4.4%	-0.62 [-1.48, 0.24]		
Yañez-García et al. 2019_U16	3.14	0.1	11	3.18	0.11	11	4.5%	-0.37 [-1.21, 0.48]		
Yañez-García et al. 2019_U18	3.09	0.11	11	3.11	0.11	11	4.5%	-0.17 [-1.01, 0.66]		
Total (95% CI)			254			254	100.0%	-0.55 [-0.88, -0.22]	•	
Heterogeneity: $Tau^2 = 0.46$; $Chi^2 = 7$	2.32, d	f = 23 (P < 0.0	0001);	$l^2 = 68\%$	6		-		
Test for overall effect: Z = 3.23 (P =	0.001)								-4 -2 U 2 4 Positive effects Negative effects	



3.5.1. Age

Figure 6A shows the forest plot for the age sub-groups analysis on NPH. Moderate to high level of heterogeneity was found in all the analysis except from the U-12 group with low levels (I², 0%, p = 0.46). Significant large positive effect was found in the U-12 sub-groups (SMD, -1.38; 95% CI: -2.28 to -0.48; I², 0%; *Z*, 3.01; p = 0.003). No significant effect was found either in the U-14 (SMD, -0.52; 95% CI: -1.43 to 0.43; I², 84%; *Z*, 1.07;

Study or Subgroup	Mean	Post SD	Total	Mean	Pre SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Hernández et al. 2018 NR	11	1.1	7	12.3	1.1	7	3.6%	-1.11 [-2.26, 0.05]	
Hernández et al. 2018 R	10.3	0.7	6	12.1	1.1	6	2.9%	-1.80 [-3.24, -0.37]	
ubtotal (95% CI)			13			13	6.5%	-1.38 [-2.28, -0.48]	•
leterogeneity: $Tau^2 = 0.00$; $Chi^2 =$ fest for overall effect: $Z = 3.01$ (P	= 0.55, df = = 0.003)	= 1 (P =	0.46);	$ ^2 = 0\%$					
.1.2 U-14									
igueira et al. 2020_FLAT	13.21	1.88	15	11.62	0.77	15	4.7%	1.08 [0.30, 1.85]	
igueira et al. 2020_SLOPE	13.11	0.74	16	14.37	0.8	16	4.6%	-1.59 [-2.40, -0.79]	
onzalo-Skok et al. 2019_BV	7.21	0.4	10	7.37	0.41	10	4.3%	-0.38 [-1.26, 0.51]	
ionzalo-Skok et al. 2019_UH	7.01	0.19	10	7.25	0.22	10	4.1%	-1.12 [-2.08, -0.16]	
anez-Garcia et al. 2019_014	3.34	0.18	11	3.46	0.19	11	4.4%	-0.62 [-1.48, 0.24]	
eterogeneity: $Tau^2 = 0.08$: Chi ² -	- 24 72 df	= 4 (P	< 0.00	01)· 1 ² -	84%	02	22.270	-0.52 [-1.47, 0.45]	
est for overall effect: $Z = 1.07$ (P	= 0.29)	= 4 (P	< 0.000	51), 1 =	0470				
.1.3 U-16									
ksović et al. 2020	3.36	0.169	16	3.48	0.149	16	4.9%	-0.73 [-1.45, -0.02]	
rede et al. 2018	5.5	0.32	9	5.54	0.2	9	4.2%	-0.14 [-1.07, 0.78]	
Attene et al. 2014_IT	6.41	0.1	8	6.83	0.24	8	3.2%	-2.16 [-3.47, -0.85]	
Attene et al. 2014_RST	6.53	0.19	8	6.74	0.3	8	3.9%	-0.79 [-1.82, 0.24]	
Attene et al. 2015b_IRST	5.959	0.18	9	5.68	0.198	9	3.8%	1.40 [0.34, 2.46]	
Attene et al. 2015D_RST	5.94	0.31	9	6.04	0.35	9	4.2%	-0.29 [-1.22, 0.64]	
Cottlieb et al 2014_PT	3.01	0.13	10	3.03	0.12	10	4.2%	-0.15 [-1.08, 0.77]	
añez-García et al 2019 1116	2.99	0.07	11	3.18	0.11	11	4.2%	-0.37 [-1.75, 0.09]	
Subtotal (95% CI)	5.14	0.1	89	5.10	0.11	89	37.2%	-0.42 [-0.93. 0.09]	•
leterogeneity: $Tau^2 = 0.37$; $Chi^2 =$	= 20.96, df	= 8 (P =	= 0.00	7); l ² =	62%				•
est for overall effect: $Z = 1.63$ (P	= 0.10)								
.1.4 U-18		0.41	~	0.07	0.15	~	3 694	2081465 1855	
Isadi et al. 2016	7.45	0.41	8	8.87	0.46	8	2.6%	-3.08 [-4.65, -1.51]	
Souteraa et al. 2020	10.6	0.4	16	11.3	0.6	16	4.7%	-1.34 [-2.11, -0.56]	
Conzalo-Skok et al. 2017 RI	6.56	0.2	11	6.63	0.2	11	4.470	-0.30 [-1.45, 0.28]	
Gonzalo-Skok et al. 2017 LINI	6.57	0.23	11	6.5	0.18	11	4.5%	0.33 [-0.52 1 17]	
Meszler & Váczi 2019	11.13	0.63	9	10,96	0.48	9	4.2%	0.29 [-0.64, 1.22]	
simachidis et al. 2010	5.02	0.23	13	5.29	0.7	13	4.7%	-0.50 [-1.28. 0.28]	
	3.09	0.11	11	3.11	0.11	11	4.5%	-0.17 [-1.01, 0.66]	
'añez-García et al. 2019_U18			90			90	34.1%	-0.55 [-1.11, 0.01]	◆
Yañez–García et al. 2019_U18 Subtotal (95% CI)			50						
/añez-García et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² =	= 22.08, df	= 7 (P =	= 0.003	2); I ² =	68%				
/añez-García et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Fest for overall effect: Z = 1.91 (P	= 22.08, df = 0.06)	= 7 (P =	= 0.003	2); I ² =	68%				
Yañez-García et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P Total (95% CI)	= 22.08, df = 0.06)	= 7 (P =	= 0.002 254	2); I ² =	68%	254	100.0%	-0.55 [-0.88, -0.22]	•
Vañez-Carcía et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P Total (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² =	= 22.08, df = 0.06) = 72.32, df	= 7 (P =	= 0.003 254 7 < 0.00	2); I ² =	68% ² = 68%	254	100.0%	-0.55 [-0.88, -0.22]	- <u>+</u> - <u>2</u> 0 <u>2</u> <u>4</u>
Yañez-Carcía et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P Total (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Test for subgroup differences: Chi	= 22.08, df = 0.06) = 72.32, df = 0.001) 1 ² = 3.43, c	= 7 (P = = 23 (P If = 3 (P	= 0.003 254 < 0.00 = 0.33	2); l ² = 0001); l 3), l ² =	68% ² = 68% 12.4%	254	100.0%	-0.55 [-0.88, -0.22]	-4 -2 0 2 4 Positive effects Negative effects
Yañez-Carcia et al. 2019_U18 Subtotal (95% Cl) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P Fotal (95% Cl) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Fest for overall effect: Z = 3.23 (P	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c	= 7 (P = = 23 (P If = 3 (P	254 < 0.00 = 0.33	2); I ² = 0001); I 3), I ² =	68% ² = 68% 12.4%	254	100.0% A)	-0.55 [-0.88, -0.22]	-4 -2 0 2 4 Positive effects Negative effects
Yañez-Carcia et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P Total (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Fest for overall effect: Z = 3.23 (P	= 22.08, df = 0.06) = 72.32, df = 0.001) ²² = 3.43, c	= 7 (P = = 23 (P lf = 3 (P Post	254 < 0.00 = 0.33	2); ² = 0001); 3), ² =	68% ² = 68% 12.4% Pre	254 (1	100.0% A)	-0.55 [-0.88, -0.22] Std. Mean Difference	-4 -2 0 2 4 Positive effects Negative effects
Yañez-Carcia et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P Fotal (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Test for subgroup differences: Chi Study or Subgroup 2.1.1 FEMALE	= 22.08, df = 0.06) = 72.32, df = 0.001) ²² = 3.43, c Mean	= 7 (P = = 23 (P if = 3 (P <u>Post</u> <u>SD</u>	= 0.002 254 - < 0.00 = 0.32 Total	2); I ² = 0001); I 3), I ² = <u>Mean</u>	68% ² = 68% 12.4% Pre SD	254 (1 Total	100.0% A) Weight	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI	→ → → → → → → → → → → → → → → → → → →
Yañez-Carcía et al. 2019_U18 Subtotal (95% Cl) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P Total (95% Cl) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Test for subgroup differences: Chi Study or Subgroup 2.1.1 FEMALE Attene et al. 2014_IT	= 22.08, df = 0.06) = 72.32, df = 0.001) r^{2} = 3.43, c <u>Mean</u> 6.41	= 7 (P = = 23 (P lf = 3 (P <u>Post</u> <u>SD</u> 0.1	254 254 2 < 0.00 = 0.33 Total 8	2); ² = 0001); 3), ² = <u>Mean</u> 6.83	68% ² = 68% 12.4% Pre SD 0.24	254 (1 <u>Total</u> 8	100.0% A) Weight 3.2%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85]	A -2 0 2 4 Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl
Yañez-Carcía et al. 2019_U18 Subotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P Total (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Test for overall effect: Z = 3.23 (P Test for subgroup differences: Chi Study or Subgroup 2.1.1 FEMALE Attene et al. 2014_IT Attene et al. 2014_RST	= 22.08, df = 0.06) = 72.32, df = 0.001) ²² = 3.43, c <u>Mean</u> 6.41 6.53	f = 7 (P = 23 (P)) f = 23 (P) f = 3 (P) Post SD 0.1 0.19	= 0.003 $= 0.33$ $= 0.33$ $Total$ $= 8$ 8	2); $ ^2 =$ 0001); $ ^2 =$ Mean 6.83 6.74	68% ² = 68% 12.4% Pre SD 0.24 0.3	254 (1 <u>Total</u> 8 8	100.0% A) Weight 3.2% 3.9%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24]	Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl
(ariez-Garcia et al. 2019_U18 jubtoal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P Total (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Fest for subgroup differences: Chi Study or Subgroup 2.1.1 FEMALE Attene et al. 2014_ITT Attene et al. 2014_IST Bouteraa et al. 2020	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6	f = 7 (P = = 23 (P) ff = 3 (P) Post SD 0.1 0.19 0.4	$\begin{array}{r} 36\\ = 0.003\\ 254\\ - < 0.00\\ = 0.33\\ \hline \hline Total \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	2); $ ^2 =$ 0001); $ ^3$ 3), $ ^2 =$ <u>Mean</u> 6.83 6.74 11.3	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.6	254 (2 Total 8 8 16	100.0% A) <u>Weight</u> 3.2% 3.9% 4.7%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56]	Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl
(añez-Garcia et al. 2019_U18 subtotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P Fotal (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Fest for subgroup differences: Chi Study or Subgroup Call State	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13	= 7 (P = = 23 (P = 3 (P = 3 (P = 3 (P = 3 (P = 3 (P) = 0.1 0.1 0.19 0.4 0.63	$\begin{array}{c} 30\\ = 0.001\\ \hline 254\\ - < 0.00\\ = 0.33\\ \hline \hline 0.33\\ \hline \hline 0.33\\ \hline 16\\ 9\\ 16\\ 9\\ 1\\ \end{array}$	2); $ ^2 =$ 0001); $ ^2$ 3), $ ^2 =$ <u>Mean</u> 6.83 6.74 11.3 10.96	668% ² = 68% 12.4% Pre SD 0.24 0.3 0.6 0.48	254 (1 Total 8 8 16 9	100.0% A) <u>Weight</u> 3.2% 3.9% 4.7% 4.2%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.61 [-1.00 Action	A -2 0 2 4 Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl
rañez-García et al. 2019_U18 ububotal (95% CI) leterogeneity: Tau ² = 0.43; Chi ² = 'est for overall effect: Z = 1.91 (P 'otal (95% CI) leterogeneity: Tau ² = 0.46; Chi ² = 'est for overall effect: Z = 3.23 (P 'est for subgroup differences: Chi 'itudy or Subgroup L1.1 FEMALE tutene et al. 2014_RST iouteraa et al. 2020 deszler & Váczi 2019 'ubtotal (95% CI) leterogeneity: Tau ² = 0.68; Chi ² =	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df	= 7 (P = 23 (P)) $= 23 (P)$ $= 3 (P)$ $= 0.1$ $= 0.1$ $= 0.4$ $= 0.63$ $= 3 (P = 2)$	$\begin{array}{c} 30\\ = 0.001\\ \hline 254\\ - < 0.00\\ = 0.33\\ \hline \\ $	2); $I^2 =$ 0001); I 3), $I^2 =$ <u>Mean</u> 6.83 6.74 11.3 10.96); $I^2 = 7$	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.6 0.48 3%	254 (1 Total 8 8 16 9 41	100.0% A) Weight 3.2% 3.9% 4.7% 4.2% 16.0%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00]	A -2 0 2 4 Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl
añez-García et al. 2019_U18 ubtotal (95% CI) leterogeneity: Tau ² = 0.43; Chi ² = est for overall effect: Z = 1.91 (P otal (95% CI) leterogeneity: Tau ² = 0.46; Chi ² = est for overall effect: Z = 3.23 (P est for subgroup differences: Chi tudy or Subgroup .1.1 FEMALE ttene et al. 2014_IT ttene et al. 2014_IT ttene et al. 2014_RST outeraa et al. 2020 leszler & Váczi 2019 ubtotal (95% CI) leterogeneity: Tau ² = 0.68; Chi ² = est for overall effect: Z = 1.96 (P	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05)	$= 7 (P = 23 (P))$ $= 23 (P)$ $f = 3 (P)$ $\frac{Post}{SD}$ 0.1 0.19 0.4 0.63 $F = 3 (P = 3)$	$\begin{array}{r} 30\\ = 0.001\\ \hline 254\\ < < 0.00\\ = 0.33\\ \hline \\ $	2); $l^2 =$ Mean 6.83 6.74 11.3 10.96 b; $l^2 = 7$	68% ² = 68% 12.4% Pre <u>SD</u> 0.24 0.3 0.6 0.48 3%	254 (1 Total 8 8 16 9 41	100.0% A) <u>Weight</u> 3.2% 3.9% 4.7% 4.2% 16.0%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00]	Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl
añez-García et al. 2019_U18 ubtotal (95% CI) leterogeneity: Tau ² = 0.43; Chi ² = 'est for overall effect: Z = 1.91 (P 'otal (95% CI) leterogeneity: Tau ² = 0.46; Chi ² = est for overall effect: Z = 3.23 (P 'est for subgroup differences: Chi tudy or Subgroup .1.1 FEMALE tutene et al. 2014_IT titene et al. 2014_IT titene et al. 2014_RST outeraa et al. 2020 leterogeneity: Tau ² = 0.68; Chi ² = 'est for overall effect: Z = 1.96 (P .1.2 MALE krewié t al. 2020	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05)	f = 7 (P = 23 (P)) $f = 3 (P)$ $f = 3 (P)$ $f = 3 (P)$ 0.1 0.1 0.63 $f = 3 (P = 0)$ 0.160	$\begin{array}{c} 300\\ 500\\ 254\\ 254\\ 200\\ 000\\ 000\\ 000\\ 000\\ 000\\ 000\\ 00$	2); $I^2 =$ 0001); I 3), $I^2 =$ Mean 6.83 6.74 11.3 10.96); $I^2 = 7$ 2.46	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.6 0.48 3%	254 (1 Total 8 8 16 9 41	100.0% A) Weight 3.2% 3.9% 4.7% 4.2% 16.0%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00]	Std. Mean Difference IV, Random, 95% Cl
añez-García et al. 2019_U18 ubtotal (95% CI) leterogeneity: Tau ² = 0.43; Chi ² = est for overall effect: Z = 1.91 (P 'otal (95% CI) leterogeneity: Tau ² = 0.46; Chi ² = est for overall effect: Z = 3.23 (P est for overall effect: Z = 3.23 (P est for subgroup tudy or Subgroup .1.1 FEMALE Ittene et al. 2014_RST outeraa et al. 2020 leterogeneity: Tau ² = 0.68; Chi ² = est for overall effect: Z = 1.96 (P .1.2 MALE Issovi et al. 2020	= 22.08, df = 0.06) = 72.32, df = 0.001) $^{2^{2}}$ = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05)	f = 7 (P = 23 (P)) $f = 3 (P)$ $f = 3 (P)$ $f = 3 (P)$ 0.1 0.4 0.63 $f = 3 (P = 0.169)$ 0.22	$\begin{array}{c} 30 \\ = 0.000 \\ \hline 254 \\ = 0.000 \\ \hline 254 \\ = 0.000 \\ \hline 254 \\ = 0.000 \\ \hline 100 \\ = 0.000 \\ \hline 100 \\ = 0.000 \\ \hline 100 $	2); $I^2 =$ 20001); $I^2 =$ 3), $I^2 =$ Mean 6.83 6.74 11.3 10.96 2); $I^2 = 7$ 3.48 5.54	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.6 0.48 3% 0.149 0.2	254 (4 Total 8 8 8 16 9 41	100.0% A) <u>Weight</u> 3.2% 3.9% 4.7% 4.2% 16.0%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.55] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.73 [-1.45, -0.02] -0.14 [-1.02, 0.79]	A -2 0 2 4 Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl
añez-García et al. 2019_U18 ubtotal (95% Cl) leterogeneity: Tau ² = 0.43; Chi ² = lest for overall effect: Z = 1.91 (P 'otal (95% Cl) leterogeneity: Tau ² = 0.46; Chi ² = est for overall effect: Z = 3.23 (P est for subgroup differences: Chi tudy or Subgroup tudy or S	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.5 7 4 c	= 7 (P = 23 (P)) $= 23 (P)$ $= 3 (P)$ $= 3 (P)$ $= 3 (P)$ $= 3 (P)$ $= 0.169$ $= 0.32$ $= 0.42$	$\begin{array}{c} 30 \\ 254 \\ $	2); $ l^2 =$ 0001); $ l^3 =$ Mean 6.83 6.74 11.3 10.96 10.96 5.54 8.87	68% ² = 68% 12.4% Pre <u>SD</u> 0.24 0.3 0.6 0.48 3% 0.149 0.2 0.2	254 (1 Total 8 8 8 16 9 41	100.0% A) Weight 3.2% 3.9% 4.7% 4.2% 16.0% 4.9% 4.2% 2.6%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% C1 -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.73 [-1.45, -0.02] -0.14 [-1.07, 0.78] -3 08 [-4 65 - 1 51]	Positive effects Negative effects Std. Mean Difference IV, Random, 95% CI
añez-García et al. 2019_U18 ubtotal (95% CI) leterogeneity: Tau ² = 0.43; Chi ² = 'est for overall effect: Z = 1.91 (P 'otal (95% CI) leterogeneity: Tau ² = 0.46; Chi ² = est for overall effect: Z = 3.23 (P 'est for subgroup differences: Chi tudy or Subgroup .1.1 FEMALE tttene et al. 2014_RST outeraa et al. 2014_RST outeraa et al. 2020 feszler & Váczi 2019 ubtotal (95% CI) leterogeneity: Tau ² = 0.68; Chi ² = 'est for overall effect: Z = 1.96 (P .1.2 MALE ksović et al. 2020 rede et al. 2018 usadi et al. 2018	= 22.08, df = 0.06) $= 72.32, df = 0.001)$ $= 72.32, df = 0.001)$ $= 3.43, c$ $Mean$ $= 0.41$ $= 0.41$ $= 0.41$ $= 0.41$ $= 0.41$ $= 0.05)$ $= 11.13, df = 0.05)$ $= 3.36$ $= 5.5$ $= 7.45$ $= 5.95$	= 7 (P = 23 (P)) $= 23 (P)$ $f = 3 (P)$ $= 3 (P)$ 0.1	254 254 2 < 0.00 = 0.33 Total 8 8 8 8 16 9 41 = 0.01	2); $l^2 =$ 0001); $l^2 =$ Mean 6.83 6.74 11.3 10.96 3.48 5.54 8.87 5.68	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.6 0.48 3% 0.149 0.2 0.46 0.149	254 (1 Total 8 8 16 9 41	100.0% A) Weight 3.2% 3.9% 4.7% 4.7% 4.2% 16.0% 4.9% 4.2% 2.6% 3.8%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.73 [-1.45, -0.02] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1 40 [0.34 2 461]	Std. Mean Difference IV, Random, 95% Cl
rañez-García et al. 2019_U18 ububotal (95% CI) leterogeneity: Tau ² = 0.43; Chi ² = rest for overall effect: Z = 1.91 (P rotal (95% CI) leterogeneity: Tau ² = 0.46; Chi ² = rest for overall effect: Z = 3.23 (P rest for subgroup differences: Chi rest for oscillation differences: Chi rest for overall effect: Z = 1.96 (P 2.1.2 MALE kisović et al. 2020 kisodi et al. 2015 kisodi et al. 2015 kitene et al. 2015b_IRST kitene et al. 2015b_RST	= 22.08, df = 0.06) = 72.32, df = 0.001) $^{2^{2}}$ = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.5 5.959 5.94	= 7 (P = 23	254 <pre>> < 0.00</pre> 254 <pre>> < 0.00</pre> = 0.32 Total 8 8 16 9 41 = 0.01 16 9 8 9 9 9 9 9	2); ² = 0001); Mean 6.83 6.74 10.96 10.96 3.48 8.57 8.87 5.68 8.674	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.6 0.48 3% 0.149 0.2 0.46 0.198 0.35	254 (1 <u>Total</u> 8 8 8 16 9 41	100.0% A) <u>Weight</u> 3.2% 3.9% 4.7% 4.2% 16.0%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.73 [-1.45, -0.02] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64]	Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl
(añez-García et al. 2019_U18 jubitotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P Fotal (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Test for overall effect: Z = 3.23 (P Test for osubgroup differences: Chi Study or Subgroup E.1.1 FEMALE Attene et al. 2014_IT Attene et al. 2014_IT Attene et al. 2014_IT Attene et al. 2014_IT Attene et al. 2020 Meszler & Váczi 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.68; Chi ² - Test for overall effect: Z = 1.96 (P 2.1.2 MALE Aksović et al. 2020 Attene et al. 2015b_IRST Attene et al. 2015b_RST Tiqueria et al. 2020 FLAT	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.5 5.959 5.94 13.21	$= 7 (P + 1)^{-1} = 23 (P + 1)^{-1} = 23 (P + 1)^{-1} = 3 (P + 1)^{-1} = $	254 254 254 254 254 254 254 254	2); $l^2 =$ 0001); $l^2 =$ Mean 6.83 6.74 11.3 10.96); $l^2 = 7$ 3.48 8.87 5.68 8.87 5.68 8.87 5.64 9.75 9	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.6 0.48 3% 0.149 0.2 0.46 0.198 0.35 0.77	254 (1 Total 8 8 8 16 9 41	100.0% A) Weight 3.2% 3.9% 4.7% 4.7% 4.2% 4.2% 4.2% 3.8% 4.2% 4.2% 4.2% 4.7%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% C1 -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.73 [-1.45, -0.02] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.08 [0.30, 1.85]	Positive effects Negative effects Std. Mean Difference IV, Random, 95% CI
<pre>(ariaez - Carcia et al. 2019_U18 jubitotal (95% CI) letterogeneity: Tau² = 0.43; Chi² = fest for overall effect: Z = 1.91 (P fotal (95% CI) letterogeneity: Tau² = 0.46; Chi² = fest for overall effect: Z = 3.23 (P fest for subgroup differences: Chi study or Subgroup differences: Chi study or Subgroup 2.1.1 FEMALE Natene et al. 2014_IT Attene et al. 2014_IT Attene et al. 2014_IT Attene et al. 2019 Jubitotal (95% CI) letterogeneity: Tau² = 0.68; Chi² = fest for overall effect: Z = 1.96 (P 2.1.2 MALE Aksović et al. 2015 Attene et al. 2015b_RST Attene et al. 2015b_RST Attene et al. 2020_FLAT "igueira et al. 2020_FLAT "igueira et al. 2020_FLAT</pre>	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.5 7.45 5.959 5.94 13.21 13.11	= 7 (P =	254 < 0.00 = 0.32 Total 8 8 8 16 9 9 41 = 0.01 16 9 8 9 9 9 15 16	2); $l^2 =$ Mean 6.83 (0.74) (1.3), $l^2 =$ Mean 6.83 (0.74) (1.3)	68% ² = 68% Pre SD 0.24 0.3 0.6 0.48 3% 0.149 0.2 0.48 0.35 0.77 0.8	254 (1 Total 8 8 8 8 16 9 41 16 9 9 41	100.0% A) <u>Weight</u> 3.2% 4.7% 4.2% 16.0% 4.9% 4.2% 2.6% 3.8% 4.2% 4.2% 4.2%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.73 [-1.45, -0.02] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.08 [0.30, 1.85] -1.59 [-2.04, -0.79]	Std. Mean Difference IV, Random, 95% CI
rañez-García et al. 2019_U18 ububotal (95% CI) leterogeneity: Tau ² = 0.43; Chi ² = rest for overall effect: Z = 1.91 (P rotal (95% CI) rest for overall effect: Z = 3.23 (P rest for overall effect: Z = 3.23 (P rest for subgroup differences: Chi rest for overall effect: Z = 3.23 (P rest for subgroup differences: Chi rest for overall effect: Z = 3.23 (P rest for overall effect: Z = 1.96 (P 2.1.2 MALE kisović et al. 2020 rest for overall effect: Z = 1.96 (P 2.1.2 MALE kisović et al. 2015b_RST titene et al. 2015b_RST tigueira et al. 2020_FLAT igueira et al. 2020_FLAT igueira et al. 2020_FLAT igueira et al. 2020	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.5 5.959 5.94 13.21 13.11 7.4	= 7 (P + = 23 (P + sp = 23 (P + sp = 3 (P + sp = 3 (P + 0.11 - 0.19 - 0.41 - 0.41 - 0.32 - 0.33 - 0.33 - 0.33 - 0.34 - 0.35 - 0	254 2< 0.00 = 0.33 Total 8 8 8 16 9 41 = 0.01 2 16 9 9 9 9 9 9 15 16 11	2); ² = 0001); Mean 6.83 6.74 11.3 10.96); ² = 7 3.48 5.54 8.87 5.68 6.04 11.62 14.37 7.52	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.48 3% 0.149 0.2 0.46 0.198 0.35 0.77 0.8 0.25 0.77 0.8 0.25 0.27 0.35 0.77 0.8 0.25 0.27 0.35 0.45 0.45 0.45 0.55	254 (1 Total 8 8 8 8 6 9 9 41 16 9 9 9 9 9 9 9 9 9 15 16 11	100.0% A) Weight 3.2% 3.2% 4.7% 4.2% 16.0% 4.9% 4.2% 2.6% 3.8% 4.2% 4.6% 4.4% 4.4%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.73 [-1.45, -0.02] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.08 [0.30, 1.85] -1.59 [-2.40, 0.79] -0.58 [-1.43, 0.28]	Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl
Yañez-Carcia et al. 2019_U18 Yañez-Carcia et al. 2019_U18 Subbotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Fest for overall effect: Z = 1.91 (P Fotal (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Fest for overall effect: Z = 3.23 (P Fest for overall effect: Z = 3.23 (P Fest for overall effect: Z = 3.23 (P Fest for subgroup 2.1.1 FEMALE Attene et al. 2014_IT Attene et al. 2014_IT Attene et al. 2014_ST Souteraa et al. 2020 Meszler & Váczi 2019 Subtroat (95% CI) Heterogeneity: Tau ² = 0.68; Chi ² - Fest for overall effect: Z = 1.96 (P 2.1.2 MALE Aksović et al. 2020 Arede et al. 2016 Attene et al. 2015b_IRST Tigueira et al. 2020_SLOPE Gonzalo-Skok et al. 2017_BIL	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.5 5.959 5.94 13.21 13.11 7.4 6.56	= 7 (P = 23) (P = 2	$\begin{array}{c} 254 \\ 254 \\ 2 < 0.00 \\ 254 \\ 2 < 0.00 \\ 254 \\ 2 \\ 254 \\ 2 \\ 254 \\ 2 \\ 254 \\ 2 \\ 254 \\ 2 \\ 254 \\ 2 \\ 254 \\ 2 \\ 2 \\ 254 \\ 2 \\ \mathbf$	2); $l^2 =$ Mean Mean 6.83 (0.6,74) 11.3 10.96 (0.7,12) (1.2,23) (1.2,	68% ² = 68% 12.4% Pre 5D 0.24 0.36 0.48 3% 0.149 0.2 0.46 0.198 0.37 0.77 0.8 0.77 0.8 0.24	254 (1 Total 8 8 8 16 9 9 41 16 9 8 9 9 5 16 11 11	100.0% A) Weight 3.2% 3.9% 4.7% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.4% 4.5%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% C1 -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.73 [-1.45, -0.02] -0.95 [-1.90, 0.00] -0.73 [-1.45, -0.02] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.58 [-1.43, 0.28] -0.30 [-1.15, 0.54]	Positive effects Negative effects Std. Mean Difference IV, Random, 95% CI
ranez-Garcia et al. 2019_U18 jubitotal (95% CI) letterogeneity: Tau ² = 0.43; Chi ² = rest for overall effect: Z = 1.91 (P rotal (95% CI) letterogeneity: Tau ² = 0.46; Chi ² = rest for overall effect: Z = 3.23 (P rest for subgroup differences: Chi study or Subgroup 2.1.1 FEMALE Attene et al. 2014_IST olouteraa et al. 2020 Meszler & Váczi 2019 jubitotal (95% CI) letterogeneity: Tau ² = 0.68; Chi ² = rest for overall effect: Z = 1.96 (P 2.1.2 MALE Vaković et al. 2020 Væde et al. 2015b_IRST Attene et al. 2015b_IRST Attene et al. 2020_FLAT rigueira et al. 2020_FLAT	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.5 5.959 5.94 13.11 7.4 6.56 6.57	= 7 (P + 23) (P + 2	$\begin{array}{c} 254 \\ 2 < 0.00 \\ 254 \\ 2 < 0.00 \\ 254 \\ 2 < 0.00 \\ 254 \\ 2 < 0.01 \\ 255 \\ 255 \\ 16 \\ 9 \\ 11 \\ 11 \\ 11 \end{array}$	2); ² = (0,00); 1 (0,00); 1 (0,00)	68% 2 = 68% 12.4% Pre SD 0.24 0.46 0.48 3% 0.149 0.2 0.46 0.198 0.27 0.8 0.2 0.24 0.18 0.24 0.18 0.24 0.18 0.24 0.18 0.24 0.18 0.24 0.18 0.24 0.18 0.24 0.18 0.24 0.18 0.24 0.18 0.24 0.18 0.24 0.18 0.24 0.18	254 (1 Total 8 8 8 16 9 41 16 9 8 9 9 9 9 9 9 9 5 16 11 11	100.0% A) <u>Weight</u> 3.2% 4.7% 4.2% 16.0% 4.9% 4.2% 2.6% 3.8% 4.2% 4.2% 4.2% 4.5% 4.5%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.73 [-1.45, -0.02] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.58 [-1.43, 0.28] -0.30 [-1.55, 0.54] 0.33 [-0.52, 1.17]	Positive effects Negative effects Std. Mean Difference IV, Random, 95% CI
rañez-García et al. 2019_U18 ububotal (95% CI) leterogeneity: Tau ² = 0.43; Chi ² = rest for overall effect: Z = 1.91 (P rotal (95% CI) leterogeneity: Tau ² = 0.46; Chi ² = rest for overall effect: Z = 3.23 (P rest for subgroup differences: Chi leterogeneit et al. 2014_RST souther et al. 2014_RST souther at al. 2014_RST souther at al. 2020 deszler & Váczi 2019 ubtotal (95% CI) leterogeneity: Tau ² = 0.68; Chi ² = rest for overall effect: Z = 1.96 (P 2.1.2 MALE kksović et al. 2020 kvsdi et al. 2015b_RST titene et al. 2015b_RST titene et al. 2015b_RST tigueira et al. 2020_SLOPE jonzalo-Skok et al. 2017_BIL jonzalo-Skok et al. 2017_BIL jonzalo-Skok et al. 2017_BV	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.94 13.21 13.11 7.44 6.56 6.57 7.21	= 7 (P + = 23 (P Post SD 0.1 0.19 0.63 = 3 (P + 0.169 0.32 0.41 0.33 0.32 0.41 0.83 0.74 0.83 0.74 0.2 0.2 0.2 0.2 0.4	$\begin{array}{c} 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 255$	2); $l^2 =$ Mean Mean 6.83 6.74 1.13 10.96 3.48 8.87 5.68 8.87 5.64 11.62 (.43) 6.63 6.64 11.37 5.64 8.87 5.64 8.87 5.64 8.67 1.63 6.64 1.63 7.52 6.63 6.73 7.52 7.57 7.	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.24 0.3 0.48 3% 0.149 0.2 0.46 0.198 0.35 0.77 0.8 0.22 0.46 0.24 0.25 0.27 0.24 0.24 0.24 0.24 0.24 0.25 0.27 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.25 0.27 0.24 0.41 0.	254 (<i>L</i> Total 8 8 8 16 9 9 41 16 9 8 9 9 9 15 16 11 11 11 11 11	100.0% A) Weight 3.2% 3.2% 4.7% 4.2% 16.0% 4.2% 2.6% 3.8% 4.2% 2.6% 3.8% 4.2% 4.6% 4.2% 4.5% 4.4% 4.5% 4.3%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.73 [-1.45, -0.02] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.58 [-1.43, 0.28] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.17] -0.38 [-1.26, 0.51]	Std. Mean Difference IV, Random, 95% CI
ranez-Garcia et al. 2019_U18 jubbotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P Fotal (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Fest for overall effect: Z = 3.23 (P Fest for osubgroup differences: Chi Study or Subgroup differences: Chi Study or	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.959 5.94 13.21 13.11 7.4 6.56 6.57 7.21 7.21	= 7 (P + 2)	254 2 < 0.00 = 0.32 Total 8 8 8 16 9 9 41 = 0.012 16 9 9 8 9 9 9 15 16 61 11 11 11 10 10	2); $l^2 =$ Mean 6.83 6.74 11.62 1.62 3.48 5.54 8.87 5.54 8.87 5.54 8.87 5.54 6.63 6.63 6.63 7.52 6.63 7.52	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.46 0.48 3% 0.149 0.2 0.46 0.198 0.35 0.77 0.8 0.77 0.8 0.77 0.24 0.78 0.77 0.77 0.79 0.74 0.74 0.79 0.74 0.74 0.79 0.74 0.79 0.74 0.79 0.74 0.79 0.77 0.79 0.77 0.79 0.77 0.79 0.79 0.77 0.79 0.79 0.79 0.77 0.79 0.77 0.79 0.77 0.79 0.77 0.79 0.77 0.74 0.77 0	254 ((<u>Total</u> 8 8 8 8 9 41 16 9 9 9 9 9 9 9 9 15 16 16 11 11 11 10 10	100.0% A) Weight 3.2% 3.9% 4.7% 4.2% 4.5%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% C1 -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.95 [-1.90, 0.00] -0.95 [-1.90, 0.00] -0.95 [-1.22, 0.64] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.58 [-1.43, 0.28] -0.30 [-1.5, 0.54] 0.33 [-0.52, 1.17] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16]	Positive effects Negative effects Std. Mean Difference IV, Random, 95% CI
<pre>(ariaez - Garcia et al. 2019_U18 jubtoat (95% CI) leterogeneity: Tau² = 0.43; Chi² = fest for overall effect: Z = 1.91 (P fotal (95% CI) leterogeneity: Tau² = 0.46; Chi² = fest for overall effect: Z = 3.23 (P fest for subgroup differences: Chi study or Subgroup differences: Chi study or Subgroup differences: Chi study or Subgroup deszler & Váczi 2019 jubtoat (95% CI) leterogeneity: Tau² = 0.68; Chi² = fest for overall effect: Z = 1.96 (P 2.1.2 MALE Vasović et al. 2015 State et al. 2015 Sonzalo-Skok et al. 2017_UNI Sonzalo-Skok et al. 2017_UNI Sonzalo-Skok et al. 2019_UH Sottlieb et al. 2014_PT</pre>	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.5 5.959 5.94 13.11 7.4 6.56 6.57 7.21 7.01 3.01	= 7 (P =	$\begin{array}{c} 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 255$	2); $l^2 =$ Mean 6.83 10.96 3.48 5.54 8.67 11.3 10.96 5.54 8.67 11.3 10.96 5.54 8.67 11.3 10.96 5.54 8.67 11.3 10.96 5.54 8.67 11.3 10.96 5.54 8.67 5.54 8.75 5.54 8.67 5.54 8.67 5.54 8.67 5.54 8.67 5.54 8.67 5.54 8.67 5.54 8.67 5.54 8.67 5.54 8.67 5.54 8.67 5.54 8.67 5.54 8.67 5.54 8.67 5.54 8.67 5.54 8.67 5.54 8.67 5.54 8.67 5.54 8.67 5.57 7.77 7.25 7.37 7.25 7.37 7.25 7.37 7.25 7.37 7.25 7.37 7.25 7.37 7.25 7.37 7.25 7.37 7.25 7.37 7.25 7.37 7.25 7.37 7.25 7.37 7.25 7.37 7.25 7.37 7.25 7.37 7.25 7.37 7.25 7.37 7.25 7.37 7.37 7.25 7.37 7.	68% ² = 68% 12.4% Pre SD 0.24 0.48 0.6 0.48 3% 0.149 0.2 0.48 0.198 0.2 0.48 0.198 0.2 0.49 0.2 0.48 0.198 0.2 0.48 0.49 0.2 0.48 0.4	254 (A Total 8 8 8 9 41 16 9 9 41 16 9 9 9 9 15 5 16 11 11 11 10 0 10 0 9	100.0% A) <u>Weight</u> 3.2% 3.9% 4.7% 4.2% 16.0% 4.2% 4.6% 4.2% 4.5% 4.3% 4.5% 4.3% 4.3% 4.3% 4.3%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.73 [-1.45, -0.02] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.08 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.08 [0.34, 2.46] -0.58 [-1.43, 0.28] -0.30 [-1.5, 0.54] 0.33 [-0.52, 1.17] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77]	Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl
ranez-Garcia et al. 2019_U18 jubtoal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P fotal (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Test for overall effect: Z = 3.23 (P Test for overall effect: Z = 3.23 (P Test for subgroup bitotal (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 1.96 (P 2.1.1 FEMALE Attene et al. 2014_RST Souteraa et al. 2020 Meszler & Váczi 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.68; Chi ² = Test for overall effect: Z = 1.96 (P 2.1.2 MALE Vaced et al. 2015b_RST Hitene et al. 2015b_RST Hitene et al. 2015b_RST Tigueira et al. 2020_FLAT Tigueira et al. 2020_FLAT Tigueira et al. 2020_FLAT Tigueira et al. 2015_RST Hitene et al. 2015_DCPE Sonzalo-Skok et al. 2017_BLL Sonzalo-Skok et al. 2019_BV Sonzalo-Skok et al. 2014_ST Southebet al. 2014_ST	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.94 13.21 13.11 7.44 6.56 6.57 7.21 7.01 3.01 2.99	= 7 (P =	254 254 254 254 254 254 254 254	2); $l^2 =$ Mean Mean Mean 1 , $l^2 =$ 1 ,	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.48 3% 0.149 0.2 0.46 0.198 0.35 0.77 0.8 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.198 0.2 0.46 0.199 0.2 0.2 0.199 0.2 0.149 0.2 0.2 0.149 0.2 0.2 0.149 0.2 0.2 0.149 0.2 0.2 0.2 0.2 0.2 0.2 0.149 0.2 0.2 0.19 0.2 0.2 0.2 0.2 0.2 0.199 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	254 (1 Total 8 8 8 16 9 9 41 16 9 8 9 9 9 15 16 10 11 11 11 11 10 10 9	100.0% A) Weight 3.2% 3.2% 4.7% 4.2% 16.0% 4.2% 2.6% 3.8% 4.2	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.59 [-2.40, -0.79] -0.58 [-1.43, 0.28] -0.30 [-1.15, 0.54] 0.33 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -0.83 [-1.75, 0.09]	Std. Mean Difference IV, Random, 95% Cl
<pre>(ariaez - Garcia et al. 2019_U18 jubitotal (95% CI) leterogeneity: Tau² = 0.43; Chi² = fest for overall effect: Z = 1.91 (P fotal (95% CI) leterogeneity: Tau² = 0.46; Chi² = fest for overall effect: Z = 3.23 (P fest for subgroup differences: Chi study or Subgroup differences: Chi study or Subgroup differences: Chi study or Subgroup 2.1.1 FEMALE Nation et al. 2014_IST souteraa et al. 2020 Meszler & Váczi 2019 Jubitotal (95% CI) leterogeneity: Tau² = 0.68; Chi² = fest for overall effect: Z = 1.96 (P 2.1.2 MALE Nksović et al. 2019 Jubitotal (95% CI) leterogeneity: Tau² = 0.68; Chi² = fest for overall effect: Z = 1.96 (P 2.1.2 MALE Nksović et al. 2015b_IRST Nittene et al. 2015b_IRST Nittene et al. 2020_SLOPE Jonzalo-Skok et al. 2017_BIL Jonzalo-Skok et al. 2017_BIL Jonzalo-Skok et al. 2017_BIL Jonzalo-Skok et al. 2019_UH Jottlieb et al. 2014_PT Jottlieb et al. 2014_NR</pre>	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.959 5.94 13.21 13.11 7.4 6.56 6.57 7.21 7.01 3.01 2.99 2.19 11	= 7 (P + 23) (P + 2	254 254 254 254 254 254 254 254	2); $l^2 =$ Mean Mean 6.83 6.73 10.96 (); $l^2 = 7$ 3.48 5.54 8.87 5.68 6.03 (); $l^2 = 7$ 3.48 5.54 4.87 5.54 6.63 6.63 6.63 6.63 6.75 7.52 6.63 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 3.07 7.25 7.37 7.72 7.25 7.25 7.37 7.25 7.25 7.37 7.52 7.55 7.57	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.6 0.48 0.3% 0.149 0.2 0.46 0.198 0.37 0.48 0.37 0.48 0.37 0.48 0.32 0.48 0.198 0.22 0.46 0.198 0.22 0.41 0.198 0.24 0.198 0.24 0.198 0.24 0.198 0.25 0.48 0.198 0.25 0.48 0.198 0.25 0.48 0.198 0.25 0.48 0.198 0.25 0.48 0.198 0.25 0.48 0.198 0.25 0.48 0.198 0.25 0.48 0.198 0.25 0.48 0.198 0.25 0.24 0.198 0.25 0.24 0.198 0.25 0.24 0.198 0.24 0.12 0.24 0.12 0.24 0.12 0.24 0.12 0.24 0.24 0.24 0.24 0.24 0.22 0.24 0.22 0.24 0.12 0.24 0.22 0.24 0.12 0.22 0.12 0.24 0.12 0.12 0.24 0.12 0.	254 (<i>I</i> Total 8 8 8 9 9 9 41 16 9 9 9 15 16 11 11 11 11 10 0 10 0 7 7	100.0% A) Weight 3.2% 3.9% 4.7% 4.2% 4.5%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.44, 1.22] -0.95 [-1.90, 0.00] -0.95 [-1.90, 0.00] -0.95 [-1.90, 0.00] -0.95 [-1.90, 0.00] -0.58 [-1.43, 0.28] -0.30 [-1.5, 0.54] 1.26 [-0.29, -0.15] -0.36 [-1.5, 0.54] 0.33 [-0.52, 1.17] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -0.83 [-1.75, 0.09] -1.11 [-2.26, 0.05] -1.11 [-2.26, 0.05]	Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl
rafiez-Garcia et al. 2019_U18 jubitotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P fotal (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Fest for subgroup differences: Chi Study or Subgroup 2.1.1 FEMALE Attene et al. 2014_RST Souteraa et al. 2020 Meszler & Váczi 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.68; Chi ² = Test for overall effect: Z = 1.96 (P 2.1.2 MALE Aksović et al. 2015_RST Attene et al. 2015b_RST Attene et al. 2015b_RST Attene et al. 2015b_RST Attene et al. 2015b_RST Attene et al. 2020_IAT Sonzalo-Skok et al. 2017_UNI Sonzalo-Skok et al. 2017_UNI Sonzalo-Skok et al. 2017_UNI Sonzalo-Skok et al. 2019_W Sortlieb et al. 2014_FT Sottlieb et al. 2014_FT Sottlieb et al. 2014_FT Sottlieb et al. 2014_RR	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.366 5.5 5.959 5.94 13.11 7.4 6.566 6.57 7.21 7.01 3.01 2.99 11 10.3 0.1 2.99 11	= 7 (P =	254 < 0.00 254 < 0.01 = 0.3: Total 8 8 8 16 9 41 = 0.01; 16 9 9 11 11 11 11 10 10 0 9 10 10 10 10 10 10 10 10 10 10	2); $ 1^2 =$ Mean Mean 6.83 (1.13), $ 1^2 =$ 6.83 (1.13) (1.96) (1.12) (1.13	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.6 0.48 3% 0.149 0.2 0.46 0.198 0.2 0.48 0.198 0.2 0.24 0.198 0.2 0.24 0.198 0.2 0.24 0.198 0.2 0.2 0.4 0.19 0.2 0.2 0.4 0.19 0.2 0.2 0.4 0.19 0.2 0.4 0.198 0.2 0.2 0.4 0.198 0.2 0.2 0.4 0.198 0.2 0.4 0.198 0.2 0.2 0.4 0.198 0.2 0.2 0.4 0.198 0.2 0.2 0.2 0.4 0.198 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	254 (1 Total 8 8 8 16 9 9 41 16 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	100.0% A) weight 3.2% 3.9% 4.7% 4.2% 16.0% 4.9% 4.2% 2.6% 3.8% 4.2% 4.5% 4.2% 4.5% 4.3% 4.3% 4.3% 4.2% 4.3% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.73 [-1.45, -0.02] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.08 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.08 [0.34, 2.46] -0.30 [-1.15, 0.54] 0.33 [-1.25, 0.23] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -0.83 [-1.75, 0.09] -1.15 [-2.68, 0.51] -1.12 [-2.68, 0.51] -1.12 [-2.68, 0.51] -1.12 [-2.68, -0.51] -1.12 [-2.66, 0.51] -1.12 [-2.66, 0.51] -1.12 [-2.66, 0.51] -1.12 [-2.66, 0.51] -1.12 [-2.66, 0.51] -1.12 [-2.66, 0.51] -1.12 [-2.66, 0.51] -1.14 [-2.76, 0.07] -1.14 [-2.76, 0.07] -1.15 [-2.	Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl
Yañez-Carcía et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P Fotal (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Fest for overall effect: Z = 3.23 (P Fest for subgroup differences: Chi Study or Subgroup Z.1.1 FEMALE Attene et al. 2014_IT Attene et al. 2020 Meszler & Váczi 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.68; Chi ² = Test for overall effect: Z = 1.96 (P Z.1.2 MALE Aksović et al. 2020 Arede et al. 2015b_IRST Attene et al. 2015b_IRST Gonzalo-Skok et al. 2017_UNI Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Hernández et al. 2018_R Tsimachidis et al. 2010	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.5 5.959 5.94 13.21 13.11 7.4 6.56 6.57 7.21 7.01 3.01 2.99 11 10.3 5.02	= 7 (P + = 23 (P Post SD 0.1 0.19 0.63 = 3 (P + 0.169 0.32 0.41 0.33 0.32 0.41 0.33 0.32 0.41 0.33 0.42 0.23 0.4 0.13 0.1 0.10 0.10 0.32 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.	254 254 254 254 254 254 254 254	2); $l^2 =$ Mean Mean Mean Mean 1 3 , $l^2 =$ 6 .83 6 .74 1 .13 1 0.96 3 .48 8 .87 5 .68 8 .87 5 .64 1 .13 1 0.96 1 .13 1 0.96 1 .13 1 .13 1 0.96 1 .13 1 .13 1 .0.96 1 .13 1 .13 1 .0.96 1 .13 1 .13 1 .0.96 1 .13 1 .13 1 .0.96 1 .13 1 .21 5 .29 1 .23 1 .21 1 .52 1 .23 1 .21 1 .52 1 .23 1 .21 1 .52 1 .52 1 .54 1 .55 1 .54 1 .55 1 .55 	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.24 0.3 0.48 3% 0.149 0.2 0.46 0.198 0.35 0.77 0.8 0.2 0.46 0.199 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.149 0.2 0.24 0.128 0.24 0.3 0.27 0.24 0.128 0.22 0.24 0.128 0.2 0.24 0.19 0.2 0.24 0.35 0.27 0.24 0.19 0.2 0.24 0.35 0.27 0.41 0.22 0.44 0.35 0.27 0.41 0.22 0.41 0.22 0.41 0.22 0.41 0.22 0.41 0.22 0.41 0.22 0.41 0.41 0.22 0.27 0.24 0.41 0.22 0.24 0.111 0.22 0.24 0.24 0.24 0.41 0.22 0.24 0.111 0.22 0.24 0.24 0.22 0.24 0.41 0.22 0.111 1.11 1.11 0.7 0.7 0.7 0.7 0.7 0.8 0.22 0.1111 0.11111 0.11111 0.11111 0.11111 0.1111111111	254 (1 Total 8 8 8 8 9 9 41 16 9 8 9 9 15 16 11 11 11 10 10 0 7 7 6 10 10 7 10 10 10 10 10 10 10 10 10 10 10 10 10	100.0% A) Weight 3.2% 3.9% 4.7% 4.2% 16.0% 4.2% 2.6% 3.8% 4.2% 3.8% 4.2% 3.8% 4.2% 3.8% 4.2% 3.6% 2.9% 4.7% 4.2% 4.3% 4.3% 4.3% 4.3% 4.3% 4.3% 4.3% 4.3% 4.3% 4.3% 4.3% 4.3% 4.3% 4.3% 4.3% 4.3% 4.2% 4.3% 4.2% 4.3% 4.2% 4.3% 4.2% 4.3% 4.2	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.59 [-2.40, -0.79] -0.58 [-1.43, 0.28] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.17] -0.38 [-1.26, 0.51] 1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -0.83 [-1.75, 0.09] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] -0.50 [-1.28, 0.28] -0.50 [-1.28, 0.28]	A -2 0 2 4 Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl
Yañez-Carcía et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Fest for overall effect: Z = 1.91 (P Total (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Fest for subgroup Z.1.1 FEMALE Attene et al. 2014_IT Attene et al. 2015_IS For overall effect: Z = 1.96 (P Z.1.2 MALE Aksović et al. 2015 Attene et al. 2015b_IRST Attene et al. 2015_IRST Attene et al. 2015b_IRST Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_FT Gottlieb et al. 2014_FT Hernández et al. 2018_R Fismachidis et al. 2010 Vănez-Carcía et al. 2019_UT4	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.959 5.94 13.21 13.11 7.4 6.56 6.57 7.21 7.21 7.01 3.01 2.99 11 10.3 5.02 2.34 2.34	= 7 (P + 23) (P + 2	= 0.000 254 < 0.00 = 0.33 Total 8 8 8 9 41 = 0.01; 16 9 8 9 9 15 16 11 11 10 0 9 10 10 11 11 11 11 11 11 11 11	2); ² = (),	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.6 0.48 0.3% 0.48 0.3% 0.149 0.22 0.46 0.198 0.37 0.78 0.24 0.18 0.24 0.18 0.24 0.18 0.24 0.18 0.24 0.19 0.24 0.19 0.24 0.19 0.24 0.19 0.24 0.19 0.25 0.24 0.19 0.25 0.24 0.19 0.25 0.24 0.19 0.25 0.24 0.19 0.25 0.24 0.19 0.25 0.24 0.19 0.25 0.24 0.19 0.25 0.24 0.19 0.25 0.24 0.19 0.25 0.24 0.19 0.25 0.24 0.19 0.25 0.24 0.19 0.25 0.24 0.19 0.25 0.24 0.25 0.24 0.19 0.25 0.24 0.24 0.19 0.25 0.24 0.25 0.25 0.25 0.24 0.25 0.55	254 (<i>I</i> Total 8 8 8 9 9 4 1 16 9 9 9 9 9 9 9 9 9 9 9 9 9 9 5 16 11 11 11 10 0 0 9 7 6 6 13 11 11 11 11 11 11 11 11 11 11 11 11	100.0% A) Weight 3.2% 3.9% 4.7% 4.2% 16.0% 4.9% 4.2% 4.5% 4.7	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.95 [-1.90, 0.00] -0.95 [-1.90, 0.00] -0.95 [-1.22, 0.64] 1.80 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.08 [-3.65, -1.51] 1.40 [0.34, 2.46] -0.30 [-1.5, 0.54] -0.30 [-1.5, 0.54] 0.33 [-0.52, 1.17] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -0.83 [-1.75, 0.09] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] -0.50 [-1.28, 0.28] -0.62 [-1.48, 0.24] -0.62 [-1.48, 0.24]	Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl
rafiez-Garcia et al. 2019_U18 jubitotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P fotal (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Fest for overall effect: Z = 3.23 (P Fest for subgroup 2.1.1 FEMALE Attene et al. 2014_RST Souteraa et al. 2020 Meszler & Váczi 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.68; Chi ² = Test for overall effect: Z = 1.96 (P 2.1.2 MALE Aksović et al. 2015_RST Attene et al. 2015b_RST Attene et al. 2015b_RST Attene et al. 2015b_RST Attene et al. 2015b_RST Attene et al. 2020_IAT Sozialo-Skok et al. 2016 Gonzalo-Skok et al. 2017_UNI Gonzalo-Skok et al. 2017_UNI Gonzalo-Skok et al. 2017_UNI Gonzalo-Skok et al. 2019_UH Gonzalo-Skok et al. 2019_UH	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.5 5.959 5.94 13.11 7.4 6.57 7.21 7.01 3.01 2.99 11 10.3 5.02 3.34 3.14 2.02	= 7 (P = = 23 (P f = 3 (P Post 5D 0.1 0.1 0.4 0.63 (P 0.4 0.32 0.41 0.31 1.88 0.74 0.2 0.23 0.41 0.31 0.17 0.23 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.1	$\begin{array}{c} 254 \\ 254 \\ < 0.00 \\ 254 \\ = 0.33 \\ \hline \mathbf{70tal} \\ 8 \\ 8 \\ 8 \\ 16 \\ 9 \\ 9 \\ 9 \\ 9 \\ 11 \\ 11 \\ 11 \\ 11 \\ 11 \\ 10 \\ 10 \\ 0 \\ 9 \\ 11 \\ 11 \\ 11 \\ 10 \\ 10 \\ 10 \\ 11$	2); $ i^2 =$ Mean Mean 6.83 6.74 11.3 10.96 6.74 11.3 10.96 6.74 11.3 10.96 6.74 11.3 10.96 6.74 11.3 10.96 6.74 11.3 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.74 1.33 10.96 6.54 1.33 10.96 6.54 1.33 10.96 6.54 1.33 10.96 6.54 1.33 10.96 6.54 1.33 10.96 6.54 1.33 10.96 6.54 1.33 10.96 6.54 1.33 1.34 1.37 1.33 1.33 1.33 1.34 1.37 1.34 1.37 1.34 1.37 1.34 1.37 1.34 1.37 1.34 1.37 1.34	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.6 0.48 3% 0.149 0.2 0.46 0.198 0.2 0.48 0.198 0.2 0.49 0.2 0.48 0.4 0.4 0.4 0.4 0.4 0.4 0.6 0.4 0.4 0.4 0.6 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.6 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4	254 (1 Total 8 8 8 16 9 9 41 16 9 9 9 9 9 9 9 9 9 9 9 9 9 15 16 16 11 11 11 11 11 11 11 11 11 11 11	100.0% A) weight 3.2% 3.9% 4.7% 4.2% 16.0% 4.9% 4.2% 2.6% 3.8% 4.2% 4.6% 4.4% 4.5% 4.3% 4.2% 4.3% 4.2% 4.5% 4.2% 4.5% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.73 [-1.45, -0.02] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.08 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.08 [0.34, 2.46] -0.39 [-1.50, 54] 0.33 [-1.55, 0.21] -1.15 [-2.68, -0.16] -0.15 [-1.08, 0.77] -0.83 [-1.75, 0.09] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] -0.50 [-1.28, 0.28] -0.62 [-1.48, 0.24] -0.37 [-1.21, 0.48] -0.37 [-1.21, 0.48] -0.37 [-1.21, 0.48]	Positive effects Negative effects Std. Mean Difference IV, Random, 95% CI
Yañez-Carcía et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Fest for overall effect: Z = 1.91 (P Fotal (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Fest for overall effect: Z = 3.23 (P Fest for overall effect: Z = 3.23 (P Fest for subgroup differences: Chi Subdy and Subgroup differences: Chi Attene et al. 2014_RST Souteraa et al. 2014_RST Souteraa et al. 2014_RST Souteraa et al. 2014_RST Souteraa et al. 2020 Veszler & Váczi 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.68; Chi ² = Fest for overall effect: Z = 1.96 (P 2.1.2 MALE Aksović et al. 2020 Attene et al. 2015b_RST Attene et al. 2015b_RST Hattene et al. 2015b_RST Tigueira et al. 2020_FLAT Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Sonzalo-Skok et al. 2016 Sonzalo-Skok et al. 2019_BV Sonzalo-Skok et al. 2019_BV Sonzalo-Skok et al. 2019_BV Sonzalo-Skok et al. 2019_BV Sonzalo-Skok et al. 2019_BV Fernández et al. 2018_R Fismachidis et al. 2019_U16 (añez-Carcía et al. 2019_U16 (añez-Carcía et al. 2019_U18) U167	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c Mean 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.5 7.45 5.959 5.94 13.21 13.11 7.4 6.56 6.57 7.21 7.21 7.21 7.21 13.11 7.4 6.56 6.57 7.21 7.21 13.11 1.21 1.21 1.21 1.21 1.21 1.21	= 7 (P + = 23 (P Post SD 0.1 0.19 0.63 = 3 (P + 0.169 0.32 0.41 0.32 0.41 0.18 0.32 0.41 0.18 0.74 0.23 0.4 0.07 1.1 1.7 0.07 0.11 0.11	254 254 254 254 254 254 254 254	2); $l^2 =$ Mean Mean Mean 1 3 , $l^2 =$ 1 6 .83 6 .74 1 .13 1 0.96 3 .48 8 .87 5 .68 8 .87 5 .64 1 .13 1 0.96 1 .13 1 0.96 1 .13 1 0.96 1 .13 1 .13 1 .13 1 .15 5 .54 1 .6.34 1 .13 1 .13 1 .15 1	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.48 0.48 3% 0.149 0.2 0.46 0.198 0.2 0.46 0.198 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.47 0.199 0.2 0.46 0.199 0.2 0.47 0.19 0.2 0.46 0.19 0.2 0.41 0.17 0.8 0.2 0.41 0.19 0.2 0.41 0.19 0.2 0.41 0.19 0.2 0.41 0.19 0.2 0.41 0.19 0.2 0.41 0.19 0.2 0.41 0.19 0.2 0.41 0.19 0.2 0.41 0.11 0	254 (1 Total 8 8 8 8 16 9 9 41 11 11 11 11 11 11 10 10 9 10 7 6 13 11 11 11 11 12 13	100.0% Weight 3.2% 3.9% 4.7% 4.2% 16.0% 4.9% 4.2% 2.6% 3.8% 4.2% 2.6% 3.8% 4.2% 4.5% 4.5% 4.5% 4.5% 4.5% 84.0%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.59 [-2.40, -0.79] -0.58 [-1.43, 0.28] -0.30 [-1.15, 0.54] 0.33 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.48, 0.24] -0.35 [-1.24, 0.32] -0.50 [-1.28, 0.28] -0.62 [-1.48, 0.24] -0.37 [-0.31, -1.21, 0.48] -0.47 [-0.38, -0.12]	A Positive effects Negative effects
(añez-Garcia et al. 2019_U18 subtotal (95% CI) Heterogeneity: Tau ² = 0.43; Chi ² = Test for overall effect: Z = 1.91 (P Fotal (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P Fest for overall effect: Z = 3.23 (P Fest for subgroup L1.I FEMALE Attene et al. 2014_RST Souteraa et al. 2014_RST Souteraa et al. 2014_RST Souteraa et al. 2020 Meszler & Váczi 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.68; Chi ² = Test for overall effect: Z = 1.96 (P 2.1.2 MALE Vaced et al. 2015b_RST Hitene et al. 2014_DT Sonzalo-Skok et al. 2016 Sonzalo-Skok et al. 2019_BV Sonzalo-Skok et al. 2019_BV Sonzalo-Skok et al. 2019_BV Sonzalo-Skok et al. 2019_BV Sonzalo-Skok et al. 2019_BV Hernández et al. 2018_R *simachidis et al. 2019_U14 'añez-Garcia et al. 2019_U18 'añez-Garcia et al. 201	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c Mean 6.41 6.53 10.13 11.13 = 11.13, df = 0.05) 3.36 6.55 7.45 5.959 5.94 13.21 13.11 7.4 6.56 6.57 7.21 7.01 3.01 2.99 11 10.3 3.5.02 3.34 3.14 3.09 = 57.92, df	= 7 (P + 23) (P + 2	$\begin{array}{c} 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 254 \\ 255$	2); $l^2 =$ Mean Mean Mean 1 3 , $l^2 =$ 1 6 .83 6 .74 1 .13 1 0.96 6 .74 1 .13 1 0.96 6 .74 1 .13 1 0.96 6 .74 1 .13 1 0.96 1 .13 1 0.96 1 .13 1 .13 1 .0.96 1 .13 1 .13 1 .0.96 1 .13 1 .13 1 .0.96 1 .13 1 .13 1 .0.96 1 .13 1 .13 1 .13 1 .13 1 .13 1 .13 1 .12 1 .23 1 .13 1 .13 1 .13 1 .21 1 .2.93 1 .21 1 .2.93 1 .2.13 1 .2.13 1 .2.14 1 .2.31 1 .2.13 1 .2.13 1 .2.14 1 .2.31 1 .2.14 1 .2.15 1	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.48 0.48 3% 0.149 0.2 0.46 0.198 0.2 0.46 0.198 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.46 0.199 0.2 0.47 0.19 0.2 0.46 0.19 0.2 0.46 0.19 0.2 0.47 0.17 0.8 0.2 0.41 0.111 0.1	254 (1 Total 8 8 8 8 9 9 41 11 11 11 11 11 10 10 9 9 10 7 6 13 11 11 11 11 213	100.0% Weight 3.2% 3.9% 4.7% 4.2% 16.0% 4.2% 2.6% 3.8% 4.2% 2.6% 3.8% 4.2% 4.5% 4.5% 4.5% 4.5% 84.0%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.59 [-2.40, -0.79] -0.58 [-1.43, 0.28] -0.30 [-1.15, 0.54] 0.33 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.80, 0.77] -0.83 [-1.75, 0.09] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] -0.50 [-1.28, 0.28] -0.62 [-1.48, 0.24] -0.37 [-1.01, 0.66] -0.47 [-0.83, -0.12]	A Positive effects Negative effects
rañez-García et al. 2019_U18 ububotal (95% CI) leterogeneity: Tau ² = 0.43; Chi ² = rest for overall effect: Z = 1.91 (P rotal (95% CI) leterogeneity: Tau ² = 0.46; Chi ² = rest for overall effect: Z = 3.23 (P rest for overall effect: Z = 3.23 (P rest for subgroup differences: Chi tudy or Subgroup .1.1 FEMALE ttene et al. 2014_RST outeraa et al. 2020 deszler & Váczi 2019 ubtotal (95% CI) leterogeneity: Tau ² = 0.68; Chi ² = rest for overall effect: Z = 1.96 (P .1.2 MALE uksović et al. 2020 verde et al. 2018 usadi et al. 2016 strate et al. 2015b_RST titene et al. 2018_NR lernández et al. 2018_NR lernández et al. 2018_NR lernández et al. 2018_NR lernández et al. 2019_U14 añez-García et al. 2019_U15 añez-García et al. 2019_U16 añez-García et al. 2019_U16 añez-García et al. 2019_U17 bitotal (95% CI) leterogeneity: Tau ² = 0.43; Chi ² = set for overall effect: Z = 2.61 (P	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 5.94 13.21 13.11 7.44 6.56 6.57 7.21 7.21 13.11 7.44 6.56 6.57 7.21 13.30 10.299 11 10.3 5.02 3.34 3.09 = 57.92, df = 0.009)	= 7 (P + 23) (P + 2	$\begin{array}{c} 254 \\ 254 \\ < 0.00 \\ 254 \\ = 0.33 \\ \hline 75 \\ $	2); $ ^2 =$ Mean Mean 6.83 6.74 11.3 10.96 3.48 8.57 3.48 8.77 5.68 4.87 5.54 11.62 1.13 10.96 3.48 8.77 5.54 4.87 5.54 4.87 7.52 6.63 3.07 11.3 3.07 12.3 3.07 12.3 3.07 12.3 3.07 12.3 3.07 12.3 3.07 12.3 3.07 12.3 3.07 12.3 3.07 12.3 3.07 12.3 3.07 12.3 12.3 12.3 13.4 13.3 10.96 13.5 13.5 14.3 15.54 13.3 10.96 13.55 14.37 17.52 14.37 17.52 14.37 17.52 14.37 17.52 13.03 3.07 12.3 3.07 12.3 3.07 12.3 3.07 12.3 3.18 3.11 5.54 4.37 12.3 3.07 12.3 3.18 3.11 5.29 3.48 3.11 5.29 5.54 5.555 5.54 5.54 5.555 5.54 5.555 5.545	68% ² = 68% 12.4% Pre SD 0.24 0.24 0.3 0.6 0.48 3% 0.149 0.2 0.46 0.198 0.2 0.46 0.199 0.2 0.48 0.48 0.41 0.2 0.48 0.44 0.135 0.77 0.8 0.42 0.46 0.149 0.2 0.46 0.149 0.2 0.46 0.149 0.2 0.46 0.149 0.2 0.46 0.149 0.2 0.46 0.149 0.2 0.46 0.135 0.77 0.8 0.2 0.2 0.46 0.135 0.77 0.8 0.2 0.2 0.48 0.149 0.2 0.2 0.46 0.135 0.77 0.8 0.2 0.2 0.2 0.2 0.2 0.46 0.135 0.77 0.8 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	254 (1 Total 8 8 8 16 9 9 41 11 11 11 11 11 11 11 11 11 11 11 11	100.0% Weight 3.2% 3.9% 3.9% 4.7% 4.2% 16.0% 4.9% 4.2% 2.6% 3.8% 4.2% 4.2% 4.2% 4.5% 4.5% 4.5% 4.5% 84.0%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.90, 0.00] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.04 [0.34, 2.46] -0.59 [-2.20, -0.79] -0.58 [-1.43, 0.28] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.17] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.28, 0.72] -0.83 [-1.75, 0.09] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] -0.50 [-1.28, 0.28] -0.50 [-1.28, 0.28] -0.50 [-1.28, 0.24] -0.57 [-1.21, 0.48] -0.17 [-1.01, 0.66] -0.47 [-0.83, -0.12]	A -2 0 2 4 Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl
rañez-García et al. 2019_U18 ububotal (95% CI) leterogeneity: Tau ² = 0.43; Chi ² = rest for overall effect: Z = 1.91 (P rotal (95% CI) leterogeneity: Tau ² = 0.46; Chi ² = rest for overall effect: Z = 3.23 (P rest for subgroup differences: Chi itudy or Subgroup 1.11 FEMALE Nature et al. 2014_RST Noutrea et al. 2014_RST Noutrea et al. 2014_RST Noutrea et al. 2014_RST Noutrea et al. 2020 deszler & Váczi 2019 ubutotal (95% CI) leterogeneity: Tau ² = 0.68; Chi ² = rest for overall effect: Z = 1.96 (P 1.12 MALE Nature et al. 2018 Nature et al. 2018 Nature et al. 2018 Nature et al. 2018_RST tigueira et al. 2020_FLAT rigueira et al. 2020_FLAT rigueira et al. 2020_FLAT rigueira et al. 2018_RST titten et al. 2015_RST titten et al. 2015_RST titten et al. 2015_RST titten et al. 2018_RST rigueira et al. 2018_RST rigueira et al. 2018_RST titten et al. 2018_RST titten et al. 2018_RST idernández et al. 2018_R rismachidis et al. 2019_UH conzalo-Skok et al. 2019_UH conzalo-Skok et al. 2019_BV conzalo-Skok et al. 2019_UH conzalo-Skok et	= 22.08, df = 0.06) = 72.32, df = 0.001) ² = 3.43, c <u>Mean</u> 6.41 6.53 10.6 11.13 = 11.13, df = 0.05) 3.36 6.57 7.45 5.959 5.94 13.21 13.11 7.4 6.56 6.57 7.21 7.21 7.01 3.01 2.99 11 10.3 5.02 3.34 3.09 = 57.92, df = 0.009)	= 7 (P + 23) (P + 2	$\begin{array}{c} 254 \\ 254 \\ < 0.00 \\ 254 \\ = 0.33 \\ \hline 75 \\ $	2); $ ^2 =$ Mean Mean 6.83 6.74 11.3 10.96 1.12 3.48 8.87 5.64 11.62 1.13 10.96 1.12 7.52 6.63 1.13 10.96 1.13 10.96 1.13 1.15 1	68% ² = 68% 12.4% Pre SD 0.24 0.3 0.6 0.48 3% 0.149 0.2 0.46 0.149 0.2 0.48 0.149 0.2 0.48 0.48 0.41 0.2 0.48 0.48 0.48 0.49 0.2 0.48 0.49 0.2 0.48 0.48 0.48 0.48 0.49 0.2 0.48 0.48 0.48 0.48 0.48 0.49 0.2 0.48 0.48 0.49 0.2 0.48 0.48 0.49 0.2 0.48 0.48 0.49 0.2 0.48 0.49 0.2 0.48 0.49 0.2 0.48 0.41 0.21 0.11 0.11 0.12 0.11 0.12 0.11 0.12 0.11	254 (1 Total 8 8 8 16 9 9 41 16 9 8 8 9 9 9 9 9 15 16 11 11 11 11 10 10 0 7 6 13 11 11 11 11 213 254	100.0% Weight 3.2% 3.9% 3.9% 4.7% 4.2% 16.0% 4.9% 4.2% 2.6% 3.8% 4.2% 4.2% 4.2% 4.2% 4.4% 4.5% 4.3% 4.3% 4.5% 84.0% 100.0%	-0.55 [-0.88, -0.22] Std. Mean Difference IV, Random, 95% CI -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -1.34 [-2.11, -0.56] 0.29 [-0.64, 1.22] -0.95 [-1.82, 0.24] -0.95 [-1.90, 0.00] -0.14 [-1.07, 0.78] -3.08 [-4.65, -1.51] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.08 [0.34, 2.46] -0.29 [-1.22, 0.64] 1.08 [0.34, 2.46] -0.30 [-1.15, 0.54] -0.36 [-1.28, 0.71] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.28, 0.28] -0.62 [-1.48, 0.24] -0.67 [-1.48, 0.24] -0.67 [-1.48, 0.24] -0.47 [-0.83, -0.12]	A -2 0 2 4 Positive effects Negative effects Std. Mean Difference IV, Random, 95% Cl

p = 0.29), U-16 (SMD, -0.42; 95% CI: -0.93 to 0.09; I², 62%; Z, 1.63; p = 0.10) and U-18 sub-groups (SMD, -0.55; 95% CI: -1.11 to 0.01; I², 68%; Z, 1.87; p = 0.06).

(B)

Figure 6. Cont.

Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
2.1.1 ELITE									
Asadi et al. 2016	7.45	0.41	8	8.87	0.46	8	2.6%	-3.08 [-4.65, -1.51]	
Attene et al. 2014 IT	6.41	0.1	8	6.83	0.24	8	3.2%	-2.16 [-3.47, -0.85]	
Attene et al. 2014 RST	6.53	0.19	8	6.74	0.3	8	3.9%	-0.79 [-1.82, 0.24]	
Attene et al. 2015b IRST	5.959	0.18	9	5.68	0.198	9	3.8%	1.40 [0.34, 2.46]	
Attene et al. 2015b RST	5.94	0.31	9	6.04	0.35	9	4.2%	-0.29 [-1.22, 0.64]	
Figueira et al. 2020 FLAT	13.21	1.88	15	11.62	0.77	15	4.7%	1.08 [0.30, 1.85]	
Figueira et al. 2020 SLOPE	13.11	0.74	16	14.37	0.8	16	4.6%	-1.59 [-2.40, -0.79]	
Gonzalo-Skok et al. 2016	7.4	0.2	11	7.52	0.2	11	4.4%	-0.58 [-1.43, 0.28]	
Gonzalo-Skok et al. 2017 BI	6.56	0.2	11	6.63	0.24	11	4.5%	-0.30 [-1.15, 0.54]	_ _
Gonzalo-Skok et al. 2017 UNI	6.57	0.23	11	6.5	0.18	11	4.5%	0.33 [-0.52, 1.17]	
Conzalo-Skok et al. 2019 BV	7 21	0.4	10	7 3 7	0.41	10	4 3%	-0.38[-1.26, 0.51]	
Conzalo-Skok et al. 2019_UH	7.01	0 19	10	7 25	0.22	10	4 1%	-1 12 [-2 08 -0 16]	
Cottlieb et al 2014 PT	3.01	0.13	9	3.03	0.12	9	4 2%	-0.15[-1.08.0.77]	
Cottlieb et al. 2014_FT	2 00	0.15	10	3.05	0.12	10	4.2%	-0.83 [-1.75, 0.09]	
Vañez-Carcía et al. 2014_ 31	3 34	0.07	11	3.46	0.10	11	4.2%	-0.62 [-1.48 0.24]	
Vañez-García et al. 2019_014	2 14	0.10	11	2 1 2	0.19	11	4.4/0	-0.27 [-1.21, 0.48]	
Vañoz Carcía et al. 2019_010	2.00	0.1	11	2 11	0.11	11	4.3/0	-0.37 [-1.21, 0.46]	
Subtotal (95% CI)	5.09	0.11	178	5.11	0.11	178	4.5%		
Heterogeneity: $Tau^2 = 0.59$; $Chi^2 =$ Test for overall effect: $Z = 2.24$ (P	= 59.17, df = 0.03)	f = 16 (I	P < 0.0	0001); I	² = 73%	6			•
2.1.2 AMATEUR									
Aksović et al. 2020	3.36	0.169	16	3.48	0.149	16	4.9%	-0.73 [-1.450.02]	
Arede et al. 2018	5.5	0.32	9	5.54	0.2	9	4.2%	-0.14 [-1.07. 0.78]	
Bouteraa et al. 2020	10.6	0.4	16	11.3	0.6	16	4.7%	-1.34 [-2.110.56]	— <u> </u>
Hernández et al. 2018 NR	11	1.1	7	12.3	1.1	7	3.6%	-1.11 [-2.26. 0.05]	
Hernández et al. 2018 R	10.3	0.7	6	12.1	1.1	6	2.9%	-1.80 [-3.24 -0.37]	I
Meszler & Váczi 2019	11.13	0.63	ğ	10.96	0.48	q	4 2%	0.29 [-0.64 1.22]	_ _
Tsimachidis et al. 2010	5.02	0.23	13	5.29	0.7	13	4 7%	-0.50 [-1.28 0.28]	
Subtotal (95% CI)	5.02	0.23	76	5.23	0.7	76	29.1%	-0.70 [-1.170.22]	◆
Heterogeneity: $Tau^2 = 0.19$; $Chi^2 =$ Test for overall effect: $Z = 2.86$ (P	= 11.33, df = 0.004)	f = 6 (P	= 0.08); $I^2 = 4$	7%			,,	•
Total (95% CI)			254			254	100.0%	-0.55 [-0.880.22]	•
Heterogeneity: $Tau^2 = 0.46$: $Chi^2 =$	= 72.32. df	f = 23 (P < 0.0	0001):	$^{2} = 68\%$	6			
Test for overall effect: $Z = 3.23$ (P	= 0.001	(,, -					-4 -2 0 2
Test for subgroup differences: Chi	$^{2} = 0.38$	f = 1 (F)	P = 0.54	4), $ ^2 =$	0%				Positive effects Negative effects
				.,, .		(\mathbf{C}		
							\mathbf{C}		
		Deet			Dee	`	<i>′</i> .	Cad Maan Difference	Std. Maan Difference
Study or Subgroup	Mean	Post	Total	Moan	Pre	Total	Weight	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	Post SD	Total	Mean	Pre SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING	Mean	Post SD	Total	Mean	Pre SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Std. Mean Difference IV, Random, 95% CI
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016	Mean 7.45	Post SD	Total 8	Mean 8.87	Pre SD 0.46	Total 8	Weight	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020	Mean 7.45 10.6	Post SD 0.41 0.4	Total 8 16	Mean 8.87 11.3	Pre SD 0.46 0.6	Total 8 16	Weight 2.6% 4.7%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT	Mean 7.45 10.6 13.21	Post SD 0.41 0.4 1.88	Total 8 16 15	Mean 8.87 11.3 11.62	Pre SD 0.46 0.6 0.77	Total 8 16 15	Weight 2.6% 4.7% 4.7%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE	Mean 7.45 10.6 13.21 13.11	Post SD 0.41 0.4 1.88 0.74	Total 8 16 15 16	Mean 8.87 11.3 11.62 14.37	Pre SD 0.46 0.6 0.77 0.8	Total 8 16 15 16	Weight 2.6% 4.7% 4.7% 4.6%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_FLOPE Gonzalo-Skok et al. 2019_BV	Mean 7.45 10.6 13.21 13.11 7.21	Post SD 0.41 0.4 1.88 0.74 0.4	Total 8 16 15 16 10	Mean 8.87 11.3 11.62 14.37 7.37	Pre SD 0.46 0.6 0.77 0.8 0.41	Total 8 16 15 16 10	Weight 2.6% 4.7% 4.7% 4.6% 4.3%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH	Mean 7.45 10.6 13.21 13.11 7.21 7.01	Post SD 0.41 0.4 1.88 0.74 0.4 0.4 0.19	Total 8 16 15 16 10 10	Mean 8.87 11.3 11.62 14.37 7.37 7.25	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22	Total 8 16 15 16 10 10	Weight 2.6% 4.7% 4.7% 4.6% 4.3% 4.1%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT	Mean 7.45 10.6 13.21 13.11 7.21 7.01 3.01	Post 5D 0.41 0.4 1.88 0.74 0.74 0.4 0.19 0.13	Total 8 16 15 16 10 10 9	Mean 8.87 11.3 11.62 14.37 7.37 7.25 3.03	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12	Total 8 16 15 16 10 10 9	Weight 2.6% 4.7% 4.7% 4.6% 4.3% 4.1% 4.2%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_NR	Mean 7.45 10.6 13.21 13.11 7.21 7.01 3.01 11	Post SD 0.41 0.4 1.88 0.74 0.4 0.19 0.13 1.1	Total 8 16 15 16 10 10 9 7	Mean 8.87 11.3 11.62 14.37 7.37 7.25 3.03 12.3	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 1.1	Total 8 16 15 16 10 10 9 7	Weight 2.6% 4.7% 4.7% 4.6% 4.3% 4.1% 4.2% 3.6%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_R Hernández et al. 2018_R	Mean 7.45 10.6 13.21 13.11 7.21 7.01 3.01 11 10.3	Post SD 0.41 0.4 1.88 0.74 0.4 0.19 0.13 1.1 0.7	Total 8 16 15 16 10 10 9 7 6	Mean 8.87 11.3 11.62 14.37 7.37 7.25 3.03 12.3 12.1	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 1.1 1.1	Total 8 16 15 16 10 10 9 7 6	Weight 2.6% 4.7% 4.6% 4.6% 4.3% 4.1% 4.2% 3.6% 2.9%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_NR Meszler & Váczi 2019	Mean 7.45 10.6 13.21 13.11 7.21 7.01 3.01 11 10.3 11.13	Post SD 0.41 0.4 1.88 0.74 0.4 0.19 0.13 1.1 0.7 0.63	Total 8 16 15 16 10 10 9 7 6 9	Mean 8.87 11.3 11.62 14.37 7.25 3.03 12.3 12.1 10.96	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 1.1 1.1 0.48	Total 8 16 15 16 10 10 9 7 6 9	Weight 2.6% 4.7% 4.6% 4.3% 4.1% 3.6% 2.9% 4.2%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_R Meszler & Váczi 2019 Tsimachidis et al. 2010	Mean 7.45 10.6 13.21 13.11 7.21 7.01 3.01 11 10.3 11.13 5.02	Post SD 0.41 0.4 1.88 0.74 0.4 0.19 0.13 1.1 0.7 0.63 0.23	Total 8 16 15 16 10 10 9 7 6 9 13	Mean 8.87 11.3 11.62 14.37 7.25 3.03 12.3 12.1 10.96 5.29	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 1.1 1.1 0.48 0.7	Total 8 16 15 16 10 10 9 7 6 9 13	Weight 2.6% 4.7% 4.6% 4.3% 4.1% 4.2% 3.6% 2.9% 4.2% 4.7%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Hernández et al. 2018_R Hernández et al. 2018_R Meszler & Váczi 2019 Tsimachidis et al. 2010 Subtotai (95% CI)	Mean 7.45 10.6 13.21 13.11 7.21 7.01 3.01 11 10.3 11.13 5.02	Post SD 0.41 0.4 1.88 0.74 0.4 0.19 0.13 1.1 0.7 0.63 0.23	Total 8 16 15 16 10 10 9 7 6 9 13 119	Mean 8.87 11.3 11.62 14.37 7.37 7.25 3.03 12.3 12.1 10.96 5.29	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 1.1 1.1 0.48 0.7	Total 8 16 15 16 10 10 9 7 6 9 13 119	Weight 2.6% 4.7% 4.7% 4.7% 4.3% 4.3% 4.1% 4.2% 3.6% 2.9% 4.2% 4.7% 44.7%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_R Meszler & Váczi 2019 Tsimachidis et al. 2010 Subtotal (95% CI) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P	Mean 7.45 10.6 13.21 13.11 7.21 7.01 3.01 11 10.3 11.13 5.02 = 46.12, df = 0.01)	Post SD 0.41 0.4 1.88 0.74 0.4 0.19 0.13 1.1 0.7 0.63 0.23 f = 10 (0	8 16 15 16 10 9 7 6 9 13 119 P < 0.00	Mean 8.87 11.3 11.62 14.37 7.25 3.03 12.3 12.1 10.96 5.29 00001); I	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 1.1 1.1 0.48 0.7 2 = 78%	Total 8 16 15 16 10 10 9 7 6 9 13 119	Weight 2.6% 4.7% 4.6% 4.3% 4.3% 4.3% 3.6% 2.9% 4.2% 4.7% 44.7%	Std. Mean Difference IV, Random, 95% Cl -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_R Meszler & Váczi 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI	Mean 7.45 10.6 13.21 13.11 7.01 3.01 111 10.3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN	Post SD 0.41 0.4 1.88 0.74 0.4 0.19 0.13 1.1 0.7 0.63 0.23 f = 10 (0 NG	Total 8 16 15 16 10 9 7 6 9 13 119 P < 0.00	Mean 8.87 11.3 11.62 14.37 7.37 7.25 3.03 12.1 10.96 5.29 00001); I	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 1.1 1.1 0.48 0.7 ² = 78%	Total 8 16 15 16 10 10 9 7 6 9 13 119 6	Weight 2.6% 4.7% 4.7% 4.3% 4.3% 4.1% 4.2% 3.6% 2.9% 4.2% 4.7% 44.7%	Std. Mean Difference IV, Random, 95% Cl -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_FLAT Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_NR Hernández et al. 2018_R Meszler & Váczi 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018	Mean 7.45 10.6 13.21 13.11 7.21 7.01 3.01 11 10.3 11 5.02 = 46.12, dH = 0.01) NDITIONIN 5.5	Post SD 0.41 0.4 1.88 0.74 0.4 0.19 0.13 1.1 0.7 0.63 0.23 f = 10 (0 NG 0.32	Total 8 16 15 16 10 9 7 6 9 13 119 P < 0.00	Mean 8.87 11.3 11.62 14.37 7.25 3.03 12.3 12.3 12.9 00001); I 5.54	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 1.1 1.1 0.48 0.7 2 = 78%	Total 8 16 15 10 10 9 7 6 9 13 119 6 9	Weight 2.6% 4.7% 4.6% 4.3% 4.1% 4.2% 3.6% 2.9% 4.2% 4.7% 44.7%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.14 [-1.07, 0.78]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Hernández et al. 2014_PT Hernández et al. 2018_R Meszler & Váczi 2019 Tsimachidis et al. 2010 Subtotal (95% CI) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2016	Mean 7.45 10.6 13.21 13.11 7.01 3.01 11 10.3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN 5.5 7.4	Post SD 0.41 0.4 1.88 0.74 0.4 0.19 0.13 1.1 0.7 0.63 0.23 f = 10 (0 NG 0.32 0.2	Total 8 16 10 9 7 6 9 13 10P < 0.00	Mean 8.87 11.3 11.62 14.37 7.25 3.03 12.3 12.1 10.96 5.29 00001); 1 5.54 7.52	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 1.1 1.1 0.48 0.7 2 = 78%	Total 8 16 15 10 10 9 7 6 9 13 119 6 9 11	Weight 2.6% 4.7% 4.7% 4.3% 4.3% 4.3% 4.2% 4.2% 4.2% 44.7%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.14 [-1.07, 0.78] -0.58 [-1.43, 0.28]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_R Meszler & Váczi 2019 Tsimachidis et al. 2010 Subtotal (95% CI) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2016 Gonzalo-Skok et al. 2017 BIL	Mean 7.45 10.6 13.21 13.11 7.01 10.3 11 10.3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN 5.5 7.4 6.56	Post SD 0.41 0.4 1.88 0.74 0.4 0.19 0.13 1.1 0.7 0.63 0.23 f = 10 (0 NG 0.32 0.2 0.2	Total 8 16 10 9 13 119 P < 0.00	Mean 8.87 11.3 11.62 14.37 7.25 3.03 12.3 12.3 12.1 10.96 5.29 00001); 1 5.54 7.52 6.63	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 1.1 1.1 0.48 0.7 2 = 789 0.2 0.2 0.24	Total 8 16 15 16 10 10 9 7 6 9 13 119 6 9 11 11	Weight 2.6% 4.7% 4.6% 4.3% 4.2% 3.6% 2.9% 4.2% 4.2% 4.2% 4.7% 4.4%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.14 [-1.07, 0.78] -0.30 [-1.15, 0.54]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_FLAT Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_NR Hersón (2018) Subtotal (95% CI) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_UNI	Mean 7.45 10.6 13.21 13.11 7.21 7.01 3.01 11 15.5 7.4 6.56 6.57	Post SD 0.41 0.4 1.88 0.74 0.4 0.7 0.13 1.1 0.7 0.63 0.23 f = 10 (0 NG 0.2 0.2 0.2 0.2 0.2	Total 8 16 15 16 10 9 7 6 9 13 119 P < 0.00	Mean 8.87 11.3 11.62 14.37 7.25 3.03 12.3 12.1 10.96 5.29 00001); 1 5.54 7.52 6.63 6.5	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 1.1 1.1 0.48 0.7 ² = 789 0.2 0.2 0.2 0.2 0.2 0.2	Total 8 16 15 16 10 10 9 7 6 9 13 119 6 9 11 11 11	Weight 2.6% 4.7% 4.6% 4.3% 4.1% 4.2% 4.2% 4.7% 4.7% 44.7%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.14 [-1.07, 0.78] -0.58 [-1.43, 0.28] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.17]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_R Meszler & Váczi 2019 Tsimachidis et al. 2010 Subtotal (95% CI) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2019_U14	Mean 7.45 10.6 13.21 13.11 7.01 3.01 11 10.3 3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN 5.5 7.4 4.6.56 6.57 3.34	Post SD 0.41 0.4 1.88 0.74 0.4 0.4 0.4 1.88 0.74 0.13 1.1 0.7 0.63 0.23 f = 10 (0 NG 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	Total 8 16 15 16 10 9 7 6 9 13 119 P < 0.00	Mean 8.87 11.3 11.62 14.37 7.25 3.03 12.3 12.1 10.96 5.29 00001); 1 5.54 7.52 6.63 6.5 3.46	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 1.1 1.1 1.1 0.48 0.7 2 = 78% 0.2 0.2 0.24 0.12 0.2 0.24 0.12 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.	Total 8 8 166 155 166 100 100 9 9 7 7 6 9 9 3 119 6 9 111 111 111 111	Weight 2.6% 4.7% 4.7% 4.3% 4.3% 4.3% 4.2% 4.2% 4.2% 4.7% 44.7%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.14 [-1.07, 0.78] -0.58 [-1.43, 0.28] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.17] -0.62 [-1.48, 0.28]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_R Meszler & Váczi 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U14	Mean 7.45 10.6 13.21 13.11 7.21 7.01 3.01 11 10.3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN 5.5 7.4 6.56 6.57 3.34	Post SD 0.41 0.4 0.41 0.4 0.41 0.4 0.41 0.4 0.41 0.4 0.41 0.4 0.41 0.4 0.41 0.4 0.19 0.13 1.1 0.7 0.63 0.23 0.42 0.22 0.22 0.22 0.22 0.22 0.23 0.12 0.22 0.22 0.23 0.12 0.23 0.12	Total 8 8 16 15 15 16 10 10 9 9 7 7 6 9 9 11 11 11 11 11 11 11 11 11 11 11 11	Mean 8.87 11.3 11.62 14.37 7.25 3.03 12.3 12.3 12.3 10.96 5.29 00001); 1 5.54 7.52 6.63 6.5 3.46	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 1.1 1.1 1.1 1.1 0.48 0.7 7 2 = 78% 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	Total 8 8 16 15 16 10 10 10 10 9 9 7 7 6 9 9 13 119 6 9 9 11 11 11 11 11 11 11 11	Weight 2.6% 4.7% 4.6% 4.3% 4.3% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.5% 4.4% 4.5% 4.4% 4.5% 4.4%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.14 [-1.07, 0.78] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.17] -0.62 [-1.48, 0.24] -0.37 [-1.21 0.49]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_FLAT Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Hernández et al. 2018_NR Hernández et al. 2018_NR Hernández et al. 2018_NR Hernández et al. 2018_NR Hernández et al. 2018_NR Hersández et al. 2018_NR Hetrogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2019_U16 Yañez-García et al. 2019_U16 Yañez-García et al. 2019_U18	Mean 7.45 10.6 13.21 13.11 7.01 3.01 11 10.3 11.13 5.02 = 46.12, dH = 0.01) NDITIONIN 5.5 7.4 6.56 6.57 3.34 3.14	Post SD 0.41 .0.4 0.4 .0.4 0.8 .0.7 0.13 .1.1 0.7 0.633 0.23 .2.3 5 = 10 (0 NCC 0.23 0.23 0.23 0.18 0.13	Total 8 16 15 16 10 9 7 6 9 113 119 9 11 11 11 11 11 11 11	Mean 8.87 11.3 11.62 14.37 7.25 3.03 12.1 10.96 5.29 00001); 1 5.54 7.52 6.63 3.65 3.46 3.18 3.11	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 0.12 0.12 0.12 0.48 0.7 7 2 = 78% 0.2 0.24 0.22 0.24 0.2 0.2 0.24 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	Total 8 16 15 16 10 10 9 7 6 9 13 119 6	Weight 2.6% 4.7% 4.6% 4.3% 4.1% 4.2% 4.2% 4.2% 4.7% 4.7% 4.7% 4.7%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.14 [-1.07, 0.78] -0.58 [-1.43, 0.28] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.17] -0.62 [-1.48, 0.24] -0.37 [-1.21, 0.48] -0.17 [-1.21, 0.48]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Hernández et al. 2018_NR Hernández et al. 2018_R Meszler & Váczi 2019 Tsimachidis et al. 2010 Subtotal (95% CI) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U16 Yañez-García et al. 2019_U18 Subtotal (95% CI)	Mean 7.45 10.6 13.21 13.11 7.01 3.01 11 10.3 3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN S.5 7.4 4 6.56 6.57 7.3,34 3.14 3.09	Post SD 0.41 0.4 0.4 1.88 0.74 0.63 0.13 1.1 0.7 0.63 0.23 0.23 f = 10 (0 0.32 VC 0.22 0.23 0.23 0.32 0.23 0.32 0.23 0.32 0.23 0.32 0.23 0.32 0.23 0.32 0.23 0.32 0.23 0.32 0.23 0.32 0.23 0.32 0.23 0.32 0.23 0.32 0.23 0.33 0.33 0.11 0.11	Total 8 16 15 16 10 9 13 13 119 P < 0.0	Mean 8.87 11.3 11.62 7.37 7.25 3.03 12.3 12.1 10.96 5.29 00001); 1 5.54 7.52 6.63 6.5 5.54 7.52 6.63 6.5 5.46 3.18 3.11	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 0.12 0.12 0.7 0.48 0.7 0.7 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	Total 8 8 16 15 5 16 10 10 9 9 7 7 6 9 9 13 119 6 6 9 11 11 11 11 11 11 11 11 11 11 11 11 1	Weight 2.6% 4.7% 4.6% 4.3% 4.2% 3.6% 2.9% 4.2% 4.2% 4.2% 4.7% 4.2% 4.7% 4.5% 4.5% 3.6% 2.5% 3.10%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.14 [-1.07, 0.78] -0.58 [-1.43, 0.28] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.77] -0.62 [-1.48, 0.24] -0.37 [-1.21, 0.48] -0.17 [-1.01, 0.66] -0.27 [-0.59, 0.06]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_NR Hernández et al. 2018_NR Hernández et al. 2018_R Meszler & Váczi 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Tau ² = 0.00; Chi ² = Test for overall effect: Z = 1.61 (P	Mean 7.45 10.6 13.21 13.11 7.01 3.01 11 10.3 11 3.01 11 5.02 = 46.12, df = 0.01) NDITIONIN 5.5 7.4 6.56 6.57 3.34 3.14 3.09 = 3.24, df = 0.11)	$\begin{array}{c} \text{Post} \\ \text{SD} \end{array} \\ 0.41 \\ 0.4 \\ 1.88 \\ 0.74 \\ 0.4 \\ 0.19 \\ 0.13 \\ 1.1 \\ 0.7 \\ 0.63 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.12 \\ 0.2 \\ 0.2 \\ 0.2 \\ 0.2 \\ 0.23 \\ 0.11$	Total 8 16 15 16 10 9 13 119 P < 0.00	Mean 8.87 11.3 11.62 14.37 7.25 3.03 12.3 12.3 10.96 5.29 00001); l 5.54 7.52 6.63 6.5 3.46 3.18 3.11 l ² = 0%	Pre SD 0.46 0.6 0.77 0.12 1.1 1.1 1.1 0.48 0.7 2 = 78% 0.2 0.22 0.24 0.2 0.24 0.18 0.11 0.11	Total 8 16 15 16 10 10 9 9 3 119 6 9 9 11 11 11 11 11 11 11 11 11 11 11 75	Weight 2.6% 4.7% 4.6% 4.3% 4.3% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.5% 4.4% 4.5% 4.5% 31.0%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.31 [-1.43, 0.28] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.17] -0.62 [-1.48, 0.24] -0.37 [-1.21, 0.48] -0.77 [-0.59, 0.06]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020_FLAT Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_NR Hernández et al. 2018_C Subtotal (95% CI) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2017_UNI Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Tau ² = 0.00; Chi ² = Test for overall effect: Z = 1.61 (P 2.1.3 ENDURANCE	Mean 7.45 10.6 13.21 7.01 3.01 11 10.3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN 5.5 7.4 6.56 6.57 3.34 3.14 3.09 = 3.24, df = = 0.11)	$\begin{array}{c} \textbf{Post} \\ \textbf{SD} \end{array} \\ 0.41 \\ 0.4 \\ 1.88 \\ 0.74 \\ 0.4 \\ 0.19 \\ 0.13 \\ 1.1 \\ 0.7 \\ 0.63 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.12 \\ 0.2$	Total 8 16 15 16 10 9 13 119 9 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 112 75 6 0.780;	Mean 8.87 11.3 11.62 14.37 7.35 3.03 12.3 10.96 5.29 00001); l 5.54 7.52 6.63 6.5 3.46 3.18 3.11 l ² = 0%	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 1.1 1.1 1.1 0.48 0.7 2 2 = 78% 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	Total 8 16 15 16 10 10 9 7 7 6 9 9 13 119 6 6	Weight 2.6% 4.7% 4.6% 4.3% 4.3% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.5% 4.4% 4.5% 4.5% 31.0%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.17] -0.62 [-1.48, 0.24] -0.37 [-1.21, 0.48] -0.17 [-1.01, 0.66] -0.27 [-0.59, 0.06]	Std. Mean Difference IV, Random, 95% CI
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Hernández et al. 2018_NR Hernández et al. 2018_NR Hernández et al. 2018_NR Hernánides et al. 2018_NR Hernánides et al. 2018_NR Hernánides et al. 2018_NR Hernánides et al. 2018_NR Hernánet et al. 2019_UT Subtotal (95% CI) Heterogeneity: Tau ² = 0.00; Chi ² = Test for overall effect: Z = 1.61 (P 2.1.3 ENDURANCE Akrouié et al. 2020	Mean 7.45 10.6 13.21 13.11 7.01 10.3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN 5.5 7.4 4.656 6.57 3.34 3.14 3.09 = 3.24, df = 0.11)	$\begin{array}{c} \text{Post} \\ \text{SD} \end{array} \\ 0.41 \\ 0.4 \\ 1.88 \\ 0.74 \\ 0.4 \\ 0.74 \\ 0.4 \\ 0.74 \\ 0.74 \\ 0.74 \\ 0.74 \\ 0.74 \\ 0.74 \\ 0.74 \\ 0.74 \\ 0.11 \\ 0.71 \\ 0.11 \\$	Total 8 16 15 16 10 9 7 7 6 9 13 119 P < 0.00 9 11 11 11 11 11 11 11 11 12 5 0 (0.78); 16 0 10 10 10 10 10 10 10 10 10	Mean 8.87 11.3 11.62 14.37 7.35 5.03 12.3 12.3 12.3 12.3 12.3 12.5 5.29 00001); I 5.54 7.52 6.63 3.18 3.11 I ² = 0%	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 1.1 1.1 1.1 0.48 0.7 2 - 789 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	Total 8 166 155 166 100 100 9 9 113 119 6 6 9 9 113 119 6 6 9 111 111 111 111 111 111 111 1	Weight 2.6% 4.7% 4.6% 4.3% 4.1% 4.2% 4.2% 4.7% 4.7% 4.7% 4.7% 4.7% 4.5% 4.5% 4.5% 31.0%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.14 [-1.07, 0.78] -0.58 [-1.43, 0.28] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.17] -0.62 [-1.48, 0.24] -0.17 [-0.10, 0.66] -0.27 [-0.59, 0.06]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2018_R Hernández et al. 2018_R Meszler & Váczi 2019 Tsimachidis et al. 2010 Subtotal (95% Cl) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U18 Subtotal (95% Cl) Heterogeneity: Tau ² = 0.00; Chi ² = Test for overall effect: Z = 1.61 (P 2.1.3 ENDURANCE Aktsović et al. 2020	Mean 7.45 10.6 13.21 13.11 7.01 3.01 11 10.3 11 10.3 11.13 5.02 = 46.12, df = 46.12, df 6.56 6.57 3.34 3.14 3.09 = 3.24, df = 0.11) 3.366	Post SD 0.41 0.4 0.4 0.4 0.4 0.4 0.8 0.74 0.4 0.8 0.74 0.4 0.8 0.74 0.4 0.74 0.13 1.1 0.63 0.23 $f = 100$ 0.32 0.23 0.22 0.23 0.22 0.23 0.23 0.160 0.169	Total 8 16 15 16 10 9 13 13 11 16	Mean 8.87 11.3 11.62 14.37 7.37 7.37 7.37 3.03 12.3 12.3 12.3 12.3 10.96 5.29 00001); I 5.544 7.52 6.63 6.5 3.48 8.11 I 2 = 0% 3.48 8.62 1.42 1.427 1	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 1.1 1.1 1.1 0.48 0.7 2 = 78% 0.22 0.24 0.48 0.7 0.2 0.24 0.18 0.11 0.11	Total 8 16 155 16 10 10 9 9 7 7 6 9 9 13 119 6 9 9 11 11 11 11 11 11 11 11 11 11 11 11	Weight 2.6% 4.7% 4.6% 4.3% 4.2% 3.6% 2.9% 4.2% 4.2% 4.7% 4.7% 4.7% 4.5% 4.5% 4.5% 31.0%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.14 [-1.07, 0.78] -0.33 [-0.52, 1.17] -0.62 [-1.48, 0.24] 0.33 [-0.52, 1.17] -0.62 [-1.48, 0.24] -0.17 [-1.01, 0.66] -0.27 [-0.59, 0.06] -0.73 [-1.45, -0.02] -0.16 [-3.47, 0.72]	Std. Mean Difference IV, Random, 95% CI
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_FLAT Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_UH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_NR Hersé SCON Subtotal (95% CI) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arded et al. 2018 Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U14 Subtotal (95% CI) Heterogeneity: Tau ² = 0.00; Chi ² = Test for overall effect: Z = 1.61 (P 2.1.3 ENDURANCE Aksović et al. 2020 Attene et al. 2014_JT	Mean 7.45 10.6 13.21 7.01 3.01 11 10.3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN 5.5 7.4 6.56 6.57 3.34 3.14 3.09 = 3.24, df = 0.11) 3.36 6.41	Post SD 0.41 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.7 0.13 0.13 1.1 0.7 0.63 0.23 0.18 0.11 0.18 0.11 0.16 0.11 0.169 0.12	Total 8 16 15 16 10 10 9 13 119 P < 0.00	Mean 8.87 11.3 11.62 14.37 7.35 3.03 12.3 10.96 5.29 00001); l 5.54 7.52 6.63 6.5 3.46 3.11 l ² = 0% 3.48 6.83	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 1.1 1.1 1.1 0.48 0.7 2 = 78% 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	Total 8 8 166 155 166 100 100 9 9 7 7 6 6 9 9 113 119 6 6 9 9 114 114 114 114 115 75 166 8 8 100 100 100 100 100 100 100 100 100	Weight 2.6% 4.7% 4.6% 4.3% 4.3% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.5% 4.5% 4.5% 31.0%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.33 [-0.52, 1.17] -0.62 [-1.48, 0.24] -0.37 [-1.21, 0.48] -0.37 [-1.21, 0.48] -0.77 [-0.59, 0.06] -0.73 [-1.45, -0.02] -2.16 [-3.47, -0.85] 0.70 [-1.20, 0.65]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Hernández et al. 2018_NR Hernández et al. 2018_NR Hernández et al. 2018_NR Hernánides et al. 2018_NR Hersández et al. 2018_NR Hersőgeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2019_U16 Yañez-García et al. 2019_U16 Subtotal (95% CI) Heterogeneity: Tau ² = 0.00; Chi ² = Test for overall effect: Z = 1.61 (P 2.1.3 ENDURANCE Aksović et al. 2020 Attene et al. 2014_IT Attene et al. 2014_RST	Mean 7.45 10.6 13.21 13.11 7.01 10.3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN S.5 7.4 6.56 6.57 3.34 3.14 3.09 = 3.24, df = 0.11) 3.36 6.41 6.53 6.54	Post SD 0.41 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.13 0.1 0.14 0.1 0.16 0.1 0.169 0.1 0.169 0.1	Total 8 16 15 16 10 10 10 10 10 10 10 10 10 10 10 11 12 6 8 8	Mean 8.87 11.3 11.62 14.37 7.37 7.33 12.1 10.96 5.29 00001); 1 5.54 7.52 6.63 3.46 6.83 6.83 6.83 6.83 6.74	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 0.12 1.11 0.48 0.7 2 = 789 0.2 0.24 0.11 0.11 0.11 0.149 0.24 0.3 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	Total 8 166 155 166 100 100 9 9 113 119 6 6 9 9 111 111 111 111 111 111 111	Weight 2.6% 4.7% 4.6% 4.3% 4.1% 4.2% 4.2% 4.7% 4.7% 4.7% 4.7% 4.7% 4.7% 4.7% 5.8% 4.7% 4.5% 4.5% 4.5% 4.5% 31.0%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.78 [-1.15, 0.54] 0.33 [-0.52, 1.17] -0.62 [-1.48, 0.24] -0.17 [-0.59, 0.06] -0.73 [-1.45, -0.02] -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] -0.79 [-1.82, 0.24] -0.79 [-1.82, 0.24] -0.79 [-1.82, 0.24] -0.79 [-1.82, 0.24]	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2018_R Hernández et al. 2018_R Meszler & Váczi 2019 Tsimachidis et al. 2010 Subtotal (95% Cl) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U18 Subtotal (95% Cl) Heterogeneity: Tau ² = 0.00; Chi ² = Test for overall effect: Z = 1.61 (P 2.1.3 ENDURANCE Aktene et al. 2014_RST Attene et al. 2014_RST Attene et al. 2014_RST	Mean 7.45 10.6 13.21 13.11 7.01 3.01 11 10.3 11 10.3 11 10.3 11.13 5.02 = 46.12, df = 46.12, df 6.56 6.57 3.34 3.14 3.09 = 3.24, df = = 0.11) 3.36 6.51 5.52	Post SD 0.41 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.13 0.1 0.63 0.23 0.7 0.2 0.23 0.2 0.23 0.2 0.23 0.2 0.23 0.2 0.23 0.2 0.23 0.1 0.11 0.11 0.16 0.169 0.16 0.19 0.18 0.2	Total 8 16 15 16 10 10 9 13 19 9 111 111 111 111 111 111 111 116 8 9 166 8 9	Mean 8.87 11.3 11.62 14.37 7.37 7.37 7.37 7.37 7.37 7.25 6.63 6.83 6.83 6.84 6.83 6.84 6.83 6.84 6.83 6.84 6.83 6.84 6.83 6.84 6.83 6.84 6.84 6.85 6.87 6.87 6.83 6.84 6.85 6.87 6.83 6.84 6.85 6.87 6.83 6.84 6.85 6.87 6.87 6.87 6.87 6.87 6.87 6.87 6.87	Pre SD 0.46 0.6 0.77 0.8 0.42 0.12 1.1 1.1 1.1 0.48 0.7 2 = 78% 0.22 0.24 0.48 0.7 2 0.24 0.11 0.11 0.11	Total 8 16 15 16 10 10 9 9 7 7 6 9 9 13 119 6 9 9 11 11 11 11 11 11 11 11 11 11 11 11	Weight 2.6% 4.7% 4.6% 4.3% 4.2% 4.2% 4.2% 4.2% 4.2% 4.7% 4.7% 4.7% 4.5% 4.5% 4.5% 4.5% 4.5% 31.0%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.15 [-1.43, 0.28] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.17] -0.62 [-1.48, 0.24] 0.37 [-1.21, 0.48] -0.17 [-1.01, 0.66] -0.27 [-0.59, 0.06] -0.73 [-1.45, -0.02] -2.16 [-3.47, -0.85] -0.79 [-1.82, 0.24] 1.40 [0.34, 2.46]	Std. Mean Difference IV, Random, 95% CI
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_FLAT Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_WH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_NR Hersández et al. 2018_NR Hersández et al. 2018_NR Hetergeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U16 Yañez-García et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Tau ² = 0.00; Chi ² = Test for overall effect: Z = 1.61 (P 2.1.3 ENDURANCE Aksović et al. 2014_IT Attene et al. 2014_RST Attene et al. 2015_RST Attene et al. 2015_RST	Mean 7.45 10.6 13.21 7.01 3.01 3.01 11 10.3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN 5.5 7.4 6.56 6.57 3.34 3.14 3.09 = 3.24, df 6.51 6.53 5.959 5.94	Post SD 0.41 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.7 0.4 0.7 0.13 1.1 0.7 0.63 0.23 0.23 0.16 0.11 0.119 0.119 0.169 0.11 0.18 0.31 0.31 0.32	Total 8 16 15 16 10 10 9 13 119 9 11	Mean 8.87 11.3 11.62 14.37 7.35 3.03 12.3 10.96 5.29 00001); l 5.54 7.52 6.63 6.5 3.46 3.11 l ² = 0% 3.48 6.83 6.74 5.68 6.64 6.63 6.7 3.11 1.42 7.55 7	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 1.1 1.1 1.1 0.48 0.7 2 = 78% 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	Total 8 8 16 155 16 10 100 9 7 7 6 9 9 13 119 6 9 9 11 11 11 11 11 11 11 11 11 11 11 11	Weight 2.6% 4.7% 4.7% 4.6% 4.3% 4.3% 4.2% 4.3% 4.2% 4.7% 44.7% 4.7% 44.7% 4.4% 4.5% 4.5% 4.5% 31.0%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.20, 0.64] 1.23 [-0.52, 1.17] -0.62 [-1.48, 0.24] -0.37 [-1.21, 0.48] -0.37 [-1.21, 0.48] -0.37 [-1.21, 0.48] -0.79 [-1.22, 0.64] -0.79 [-1.45, -0.02] -2.16 [-3.47, -0.85] -0.79 [-1.22, 0.64] -0.29 [-1.22, 0.64] -0.29 [-1.22, 0.64]	Std. Mean Difference IV, Random, 95% CI
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Hernández et al. 2018_NR Hernández et al. 2018_NR Hernández et al. 2018_NR Hernánets et al. 2018_NR Hernánets et al. 2018_NR Hernánets et al. 2010 Subtotal (95% CI) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2019_U16 Yañez-García et al. 2019_U16 Yañez-García et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Tau ² = 0.00; Chi ² = Test for overall effect: Z = 1.61 (P 2.1.3 ENDURANCE Aksović et al. 2020 Attene et al. 2014_ST Attene et al. 2014_ST Gottlieb et al. 2014_ST	Mean 7.45 10.6 13.21 13.11 7.01 10.3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN 5.5 7.4 6.56 6.57 3.34 3.14 3.09 = 3.24, df = 0.11) 3.36 6.41 6.53 5.959 5.94 2.99	Post SD 0.41 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.13 1.1 0.63 0.23 6 0.32 0.23 0.23 9 0.31 0.11 0.11 0.169 0.169 0.169 0.31 0.31 0.37	Total 8 16 15 16 10 10 10 10 10 10 10 10 10 10 10 119 111 <	Mean 8.87 11.3 11.62 14.37 7.37 7.25 3.03 12.31 10.96 5.29 $00001); 1$ 5.544 7.52 6.63 6.63 3.46 6.83 6.74 5.644 3.48 6.64 3.48 6.64 3.48 6.64 3.48 6.64 3.64	Pre SD 0.46 0.6 0.77 0.8 0.47 0.22 0.12 1.1 1 0.48 0.7 2 = 789 0.22 0.24 0.24 0.11 0.11 0.11 0.11 0.149 0.24 0.35 0.35 0.31	Total 8 166 155 161 100 99 113 119 66 99 113 119 66 99 111 111 111 111 111 111 111 1	Weight 2.6% 4.7% 4.6% 4.3% 4.1% 4.2% 4.2% 4.7% 4.7% 4.7% 4.7% 4.7% 4.7% 4.7% 4.7	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.78 [-1.43, 0.28] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.17] -0.62 [-1.48, 0.24] -0.17 [-1.01, 0.66] -0.27 [-0.59, 0.06] -0.73 [-1.45, -0.02] -2.16 [-3.47, -0.85] -0.29 [-1.22, 0.64] -0.29	Std. Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2018_R Hernández et al. 2018_R Meszler & Váczi 2019 Tsimachidis et al. 2010 Subtotal (95% Cl) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2019_U16 Yañez-García et al. 2019_U18 Subtotal (95% Cl) Heterogeneity: Tau ² = 0.00; Chi ² = Test for overall effect: Z = 1.61 (P 2.1.3 ENDURANCE Aktene et al. 2014_IT Attene et al. 2014_RST Attene et al. 2014_ST Subtotal (95% Cl) Heterogeneity: Tau ² = 0.72; Chi ² = Test for verall effect: Z = 1.33 (P	Mean 7.45 10.6 13.21 13.11 7.01 10.3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN 5.5 7.4 6.56 6.57 3.24, df = 0.11) 3.36 6.41 6.53 5.959 5.94 2.99 = 20.01, df = 0.18)	$\begin{array}{c} \text{Post} \\ \text{SD} \end{array} \\ 0.41 \\ 0.4 \\ 1.88 \\ 0.74 \\ 0.4 \\ 0.19 \\ 0.13 \\ 1.1 \\ 0.7 \\ 0.63 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.2 \\ 0.2 \\ 0.2 \\ 0.2 \\ 0.2 \\ 0.2 \\ 0.2 \\ 0.2 \\ 0.2 \\ 0.2 \\ 0.16 \\ 0.10 \\ 0.11 \\ 0.11 \\ 0.16 \\ 0.1$	Total 8 16 15 16 10 10 9 7 7 6 9 9 13 119 P < 0.0 8 9 9 111 111 111 111 111 111	Mean 8.87 11.3 11.62 14.37 7.37 7.25 3.03 12.3 12.3 10.96 5.54 7.55 6.63 6.63 3.48 6.83 6.74 5.68 6.04 3.07	Pre SD 0.46 0.6 0.77 0.8 0.42 0.12 1.1 1.1 1.1 0.48 0.7 2 2 = 78% 0.2 0.24 0.24 0.24 0.14 0.11 0.11 0.149 0.24 0.2 0.24 0.149 0.11 0.119 0.24 0.24 0.25 0.24 0.25 0.24 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25	Total 8 16 15 16 10 10 9 9 7 7 6 9 9 13 119 6 9 9 11 111 11 11 11 11 11 11	Weight 2.6% 4.7% 4.6% 4.3% 4.2% 4.2% 4.2% 4.2% 4.2% 4.7% 4.7% 4.7% 4.5% 4.5% 4.5% 4.5% 4.5% 31.0%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.17] -0.62 [-1.48, 0.24] -0.37 [-1.21, 0.48] -0.17 [-1.01, 0.66] -0.27 [-0.59, 0.06] -0.79 [-1.22, 0.64] -0.79 [-1.22, 0.64] -0.79 [-1.22, 0.64] -0.79 [-1.22, 0.64] -0.79 [-1.22, 0.64] -0.79 [-1.22, 0.64] -0.79 [-1.22, 0.64] -0.83 [-1.75, 0.09] -0.54 [-1.33, 0.25]	Std. Mean Difference IV, Random, 95% CI
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_FLAT Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_WH Gottlieb et al. 2014_PT Hernández et al. 2018_NR Hernández et al. 2018_NR Hernández et al. 2018_NR Hernández et al. 2018_NR Hernández et al. 2018_NR Hersández et al. 2018_NR Hersón overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U16 Subtotal (95% CI) Heterogeneity: Tau ² = 0.00; Chi ² = Test for overall effect: Z = 1.61 (P 2.1.3 ENDURANCE Aksović et al. 2014_ST Attene et al. 2015b_RST Gottlieb et al. 2014_ST Subtotal (95% CI) Heterogeneity: Tau ² = 0.72; Chi ² = Test for overall effect: Z = 1.33 (P	Mean 7.45 10.6 13.21 13.11 7.01 10.3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN 5.5 7.4 6.56 6.57 3.34 3.09 = 3.24, df r = 0.11) 3.36 6.41 6.53 5.959 5.94 2.99 = 20.01, df = 0.18)	$\begin{array}{c} \text{Post} \\ \text{SD} \\ \end{array} \\ \begin{array}{c} 0.41 \\ 0.4 \\ 1.88 \\ 0.74 \\ 0.4 \\ 0.19 \\ 0.13 \\ 1.1 \\ 0.7 \\ 0.63 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.16 \\ 0.11 \\ 0.11 \\ 0.11 \\ 0.11 \\ 0.11 \\ 0.11 \\ 0.16 \\ 0.169 \\ 0.11 \\ 0.169 \\ 0.11 \\ 0.17 \\ f = 5 (P \\ $	Total 8 16 15 16 10 10 9 9 13 119 P < 0.00 9 9 111 111 111 111 111 111	Mean 8.87 11.3 11.62 13.03 12.3 12.3 10.96 5.54 7.55 6.63 6.63 6.75 3.48 6.83 6.74 5.68 6.04 3.07 1); 1 ² =	Pre SD 0.46 0.6 0.77 0.8 0.47 0.22 0.12 1.1 1.1 1.1 0.48 0.7 2 = 78% 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	Total 8 16 155 16 100 100 9 7 7 6 6 9 9 13 119 6 6 9 9 111 111 111 111 111 111 111	Weight 2.6% 4.7% 4.6% 4.3% 4.2% 3.6% 2.9% 4.2% 4.2% 4.2% 4.2% 4.7% 4.2% 4.4% 4.5% 4.4% 4.5% 31.0%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.17] -0.62 [-1.48, 0.24] -0.37 [-1.21, 0.48] -0.17 [-1.01, 0.66] -0.27 [-0.59, 0.06] -0.79 [-1.42, -0.8] -0.79 [-1.42, -0.8] -0.79 [-1.22, 0.64] 1.40 [0.34, 2.46] -0.29 [-1.22, 0.64] -0.54 [-1.33, 0.25]	Std. Mean Difference IV, Random, 95% CI
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Hernández et al. 2018_NR Hernández et al. 2018_NR Hernández et al. 2018_NR Hernánides et al. 2018_NR Hersández et al. 2019_UI Subtotal (95% CI) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2019_U14 Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U16 Subtotal (95% CI) Heterogeneity: Tau ² = 0.00; Chi ² = Test for overall effect: Z = 1.61 (P Z.1.3 ENDURANCE Aksović et al. 2014_ST Attene et al. 2015_IRST Attene et al. 2014_ST Subtotal (95% CI) Heterogeneity: Tau ² = 0.72; Chi ² = Test for overall effect: Z = 1.33 (P Total (95% CI)	Mean 7.45 10.6 13.21 13.11 7.01 10.3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN S.5 7.4 6.56 6.57 3.34 3.14 3.09 = 3.24, df = 0.11) 3.366 6.41 6.53 5.959 5.94 2.99 = 20.01, df = 0.18)	$\begin{array}{c} \text{Post} \\ \text{SD} \\ \end{array} \\ \begin{array}{c} 0.41 \\ 0.4 \\ 1.88 \\ 0.74 \\ 0.4 \\ 0.13 \\ 1.1 \\ 0.74 \\ 0.4 \\ 0.13 \\ 0.13 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.23 \\ 0.16 \\ 0.10 \\ 0.11 \\ 0.11 \\ 0.11 \\ 0.11 \\ 0.11 \\ 0.15 \\ $	Total 8 16 15 16 10 10 9 7 7 6 9 13 119 P < 0.00 9 9 11 11 11 11 11 11 11 11	Mean 8.87 11.3 11.62 14.37 7.35 5.54 7.52 6.63 6.53 3.48 6.83 6.74 3.48 6.83 6.74 3.48 6.83 6.74 3.48 6.83 6.74 5.64 3.07 1); l ² =	Pre SD 0.46 0.6 0.77 0.8 0.41 0.22 1.1 1.1 1.1 0.48 0.7 2 2 = 78% 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	Total 8 166 155 160 100 100 100 100 100 100 100 100 100	Weight 2.6% 4.7% 4.7% 4.6% 4.3% 4.2% 4.3% 4.2% 4.7% 4.7% 4.7% 4.7% 4.4.7% 4.4.7% 4.5% 4.5% 4.5% 31.0% 4.2% 4.2% 4.2% 24.3%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.79 [-1.40, -0.18] -0.30 [-1.5, 0.54] -0.37 [-1.21, 0.48] -0.17 [-1.21, 0.48] -0.17 [-1.20, 0.66] -0.27 [-0.59, 0.06] -0.73 [-1.45, -0.02] -2.16 [-3.47, -0.85] -0.79 [-1.22, 0.64] -0.33 [-1.75, 0.09] -0.54 [-1.33, 0.25] -0.55 [-0.88, -0.22]	Std. Mean Difference IV, Random, 95% CI
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_SLOPE Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_W Hernández et al. 2014_PT Hernández et al. 2018_R Meszler & Váczi 2019 Tsimachidis et al. 2010 Subtotal (95% CI) Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 2.53 (P 2.1.2 MIXED STRENGTH AND COI Arede et al. 2018 Gonzalo-Skok et al. 2017_BIL Gonzalo-Skok et al. 2016 Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U16 Yañez-García et al. 2019_U18 Subtotal (95% CI) Heterogeneity: Tau ² = 0.00; Chi ² = Test for overall effect: Z = 1.61 (P 2.1.3 ENDURANCE Aktene et al. 2014_RST Attene et al. 2014_RST Attene et al. 2015_RST Gottlieb et al. 2014_ST Subtotal (95% CI) Heterogeneity: Tau ² = 0.72; Chi ² = Test for overall effect: Z = 1.33 (P Total (95% CI)	Mean 7.45 10.6 13.21 13.11 7.01 10.3 11.13 5.02 = 46.12, df = 0.01) NDITIONIN 5.5 7.4 4.56 6.57 3.34 3.14 3.09 = 3.24, df = 0.11) 3.36 6.41 6.53 5.959 5.94 2.99 = 20.01, df = 0.18) = 72.32, df	Post SD 0.41 0.4 0.4 0.4 0.4 0.4 0.8 0.74 0.4 0.8 0.74 0.4 1.88 0.74 0.41 0.8 0.13 1.1 0.70 0.63 0.23 0.23 0.40 0.322 0.23 0.22 0.23 0.22 0.23 0.22 0.23 0.22 0.24 0.22 0.23 0.12 0.10 0.11 0.169 0.169 0.17 0.17 0.18 0.31 0.31 0.31 0.51 0.51 0.51 0.51 0.51 0.51	Total 8 16 15 16 10 10 9 13 19 P 111	Mean 8.87 11.3 11.62 14.37 7.37 7.37 7.37 3.03 12.3 11.11 0.90 5.54 7.52 6.63 6.63 3.48 6.83 6.04 5.64 5.64 3.48 6.63 6.74 5.68 6.074 5.67 9.071); l ² = 00001); l	Pre SD 0.46 0.6 0.77 0.8 0.42 0.12 1.1 1.1 1.1 0.48 0.7 2 = 78% 0.22 0.24 0.48 0.7 0.22 0.24 0.48 0.7 0.2 0.24 0.48 0.11 0.11 0.11 0.149 0.24 0.5 0.5 0.5 7 7 7 8 8 0.41 0.45 0.5 7 7 7 8 0.45 0.5 7 7 7 8 0.45 0.5 7 7 7 8 0.45 7 7 7 7 8 0.45 7 7 7 7 7 8 0.45 7 7 7 7 7 7 8 0.42 2 0.12 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	Total 8 16 15 16 10 10 9 9 7 7 6 9 9 13 119 6 9 9 11 111 111 111 111	Weight 2.6% 4.7% 4.6% 4.3% 4.2% 3.6% 2.9% 4.2% 4.2% 4.7% 4.7% 4.7% 4.7% 4.5% 4.5% 4.5% 31.0% 4.2% 4.5% 2.3% 2.4.3% 100.0%	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, 0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.79 [-1.40, -0.18] -0.37 [-1.5, 0.54] 0.33 [-0.52, 1.17] -0.62 [-1.48, 0.24] -0.37 [-1.21, 0.48] -0.17 [-1.01, 0.66] -0.27 [-0.59, 0.06] -0.79 [-1.82, 0.24] 1.40 [0.34, 2.46] -0.25 [-0.88, -0.22] -0.55 [-0.88, -0.22]	Std. Mean Difference IV, Random, 95% CI
Study or Subgroup 2.1.1 PLYOMETRIC TRAINING Asadi et al. 2016 Bouteraa et al. 2020 Figueira et al. 2020_FLAT Figueira et al. 2020_FLAT Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_BV Gonzalo-Skok et al. 2019_WH Hernández et al. 2018_NR Hernández et al. 2018_NR Herzández et al. 2018_NR Heterogeneity: Tau ² = 0.82; Chi ² = Test for overall effect: Z = 1.51 Gonzalo-Skok et al. 2017_UNI Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U14 Yañez-García et al. 2019_U14 Subtotal (95% CI) Heterogeneity: Tau ² = 0.00; Chi ² = Test for overall effect: Z = 1.61 (P 2.1.3 ENDURANCE Aksović et al. 2014_ST Attene et al. 2015b_RST Gottlieb et al. 2014_ST Subtotal (95% CI) Heterogeneity: Tau ² = 0.72; Chi ² = Test for overall effect: Z = 1.33 (P Total (95% CI) Heterogeneity: Tau ² = 0.46; Chi ² = Test for overall effect: Z = 3.23 (P	Mean 7.45 10.6 13.21 13.11 7.01 3.01 11 10.3 11 10.3 11.13 5.02 = 46.12, df = 46.12, df 6.56 6.57 3.34 3.09 = 3.24, df : = 0.11) 3.36 6.41 6.53 5.959 5.94 2.99 = 20.01, df = 72.32, df = 72.32, df = 0.18)	Post SD 0.41 0.4 0.4 0.4 0.4 0.4 0.8 0.74 0.4 0.8 0.74 0.4 0.8 0.74 0.4 0.74 0.4 0.74 0.13 1.1 0.70 0.63 0.23 0.23 0.24 0.22 0.23 0.23 0.160 0.11 0.169 0.11 0.169 0.18 0.31 0.07 f = 5 (P f f = 23 (U	Total 8 16 15 16 10 10 9 7 7 6 9 9 13 119 P < 0.00 9 9 111 111 111 111 111 111	Mean 8.87 11.3 11.62 14.37 7.35 3.03 12.3 10.96 5.54 7.55 3.63 6.63 6.63 3.18 3.12 3.48 6.83 6.74 5.68 6.04 3.07 1); 1 ² = 00001); 1	Pre SD 0.46 0.6 0.77 0.8 0.47 0.22 0.12 1.1 1.1 1.1 0.48 0.7 2 = 78% 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	Total 8 16 15 15 16 10 10 9 7 7 6 9 9 13 11 9 7 7 6 9 9 13 11 9 6 4 9 9 11 11 11 11 11 11 11 11 11 11 11 11	Weight 2.6% 4.7% 4.6% 4.3% 4.2% 3.6% 2.9% 4.2% 4.2% 4.2% 4.7% 4.2% 4.7% 4.4% 4.5% 4.4% 4.5% 31.0% 4.2% 4.2% 4.2% 3.8% 4.2% 3.8% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2	Std. Mean Difference IV, Random, 95% CI -3.08 [-4.65, -1.51] -1.34 [-2.11, -0.56] 1.08 [0.30, 1.85] -1.59 [-2.40, -0.79] -0.38 [-1.26, 0.51] -1.12 [-2.08, -0.16] -0.15 [-1.08, 0.77] -1.11 [-2.26, 0.05] -1.80 [-3.24, -0.37] 0.29 [-0.64, 1.22] -0.50 [-1.28, 0.28] -0.79 [-1.40, -0.18] -0.30 [-1.15, 0.54] 0.33 [-0.52, 1.17] -0.62 [-1.48, 0.24] -0.37 [-1.21, 0.48] -0.77 [-1.21, 0.48] -0.77 [-1.21, 0.48] -0.77 [-1.21, 0.48] -0.77 [-1.21, 0.48] -0.77 [-1.22, 0.66] -0.27 [-0.59, 0.06] -0.79 [-1.22, 0.64] -0.29 [-1.22, 0.64] -0.29 [-1.22, 0.64] -0.54 [-1.33, 0.25] -0.55 [-0.88, -0.22]	Std. Mean Difference IV, Random, 95% Cl

Figure 6. Forest Plot comparing the effect of multidisciplinary interventions on neuromuscular power horizontal (NPH) considering sub-groups analysis for age (**A**), gender (**B**), level (**C**) and type of intervention (**D**) [49–51,61,62,64–68,70,71,74,77,78].

3.5.2. Gender

Figure 6B displays the forest plot for the gender sub-groups analysis on NPH. High levels of heterogeneity were found in both sub-groups. A significant positive effect was evident both in female (SMD, -0.95; 95% CI: -1.90 to 0.00; I², 73%; Z, 1.96; p = 0.05) and male sub-groups (SMD, -0.47; 95% CI: -0.83 to -0.12; I², 67%; Z, 2.61; p = 0.009), with large and small effects, respectively.

3.5.3. Competitive Level

Figure 6C shows the forest plot for competitive level sub-groups analysis on NPH. High levels of heterogeneity were evident in the elite sub-groups (I^2 , 73%, p < 0.00001), however, moderate levels were found in amateur (I^2 , 47%, p = 0.08). Both elite (SMD, -0.49; 95% CI: -0.93 to -0.06; I^2 , 73%; Z, 2.24; p = 0.03) and amateur (SMD, -0.70; 95% CI: -1.17 to -0.22; I^2 , 47%; Z, 2.86; p = 0.004) sub-groups reached significant positive effect with small and moderate effects, respectively.

3.5.4. Training Type

Figure 6D displays the forest plot for training type analysis on NPH. Except from mixed strength and conditioning (I², 0%), all the sub-groups showed high levels of heterogeneity (I² < 75%). From all the training types, only plyometric training, with a moderate effect (SMD, -0.79; 95% CI: -1.40 to -0.18; I², 78%; Z, 2.53; p = 0.01), reached significant levels in comparison to mixed strength and conditioning (SMD, -0.27; 95% CI: -0.59 to 0.06; I², 0%; Z, 1.61; p = 0.11) and endurance training (SMD, -0.54; 95% CI: -1.33 to 0.25; I², 75%; Z, 1.33; p = 0.18).

3.6. Effect on Endurance

Figure 7 illustrates de forest plot for endurance. Only 3 studies [64,65,79] were included in this analysis resulting in a significant positive large effect (SMD, 0.88; 95% CI: 0.17 to 1.58; I^2 , 50%; Z, 2.43; p = 0.02) with moderate levels of heterogeneity.

	1	Post		Pre			9	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Aschendof et al. 2019	1 895	42	11	1 498	266	11	23.6%	2.01 [0.94, 3.07]	_
Attene et al. 2014_IT	905	217	8	720	291	8	24.6%	0.68 [-0.34, 1.70]	+
Attene et al. 2014_RST	720	291	8	605	233	8	25.2%	0.41 [-0.58, 1.41]	- +
Attene et al. 2015	2 244	638	9	1 933	560	9	26.6%	0.49 [-0.45, 1.44]	
Total (95% CI)			36			36	100.0%	0.88 [0.17, 1.58]	◆
Heterogeneity: $Tau^2 = 0.26$;	$Chi^2 = 5$.96, d	f = 3 (F)	P = 0.12	1); I ² =	= 50%		-	
Test for overall effect: $Z = 2$.43 (P =	0.02)							Negative effects Positive effects

Figure 7. Forest Plot comparing the effect of multidisciplinary interventions on endurance [63,65,79].

3.7. Meta-Regression

The main results from the meta-regression model can be found in Table 4 for NPV and Table 5 for NPH. Regression models are shown in Figure 8. In NPV, considering the models that reached the minimum number of studies, only U-16 age group model was able to significantly predict changes in jump performance with small accounted variance (Adjusted $R^2 = 0.78$). Elite level model reached a significant prediction, nevertheless, moderate variability was accountable (Adjusted $R^2 = 0.57$). Even though both Male and Plyometric training models were able to significantly predict jump performance, the high levels of variance accounted in the model limits its validity predicting NPV changes (Male; Adjusted $R^2 = 0.34$, Plyometric training; Adjusted $R^2 = 0.36$).

Table 4. Meta-regression statistical analysis for neuromuscular power vertical (NPV) according to sub-groups. In bold, models that did not reach the minimum 10 studies for meta-regression analysis. * p < 0.05. N = number of included studies; F = effect; Sig = Significance.

NPV	Ν	R Squared	Adj R Squared	Sum of Squares	F	Sig
Training type						
Plyometric training	16	0.40	0.36	235.82	10.04	0.006 *
Mixed strength and conditioning	9	0.73	0.69	8.31	21.23	0.002 *
Gender						
Male	24	0.37	0.34	208.41	13.28	0.001 *
Female	5	0.97	0.96	171.94	84.95	0.003 *
Competitive level						
Elite	19	0.60	0.57	226.03	26.59	0.001 *
Amateur	9	0.63	0.58	205.12	13.66	0.006 *
Age						
U-16	13	0.8	0.78	144.06	47.87	0.001 *
U-18	8	0.59	0.51	159.77	9.21	0.019 *

Table 5. Meta-regression statistical analysis for neuromuscular power horizontal (NPH) according to sub groups. In bold, models that did not reach the minimum 10 studies for meta-regression analysis. * p < 0.05. N = number of included studies; F = effect; Sig = Significance.

NPH	Ν	R Squared	Adj R Squared	Sum of Squares	F	Sig
Training type						
Plyometric training	10	0.86	0.84	588.97	53,44	0.001 *
Mixed strength and conditioning	6	0.85	0.82	9.63	29.01	0.003 *
Endurance	5	0.96	0.95	65.37	98.26	0.001 *
Gender						
Male	19	0.83	0.83	663.03	92.40	0.001 *
Female	3	0.88	0.82	35.43	14.83	0.061
Competitive level						
Elite	16	0.84	0.82	479.59	76.65	0.001 *
Amateur	6	0.85	0.82	164.45	29.02	0.003 *
Age						
U-16	8	0.96	0.96	68.03	178.36	0.001 *
U-18	7	0.96	0.95	221.66	141.60	0.001 *



Figure 8. Meta regression models for neuromuscular power vertical (**A**–**D**) considering subgroups: training type (**A**), gender (**B**), level (**C**) and age (**D**) and neuromuscular power horizontal (**E**–**H**) considering sub-groups: training type (**E**), gender (**F**), level (**G**) and age (**H**).

In NPH, only plyometric training, male and elite level models reached the minimum number of studies for meta-regression analysis. All models significantly predict multidirectional speed and agility with very small variance accounted (Plyometric training; Adjusted $R^2 = 0.84$, Male; Adjusted $R^2 = 0.83$, Elite; Adjusted $R^2 = 0.83$).

4. Discussion

The main aim of this systematic review with meta-analysis and meta-regression was to collect, describe and analyze the effect of multidisciplinary neuromuscular and endurance interventions on performance in youth basketball players with respect to age, level, gender of the basketball players and according to the type of the intervention performed. Additionally, and considering the available data, to try to establish a prediction model on the changes in NPV and NPH considering these parameters through a meta-regression analysis. From the best of the author's knowledge this is the first systematic review with meta-analysis and meta-regression focusing on this topic in youth basketball players.

Considering the data available in the literature and included in this study, the main results indicate that multidisciplinary interventions, including plyometric training, mixed strength and conditioning, HIIT basketball programs and repeated sprint training have an overall positive effect on jump (NPV), multidirectional speed and agility (NPH) and endurance (E). However, moderate to high variability in NPH (I², 72%) and E (I², 50%) outcomes were evident and may have an impact on the conclusions. Nonetheless, considering the moderate heterogeneity found in E, more studies are needed in order to achieve conclusive evidence.

Concerning the sub-groups analysis for age, the results in vertical jump show a significant increase only in U-16 and U-18. This is supported by meta-regression analysis with U-16 model being able to predict changes in vertical jump capacity. Even though more studies are needed in U-18, the model is able to significantly explain 50% of the changes in vertical jump performance. Conversely, the results in multidirectional speed and agility showed a significant improvement in multidirectional speed and agility only in U-12 group. This differs with the meta regression analysis suggesting a good predictability of the U-16 and U-18 with very low variance. Chronological age and maturation involves periods of accelerated growth and development related to neural and hormonal changes that maximize the development of specific capacities [38]. In particular, youth basketball players experience changes in their anthropometric and physiological parameters that promote performance changes throughout their individual development in different maturational stages [81]. However, it is important to consider that maturational changes will occur simultaneously with motor control coordination evolution. Consequently, those overlapped changes will limit the effectiveness in muscular contraction due to alterations in motor unit recruitment and inter and intra muscular coordination [38]. According to Long Term Athlete Development approach [82] and the Youth Physical Development Model [37], the peak development in strength and power appears 12 to 18 month after the peak high velocity (PHV) or from around 16 years old to adulthood in terms of chronological age [32,83]. In fact, Calleja-González et al. [81] pointed U-16 as the offset for peak changes in youth players from a top basketball academy. Our results correspond with the previous literature, increasing in vertical jump, only evident in the U-16 and the U-18 age group. This in fact highlights the importance of strength and power development at this maturational stages as game demands increase with age [84] and performance needs to be higher coinciding with the difficult transition from U-18 to senior in basketball [48,85]. For this reason, strength and conditioning programs should take advantage from this "sweet spot" to develop and prepare youth basketball players for future performance and in order to facilitate the senior transition and avoid injury risk [36,86,87].

Other studies suggest that strength levels were more developed in U-14 [32,88], however, muscular power development is more evident in the adolescence due to changes related to PHV [32,89,90]. Those results support our findings, as according to the literature, vertical jump involves strength and speed during movement production and therefore muscular power [17,91]. Muscular power development post PHV might be attributed to hormonal changes, fiber type distribution and increase in muscle mass during adolescence [32,37,38]. Multiple interventions (in particular plyometric training) are a wellestablished method to improve speed in different stages from childhood to late maturity of an athlete [23,42,85,92–95]. According to the literature, in the early childhood, it seems to be primarily attributed to neural capacity, motor recruitment and coordination [33,42,96]. These changes and the high neural plasticity within the early stages could explain that only significant changes were only evident in the U-12 group. As mentioned, it is important to consider that body changes during puberty might alter coordination patterns and reduce sprint ability despite hormonal and muscle mass changes during this stage [35,97]. However, higher sprint and acceleration ability is found during PHV or post-PHV due to maturation-related changes within these stages [98–100]. This is not supported by the results from the meta-analysis. Nevertheless, assuming the low number of studies included in the meta-regression analysis, it suggests promising results as U-16 and U-18 age group models seem to predict multidirectional speed and agility changes with very low variance accounted.

Gender also had an impact on the results. Female and male improved similarly in both vertical jump and multidirectional speed and agility. Similar training loads are typically applied to male and female athletes to improve performance; although sex and physical differences exist between them [101–103]. According to the literature, it seems that muscle cross sectional area and pennation angle are more related to age, despite difference in gender can be found [104]. There is evidence showing that female athletes have a lower percentage of type I fibers as well as lower cross-sectional area in type II muscle fiber than youth male athletes [101,103,105]. This physiological and anatomical differences are associated with greater force generation and contractile velocity and as a result, with a greater power output in males [104,106]. Moreover, male youth athletes are capable of recruiting more motor units. This further contributes to the ability to create more force development and to better use the stretch-shortening cycle than female youth athletes and even more after PHV [107,108]. When comparing absolute values, it is evident that males register higher values in force, power, speed and agility than females [28,104,109,110]. However, considering relative values, this was not affected by gender [104]. For this reason, individual trainability according to gender must be considered. In this regard, Lesinski et al. [89] found similar resistance training related gains in muscle strength and vertical jump in both males and females, although few studies with female athletes were included. Research comparing youth adaptations considering gender has shown significantly greater resistance training-induced improvements in female youth athletes compared to their male counterparts. It is important to consider the lack of studies and information related to age groups included [32,87,89]. The results from the meta-analysis suggest that youth female basketball players are able to improve in a similar way than male. Additionally, considering the number of included studies (N = 5), the meta-regression analysis showed that female model seems to predict jump performance with very low variance, whereas male reached significant predictability. However, the high variance accounted alongside the reduced number of studies included limits the confidence on the model. Differently, male model seems to predict changes in multidirectional speed and agility with very low levels of variance whereas female did not reach the minimum number of studies to extract reliable conclusions. Hence, although different physiological changes related to age and maturation between gender exists, trainability of female youth basketball players may be at least similar compared with males [89]. However, more studies in female youth athletes could show a clearer picture and will help researchers to establish more adjusted prediction models.

Competitive level of the players showed that the different interventions performed in elite and amateur basketball players induced positive changes in jumping ability and in multidirectional speed and agility on both groups. Literature about youth basketball reflects a difference between amateur and elite athletes in terms of anthropometric measurements, performance outcomes and physiological capacities [111,112]. The results from this meta-analysis suggest that the trainability of the players is not related with the level and experience of the athlete. Both amateur and elite basketball players improved, in a similar way, their jumping ability performance and their multidirectional speed and agility with different interventions, although a moderate effect was evident in the amateur multidirectional speed and agility sub-groups. This is in line with the results from the meta-regression analysis as that suggests that elite and amateur models are able to predict changes in both jump performance and multidirectional speed and agility with moderate to small levels of variance accounted. It is important to note that even though the sample size for elite is high for both NPV (N = 19) and NPH (N = 16), more studies are needed in amateur athletes (N = 9) to have a higher confidence in the results of the meta-regression model to predict changes according to level of the participants. Other systematic reviews have found controversial results in jump performance [95,113], sprinting and change of direction [114] after multiple interventions. Slimani, Paravlić & Bragazzi [113] found a greater effect of plyometric training on vertical jump in elite athletes whilst Stojanović et al. [95] showed that amateur and non-elite athletes improved more effectively in vertical jump compared to elite athletes. This is most probably due to a higher response in the unexperienced athletes. However, the unbalanced comparison among studies (15 non-elite vs. 1 elite) and the fact that this review only included female athletes makes it difficult to compare to our findings. Considering the results in multidirectional speed, the results from Thapa et al. [114] indicate that elite athletes have greater response to training in 30 m linear sprint and change of direction. The authors attribute those results to the higher strength levels and more fast twitch muscle fibers of elite compared to amateur athletes [114]. Conversely, the highest positive effect in this meta-analysis was found in the amateur multidirectional speed and agility sub-groups. With respect to the available literature and the results from the meta-analysis and the meta-regression analysis, it is still unclear if trainability is linked to the level of the athletes. For this reason, trainability should be an important factor to consider in future studies as the interventions will be applied to youth basketball players with different levels and years of experience.

Concerning the type of the intervention used, the results show that plyometric training and mixed strength and conditioning interventions improve vertical jump, but only plyometric training could induce significant changes in multidirectional speed and agility. The results from the meta-regression analysis suggest that plyometric training could predict changes in multidirectional speed and agility with very low levels of variance. However, mixed strength training also seems to predict NPH changes with very low levels of variance accounted despite the low number of studies were included. Regarding vertical jump, the models suggest that both plyometric training and mixed strength and conditioning predict jump performance, although mixed strength and conditioning model did not include enough studies to provide precise conclusions. Additionally, high to moderate variance was found in the models.

Behm et al. [41], reported that force and velocity need to be stimulated in order to improve mechanical power since both are involved in the power equation. There is evidence that both strength training [89,115] and plyometric training [24,95,116] improve vertical jump in a similar way. However, the combination of both resistance and plyometric training could promote even higher improvements in jump capacity in youth [23,32,89,114,115,117,118]. Plyometric training increases rate of force development, muscular power and muscle contraction velocity through maximizing stiffness, mean cross sectional area and peak power in all muscle fibers [115,119]. On the other hand, resistance training is able to induce similar adaptions through muscle hypertrophy, increased myosin heavy chain IIa (MHC IIa), and changes in neural adaptations such us motor unit frequency and activation [115]. Regarding speed improvement, Behm et al. [41] found a higher improve applying resistance training compared to plyometric training in adolescent and children. Although a positive effect was also found when applying plyometric training. The results from other studies also support the finding on the meta-analysis suggesting that plyometric training is beneficial in order to improve multidirectional sprint and agility [21–23,25,26,120,121]. The benefits induced by plyometric training might be due to preferential motor unit recruitment, velocity of muscle contraction and transfer of energy during sprinting [122]. Although a positive effect of plyometric training on both vertical jump and multidirectional speed is evident, specific considerations regarding technique

and training volume will be fundamental in order to avoid injury risk and high join impact on those development stages [119].

4.1. Perspective

The understanding on how to better develop youth basketball players avoiding injury risk is one of the biggest concerns for strength and conditioning coaches and sports scientist [16]. It is fundamental to identify guidelines for youth basketball development considering age, gender and level. This systematic review with meta-analysis and metaregression suggests plyometric training as the best training method to improve jump capacity in youth basketball players, especially over U-16. Consequently, plyometric training in early adolescence should focus on establishing coordination patterns and motor control, avoiding high impacts on the joints, whereas in late adolescence power development should be the target corresponding with the window of opportunity in the development stage [33,35,37,41,42,123]. The inclusion of a mixed strength and conditioning program alongside plyometric training seems to maximize those benefits at this development stages. Moreover, it has a clear potential for injury prevention in young population in different sports, hence increasing the options for long-career development [36,86,87,124,125]. Post PHV stages will be really important for strength and power development and facilitate a better transition to the higher demands in senior level and avoid injury risk. As said before, the implementation of more endurance interventions in youth basketball players should be of special interest, considering the importance of this capacity in senior high-level basketball and the lack of studies performing this type of interventions in the literature. High trainability was observed both in male and female youth basketball players. Considering the suggested prediction on the female model despite the lack of existing studies, elucidates the need for more studies to better understand female basketball players development. Competitive level and experience of the youth athletes seems to be independent of trainability and thus, should be considered in training. Both elite and amateur athletes benefit from the different interventions and improved in a similar way in jump and multidirectional speed. More data considering the potential capacity for adaptation and injury risk related to the experience and level of the youth basketball players should be considered in future research for program adaptations and applications. Safety considerations must be taken throughout the whole youth basketball players development to avoid injury risk.

Finally, considering the heterogeneity found in the performance tests used throughout the different studies included, it is necessary to establish common guidelines for performance assessment to improve study designs, to better compare outcomes, to identify and correct player weaknesses or injury risks and eventually improve player development in the future. Recent systematic reviews described the most implemented physical fitness assessments in basketball [3,27]. Likewise, high heterogeneity in the tests used to assess performance in different basketball capacities was evident. These results highlight the need for consensus assessing physical fitness and performance in basketball, especially in youth.

4.2. Limitations

Some limitations were evident in the study and should be considered. High levels of heterogeneity were evident in the measurements related to NPH and E. I² above 75% was found on the overall analysis and also in the sub-group analysis in the NPH, representing large levels of heterogeneity. This might be due to the different protocols used in the included studies. A random effect model was used to reduce the effects of this limitation [126]. In E overall analysis presented moderate levels of inconsistency with I² equal to 50%. In this case, this might be related to the few studies included in E and highlights another limitation of this meta-analysis. This issue prevented to do sub-groups analysis and investigate the effect of the interventions on E in more detail.

The available data in the literature limits the conclusions of the meta-regression analysis. However, the results suggest open directions for the future including more studies in youth basketball population. Only chronological age was considered for sub-groups analysis because insufficient data regarding maturational stage or PHV was available in the included studies. This limits the conclusions regarding age sub-groups as athletic development stages are correlated to biologic maturation and PHV but no to chronological age [33,37]. Additionally, the age sub-groups did not differ between male and female, despite differences in maturational development are evident between gender [101].

5. Conclusions

In conclusion, multidisciplinary interventions including plyometric training, mixed strength and conditioning, HIIT basketball programs and repeated sprint training are able to induce positive changes in the jump capacity, multidirectional speed and also in endurance in youth basketball players. Those capacities are key in performance in youth basketball and, therefore, it is fundamental to establish a progressive and careful training periodization of those capacities for future development and transition to senior level considering age, gender, and level to maximize performance. The data availability in the scientific literature including interventions based on gender and level of the basketballers and the lack of combination of different training interventions, elucidates the need for more studies to understand youth basketball development.

Author Contributions: A.S., V.L.-R., J.C.-G., J.E., A.P.-P. and J.B.: conceived and designed the investigation, analysed and interpreted the data, drafted the paper, and approved the final version submitted for publication. A.S., V.L.-R., J.C.-G., J.E. and A.P.-P.: analysed and interpreted the data, critically reviewed the paper and approved the final version submitted for publication. The first draft of the manuscript was written by A.S. and all authors commented on previous versions of the manuscript. A.S., V.L.-R., J.C.-G., J.E., and J.B.: critically reviewed the paper and approved the final version submitted for publication. The first draft of the manuscript. A.S., V.L.-R., J.C.-G., J.E., A.P.-P. and J.B.: critically reviewed the paper and approved the final version submitted for publication. All authors have read and agreed to the published version of the manuscript.

Funding: The authors declare no funding sources.

Institutional Review Board Statement: The University Hospital from Girona Doctor Josep Trueta (2020.193) approved this study in accordance with the Helsinki Declaration (2013) and researchers were provided the identified data to analyze.

Data Availability Statement: The data presented in this study are available within the article.

Acknowledgments: We would like to express sincere gratefulness for the knowledge and contributions from all the authors in the scientific and basketball field.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Stojanovic, E.; Stojiljkovic, N.; Scanlan, A.T.; Dalbo, V.J.; Berkelmans, D.M.; Milanovic, Z. The Activity Demands and Physiological Responses Encountered During Basketball Match-Play: A Systematic Review. *Sports Med.* **2018**, *48*, 111–135. [CrossRef] [PubMed]
- 2. Petway, A.J.; Freitas, T.T.; Calleja-González, J.; Medina Leal, D.; Alcaraz, P.E. Training load and match-play demands in basketball based on competition level: A systematic review. *PLoS ONE* **2020**, *15*, e0229212. [CrossRef] [PubMed]
- Gottlieb, R.; Shalom, A.; Calleja-González, J. Physiology of Basketball–Field Tests. J. Hum. Kinet. 2021, 77, 159–167. [CrossRef] [PubMed]
- 4. Abdelkrim, N.B.; Castagna, C.; El Fazaa, S.; El Ati, J. The effect of players' standard and tactical strategy on game demands in men's basketball. *J. Strength Cond. Res.* **2010**, *24*, 2652–2662. [CrossRef]
- 5. Abdelkrim, N.B.; Castagna, C.; Jabri, I.; Battikh, T.; El Fazaa, S.; El Ati, J. Activity profile and physiological requirements of junior elite basketball players in relation to aerobic-anaerobic fitness. *J. Strength Cond. Res.* **2010**, *24*, 2330–2342. [CrossRef]
- Bishop, D.; Wright, C. A time-motion analysis of professional basketball to determine the relationship between three activity profiles: High, medium and low intensity and the length of the time spent on court. *Int. J. Perform. Anal. Sport* 2006, *6*, 130–139. [CrossRef]
- 7. Janeira, M.; Maia, J. Game intensity in basketball. An interactionist view linking time-motion analysis, lactate concentration and heart rate. *Coach. Sport Sci. J.* **1998**, *3*, 26–30.
- 8. McInnes, S.; Carlson, J.; Jones, C.; McKenna, M. The physiological load imposed on basketball players during competition. *J. Sports Sci.* **1995**, *13*, 387–397. [CrossRef]

- Schelling, X.; Torres-Ronda, L. Conditioning for basketball: Quality and quantity of training. *Strength Cond. J.* 2013, 35, 89–94. [CrossRef]
- 10. Schelling, X.; Torres-Ronda, L. An integrative approach to strength and neuromuscular power training for basketball. *Strength Cond. J.* **2016**, *38*, 72–80. [CrossRef]
- Narazaki, K.; Berg, K.; Stergiou, N.; Chen, B. Physiological demands of competitive basketball. Scand. J. Med. Sci. Sports 2009, 19, 425–432. [CrossRef]
- 12. Scanlan, A.; Dascombe, B.; Reaburn, P. A comparison of the activity demands of elite and sub-elite Australian men's basketball competition. *J. Sports Sci.* 2011, 29, 1153–1160. [CrossRef]
- 13. Khoramipour, K.; Gaeini, A.A.; Shirzad, E.; Gilany, K.; Chashniam, S.; Sandbakk, Ø. Metabolic load comparison between the quarters of a game in elite male basketball players using sport metabolomics. *Eur. J. Sport Sci.* **2021**, *21*, 1022–1034. [CrossRef]
- Portes, R.; Jiménez, S.L.; Navarro, R.M.; Scanlan, A.T.; Gómez, M.-A. Comparing the external loads encountered during competition between elite, junior male and female basketball players. *Int. J. Environ. Res. Public Health* 2020, 17, 1456. [CrossRef]
- 15. Rinaldo, N.; Toselli, S.; Gualdi-Russo, E.; Zedda, N.; Zaccagni, L. Effects of anthropometric growth and basketball experience on physical performance in pre-adolescent male players. *Int. J. Environ. Res. Public Health* **2020**, *17*, 2196. [CrossRef]
- DiFiori, J.P.; Güllich, A.; Brenner, J.S.; Côté, J.; Hainline, B.; Ryan, E.; Malina, R.M. The NBA and youth basketball: Recommendations for promoting a healthy and positive experience. *Sports Med.* 2018, 48, 2053–2065. [CrossRef]
- 17. Smith, J.J.; Eather, N.; Morgan, P.J.; Plotnikoff, R.C.; Faigenbaum, A.D.; Lubans, D.R. The health benefits of muscular fitness for children and adolescents: A systematic review and meta-analysis. *Sports Med.* **2014**, *44*, 1209–1223. [CrossRef]
- Bagur-Calafat, C.; Farrerons-Minguella, J.; Girabent-Farrés, M.; Serra-Grima, J. The impact of high level basketball competition, calcium intake, menses, and hormone levels in adolescent bone density: A three-year follow-up. *J. Sports Med. Phys. Fit.* 2014, 55, 58–67.
- Owoeye, O.B.; Ghali, B.; Befus, K.; Stilling, C.; Hogg, A.; Choi, J.; Palacios-Derflingher, L.; Pasanen, K.; Emery, C.A. Epidemiology of all-complaint injuries in youth basketball. *Scand. J. Med. Sci. Sports* 2020, 30, 2466–2476. [CrossRef]
- Post, E.G.; Biese, K.M.; Schaefer, D.A.; Watson, A.M.; McGuine, T.A.; Brooks, M.A.; Bell, D.R. Sport-specific associations of specialization and sex with overuse injury in youth athletes. *Sports Health* 2020, 12, 36–42. [CrossRef]
- 21. Bedoya, A.A.; Miltenberger, M.R.; Lopez, R.M. Plyometric training effects on athletic performance in youth soccer athletes: A systematic review. *J. Strength Cond. Res.* **2015**, *29*, 2351–2360. [CrossRef] [PubMed]
- 22. Johnson, B.A.; Salzberg, C.L.; Stevenson, D.A. A systematic review: Plyometric training programs for young children. J. Strength Cond. Res. 2011, 25, 2623–2633. [PubMed]
- 23. Silva, A.F.; Clemente, F.M.; Lima, R.; Nikolaidis, P.T.; Rosemann, T.; Knechtle, B. The effect of plyometric training in volleyball players: A systematic review. *Int. J. Environ. Res. Public Health* **2019**, *16*, 2960. [CrossRef] [PubMed]
- Slimani, M.; Chamari, K.; Miarka, B.; Del Vecchio, F.B.; Chéour, F. Effects of plyometric training on physical fitness in team sport athletes: A systematic review. J. Hum. Kinet. 2016, 53, 231–247. [CrossRef]
- Van de Hoef, P.A.; Brauers, J.J.; van Smeden, M.; Backx, F.J.; Brink, M.S. The effects of lower-extremity plyometric training on soccer-specific outcomes in adult male soccer players: A systematic review and meta-analysis. *Int. J. Sports Physiol. Perform.* 2020, 15, 3–17. [CrossRef]
- Beato, M.; Bianchi, M.; Coratella, G.; Merlini, M.; Drust, B. Effects of plyometric and directional training on speed and jump performance in elite youth soccer players. *J. Strength Cond. Res.* 2018, *32*, 289–296. [CrossRef]
- 27. Mancha-Triguero, D.; Garcia-Rubio, J.; Calleja-González, J.; Ibanez, S.J. Physical fitness in basketball players: A systematic review. *J. Sports Med. Phys. Fit.* **2019**, *59*, 1513–1525. [CrossRef]
- Mancha-Triguero, D.; García-Rubio, J.; Gamonales, J.M.; Ibáñez, S.J. Strength and Speed Profiles Based on Age and Sex Differences in Young Basketball Players. Int. J. Environ. Res. Public Health 2021, 18, 643. [CrossRef]
- 29. Alonso, E.; Miranda, N.; Zhang, S.; Sosa, C.; Trapero, J.; Lorenzo, J.; Lorenzo, A. Peak match demands in young basketball players: Approach and applications. *Int. J. Environ. Res. Public Health* **2020**, *17*, 2256. [CrossRef]
- Delextrat, A.; Gruet, M.; Bieuzen, F. Effects of small-sided games and high-intensity interval training on aerobic and repeated sprint performance and peripheral muscle oxygenation changes in elite junior basketball players. J. Strength Cond. Res. 2018, 32, 1882–1891. [CrossRef]
- 31. Delextrat, A.; Martinez, A. Small-sided game training improves aerobic capacity and technical skills in basketball players. *Int. J. Sports Med.* **2014**, *35*, 385–391. [CrossRef]
- 32. Granacher, U.; Lesinski, M.; Büsch, D.; Muehlbauer, T.; Prieske, O.; Puta, C.; Gollhofer, A.; Behm, D.G. Effects of resistance training in youth athletes on muscular fitness and athletic performance: A conceptual model for long-term athlete development. *Front. Physiol.* **2016**, *7*, 164. [CrossRef]
- Pichardo, A.W.; Oliver, J.L.; Harrison, C.B.; Maulder, P.S.; Lloyd, R.S. Integrating models of long-term athletic development to maximize the physical development of youth. *Int. J. Sports Sci. Coach.* 2018, 13, 1189–1199. [CrossRef]
- 34. Nikolaidis, P.T.; Asadi, A.; Santos, E.J.; Calleja-González, J.; Padulo, J.; Chtourou, H.; Zemkova, E. Relationship of body mass status with running and jumping performances in young basketball players. *Muscles Ligaments Tendons J.* 2015, *5*, 187. [CrossRef]
- Ford, P.; De Ste Croix, M.; Lloyd, R.; Meyers, R.; Moosavi, M.; Oliver, J.; Till, K.; Williams, C. The long-term athlete development model: Physiological evidence and application. *J. Sports Sci.* 2011, 29, 389–402. [CrossRef]

- Bergeron, M.F.; Mountjoy, M.; Armstrong, N.; Chia, M.; Côté, J.; Emery, C.A.; Faigenbaum, A.; Hall, G.; Kriemler, S.; Léglise, M. International Olympic Committee consensus statement on youth athletic development. *Br. J. Sports Med.* 2015, 49, 843–851. [CrossRef]
- 37. Lloyd, R.S.; Oliver, J.L. The youth physical development model: A new approach to long-term athletic development. *Strength Cond. J.* **2012**, *34*, 61–72. [CrossRef]
- 38. Viru, A.; Loko, J.; Harro, M.; Volver, A.; Laaneots, L.; Viru, M. Critical periods in the development of performance capacity during childhood and adolescence. *Eur. J. Phys. Educ.* **1999**, *4*, 75–119. [CrossRef]
- Calleja-González, J.; Mielgo-Ayuso, J.; Lekue, J.A.; Leibar, X.; Erauzkin, J.; Jukic, I.; Ostojic, S.M.; Delextrat, A.; Sampaio, J.; Terrados, N. The Spanish "Century XXI" academy for developing elite level basketballers: Design, monitoring and training methodologies. *Physician Sportsmed.* 2016, 44, 148–157. [CrossRef]
- Harrison, C.B.; Gill, N.D.; Kinugasa, T.; Kilding, A.E. Development of aerobic fitness in young team sport athletes. *Sports Med.* 2015, 45, 969–983. [CrossRef]
- 41. Behm, D.G.; Young, J.D.; Whitten, J.H.; Reid, J.C.; Quigley, P.J.; Low, J.; Li, Y.; Lima, C.D.; Hodgson, D.D.; Chaouachi, A. Effectiveness of traditional strength vs. power training on muscle strength, power and speed with youth: A systematic review and meta-analysis. *Front. Physiol.* **2017**, *8*, 423. [CrossRef]
- 42. Oliver, J.L.; Lloyd, R.S.; Rumpf, M.C. Developing speed throughout childhood and adolescence: The role of growth, maturation and training. *Strength Cond. J.* 2013, *35*, 42–48. [CrossRef]
- 43. Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. *J. Clin. Epidemiol.* 2009, 62, e1–e34. [CrossRef]
- 44. Methley, A.M.; Campbell, S.; Chew-Graham, C.; McNally, R.; Cheraghi-Sohi, S. PICO, PICOS and SPIDER: A comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. *BMC Health Serv. Res.* 2014, 14, 579. [CrossRef]
- 45. Greenhalgh, T.; Peacock, R. Effectiveness and efficiency of search methods in systematic reviews of complex evidence: Audit of primary sources. *BMJ* **2005**, *331*, 1064–1065. [CrossRef]
- 46. Higgins, J.; Altman, D.; Sterne, J. Chapter 8: Assessing risk of bias in included studies. In *Cochrane Handbook for Systematic Reviews* of *Interventions*; Version 5.1.0.; The Cochrane Collaboration: Copenhagen, Denmark, 2011.
- 47. Araújo, C.; Scharhag, J. Athlete: A working definition for medical and health sciences research. *Scand. J. Med. Sci. Sports* **2016**, 26, 4–7. [CrossRef]
- 48. De la Rubia Riaza, A.; Lorenzo Calvo, J.; Mon-López, D.; Lorenzo, A. Impact of the relative age effect on competition performance in basketball: A qualitative systematic review. *Int. J. Environ. Res. Public Health* **2020**, *17*, 8596. [CrossRef]
- 49. Arede, J.; Vaz, R.; Franceschi, A.; Gonzalo-Skok, O.; Leite, N. Effects of a combined strength and conditioning training program on physical abilities in adolescent male basketball players. *J. Sports Med. Phys. Fit.* **2018**, *59*, 1298–1305. [CrossRef]
- Gonzalo-Skok, O.; Tous-Fajardo, J.; Suarez-Arrones, L.; Arjol-Serrano, J.L.; Casajús, J.A.; Mendez-Villanueva, A. Single-leg power output and between-limbs imbalances in team-sport players: Unilateral versus bilateral combined resistance training. *Int. J. Sports Physiol. Perform.* 2017, 12, 106–114. [CrossRef]
- Gonzalo-Skok, O.; Tous-Fajardo, J.; Arjol-Serrano, J.L.; Suarez-Arrones, L.; Casajús, J.A.; Mendez-Villanueva, A. Improvement of repeated-sprint ability and horizontal-jumping performance in elite young basketball players with low-volume repeatedmaximal-power training. *Int. J. Sports Physiol. Perform.* 2016, 11, 464–473. [CrossRef]
- 52. Ciacci, S.; Bartolomei, S. The effects of two different explosive strength training programs on vertical jump performance in basketball. *J. Sports Med. Phys. Fit.* 2017, *58*, 1375–1382. [CrossRef] [PubMed]
- 53. Higgins, J.P.; López-López, J.A.; Aloe, A.M. Meta-regression. In *Handbook of Meta-Analysis*; Chapman and Hall: London, UK, 2020; pp. 129–150.
- 54. Lipsey, M.W.; Wilson, D.B. Practical Meta-Analysis; SAGE Publications, Inc.: Thousand Oaks, CA, USA, 2001.
- 55. Wilson, D.B. Meta-Analysis Macros for SAS, SPSS, and Stata. Available online: http://mason.gmu.edu/~{}dwilsonb/ma.html (accessed on 8 May 2021).
- 56. Norusis, M. Documentation SPSS for Windows; SPSS Inc.: Chicago, IL, USA, 1993.
- 57. Hedges, L.V.; Olkin, I. Statistical Methods for Meta-Analysis; Academic Press: Cambridge, MA, USA, 2014.
- 58. DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7, 177–188. [CrossRef]
- 59. Cohen, J. Statistical Power Analysis for the Behavioral Sciences; Academic Press: Cambridge, MA, USA, 2013.
- 60. O'Connor, D.; Green, S.; Higgins, J.P. Defining the review question and developing criteria for including studies. In *Cochrane Handbook for Systematic Reviews of Interventions*; Cochrane Book Series; John Wiley & Sons Ltd.: Chichester, UK, 2008; pp. 81–94.
- 61. Aksović, N.; Berić, D.; Kocić, M.; Jakovljević, S.; Milanović, F. Plyometric training and sprint abilities of young basketball players. *Facta Univ. Ser. Phys. Educ. Sport* 2020, *17*, 539–548. [CrossRef]
- Asadi, A.; Ramirez-Campillo, R.; Meylan, C.; Nakamura, F.Y.; Cañas-Jamett, R.; Izquierdo, M. Effects of volume-based overload plyometric training on maximal-intensity exercise adaptations in young basketball players. *J. Sports Med. Phys. Fit.* 2016, 57, 1557–1563. [CrossRef]
- 63. Attene, G.; Iuliano, E.; Di Cagno, A.; Calcagno, G.; Moalla, W.; Aquino, G.; Padulo, J. Improving neuromuscular performance in young basketball players: Plyometric vs. technique training. *J. Sports Med. Phys. Fit.* **2015**, *55*, 1–8.

- 64. Attene, G.; Laffaye, G.; Chaouachi, A.; Pizzolato, F.; Migliaccio, G.M.; Padulo, J. Repeated sprint ability in young basketball players: One vs. two changes of direction (Part 2). *J. Sports Sci.* **2015**, *33*, 1553–1563. [CrossRef]
- Attene, G.; Pizzolato, F.; Calcagno, G.; Ibba, G.; Pinna, M.; Salernitano, G.; Padulo, J. Sprint vs. intermittent training in young female basketball players. J. Sports Med. Phys. Fit. 2014, 54, 154–161.
- 66. Bouteraa, I.; Negra, Y.; Shephard, R.J.; Chelly, M.S. Effects of combined balance and plyometric training on athletic performance in female basketball players. *J. Strength Cond. Res.* **2020**, *34*, 1967–1973. [CrossRef]
- 67. Figueira, B.; Gonçalves, B.; Abade, E.; Paulauskas, R.; Masiulis, N.; Sampaio, J. Effects of a 4-week combined sloped training program in young basketball players' physical performance. *Sci. Sports* **2020**, *35*, 172.e171–172.e179. [CrossRef]
- 68. Gonzalo-Skok, O.; Sánchez-Sabaté, J.; Izquierdo-Lupón, L.; Sáez de Villarreal, E. Influence of force-vector and force application plyometric training in young elite basketball players. *Eur. J. Sport Sci.* **2019**, *19*, 305–314. [CrossRef]
- 69. Gonzalo-Skok, O.; Tous-Fajardo, J.; Moras, G.; Arjol-Serrano, J.L.; Mendez-Villanueva, A. A repeated power training enhances fatigue resistance while reducing intraset fluctuations. *J. Strength Cond. Res.* **2019**, *33*, 2711–2721. [CrossRef]
- 70. Gottlieb, R.; Eliakim, A.; Shalom, A.; Dello-Iacono, A.; Meckel, Y. Improving anaerobic fitness in young basketball players: Plyometric vs. specific sprint training. *J. Athl. Enhanc.* **2014**, *3*, 3.
- Hernández, S.; Ramirez-Campillo, R.; Álvarez, C.; Sanchez-Sanchez, J.; Moran, J.; Pereira, L.A.; Loturco, I. Effects of plyometric training on neuromuscular performance in youth basketball players: A pilot study on the influence of drill randomization. *J. Sports Sci. Med.* 2018, 17, 372.
- 72. Matavulj, D.; Kukolj, M.; Ugarkovic, D.; Tihanyi, J.; Jaric, S. Effects of pylometric training on jumping performance in junior basketball players. *J. Sports Med. Phys. Fit.* **2001**, *41*, 159–164.
- McCormick, B.T.; Hannon, J.C.; Newton, M.; Shultz, B.; Detling, N.; Young, W.B. The effects of frontal-and sagittal-plane plyometrics on change-of-direction speed and power in adolescent female basketball players. *Int. J. Sports Physiol. Perform.* 2016, 11, 102–107. [CrossRef]
- 74. Meszler, B.; Váczi, M. Effects of short-term in-season plyometric training in adolescent female basketball players. *Physiol. Int.* **2019**, *106*, 168–179. [CrossRef]
- 75. Santos, E.J.; Janeira, M.A. Effects of complex training on explosive strength in adolescent male basketball players. *J. Strength Cond. Res.* **2008**, *22*, 903–909. [CrossRef]
- 76. Santos, E.J.; Janeira, M.A. The effects of resistance training on explosive strength indicators in adolescent basketball players. *J. Strength Cond. Res.* **2012**, *26*, 2641–2647. [CrossRef]
- 77. Tsimahidis, K.; Galazoulas, C.; Skoufas, D.; Papaiakovou, G.; Bassa, E.; Patikas, D.; Kotzamanidis, C. The effect of sprinting after each set of heavy resistance training on the running speed and jumping performance of young basketball players. *J. Strength Cond. Res.* 2010, 24, 2102–2108. [CrossRef]
- Yáñez-García, J.M.; Rodríguez-Rosell, D.; Mora-Custodio, R.; González-Badillo, J.J. Changes in Muscle Strength, Jump, and Sprint Performance in Young Elite Basketball Players: The Impact of Combined High-Speed Resistance Training and Plyometrics. J. Strength Cond. Res. 2022, 36, 478–485. [CrossRef]
- Aschendorf, P.F.; Zinner, C.; Delextrat, A.; Engelmeyer, E.; Mester, J. Effects of basketball-specific high-intensity interval training on aerobic performance and physical capacities in youth female basketball players. *Physician Sportsmed.* 2019, 47, 65–70. [CrossRef] [PubMed]
- 80. Ignjatovic, A.; Radovanovic, D.; Stankovic, R.; Marković, Z.; Kocic, J. Influence of resistance training on cardiorespiratory endurance and muscle power and strength in young athletes. *Acta Physiol. Hung.* **2011**, *98*, 305–312. [CrossRef] [PubMed]
- Calleja González, J.; Mielgo Ayuso, J.; Lekue, J.A.; Leibar, X.; Erauzkin, J.; Jukic, I.; Ostojic, S.M.; Ponce González, J.G.; Fuentes Azpiroz, M.; Terrados, N. Anthropometry and performance of top youth international male basketball players in Spanish national academy. *Nutr. Hosp.* 2018, 35, 1331–1339. [CrossRef] [PubMed]
- 82. Balyi, I.; Hamilton, A. Long-term athlete development: Trainability in childhood and adolescence. Olymp. Coach. 2004, 16, 4–9.
- Carvalho, H.M.; Coelho-e-Silva, M.; Valente-dos-Santos, J.; Gonçalves, R.S.; Philippaerts, R.; Malina, R. Scaling lower-limb isokinetic strength for biological maturation and body size in adolescent basketball players. *Eur. J. Appl. Physiol.* 2012, 112, 2881–2889. [CrossRef] [PubMed]
- Castillo, D.; Raya-González, J.; Scanlan, A.T.; Sánchez-Díaz, S.; Lozano, D.; Yanci, J. The influence of physical fitness attributes on external demands during simulated basketball matches in youth players according to age category. *Physiol. Behav.* 2021, 233, 113354. [CrossRef]
- Kelly, A.L.; Jiménez Sáiz, S.L.; Lorenzo Calvo, A.; de la Rubia, A.; Jackson, D.T.; Jeffreys, M.A.; Ford, C.; Owen, D.; Santos, S.D.L.d. Relative Age Effects in Basketball: Exploring the Selection into and Successful Transition Out of a National Talent Pathway. *Sports* 2021, 9, 101. [CrossRef]
- 86. Noyes, F.R.; Barber-Westin, S.D.; Smith, S.T.; Campbell, T.; Garrison, T.T. A training program to improve neuromuscular and performance indices in female high school basketball players. *J. Strength Cond. Res.* **2012**, *26*, 709–719. [CrossRef]
- 87. Zwolski, C.; Quatman-Yates, C.; Paterno, M.V. Resistance training in youth: Laying the foundation for injury prevention and physical literacy. *Sports Health* **2017**, *9*, 436–443. [CrossRef]
- Sander, A.; Keiner, M.; Wirth, K.; Schmidtbleicher, D. Influence of a 2-year strength training programme on power performance in elite youth soccer players. *Eur. J. Sport Sci.* 2013, 13, 445–451. [CrossRef]

- Lesinski, M.; Prieske, O.; Granacher, U. Effects and dose–response relationships of resistance training on physical performance in youth athletes: A systematic review and meta-analysis. *Br. J. Sports Med.* 2016, *50*, 781–795. [CrossRef]
- Brown, K.A.; Patel, D.R.; Darmawan, D. Participation in sports in relation to adolescent growth and development. *Transl. Pediatr.* 2017, *6*, 150. [CrossRef]
- 91. Faigenbaum, A.; Chu, D. Plyometric Training for Children and Adolescents; American College of Sports Medicine: Indianapolis, IN, USA, 2001.
- 92. Grgic, J.; Schoenfeld, B.J.; Mikulic, P. Effects of plyometric vs. resistance training on skeletal muscle hypertrophy: A review. *J. Sport Health Sci.* **2021**, *10*, 530–536. [CrossRef]
- 93. McKinlay, B.J.; Wallace, P.; Dotan, R.; Long, D.; Tokuno, C.; Gabriel, D.A.; Falk, B. Effects of plyometric and resistance training on muscle strength, explosiveness, and neuromuscular function in young adolescent soccer players. *J. Strength Cond. Res.* **2018**, 32, 3039–3050. [CrossRef]
- 94. Pardos-Mainer, E.; Lozano, D.; Torrontegui-Duarte, M.; Cartón-Llorente, A.; Roso-Moliner, A. Effects of strength vs. plyometric training programs on vertical jumping, linear sprint and change of direction speed performance in female soccer players: A systematic review and meta-analysis. *Int. J. Environ. Res. Public Health* **2021**, *18*, 401. [CrossRef]
- 95. Stojanović, E.; Ristić, V.; McMaster, D.T.; Milanović, Z. Effect of plyometric training on vertical jump performance in female athletes: A systematic review and meta-analysis. *Sports Med.* **2017**, *47*, 975–986. [CrossRef]
- 96. Rumpf, M.C.; Cronin, J.B.; Pinder, S.D.; Oliver, J.; Hughes, M. Effect of different training methods on running sprint times in male youth. *Pediatr. Exerc. Sci.* 2012, 24, 170–186. [CrossRef]
- Philippaerts, R.M.; Vaeyens, R.; Janssens, M.; Van Renterghem, B.; Matthys, D.; Craen, R.; Bourgois, J.; Vrijens, J.; Beunen, G.; Malina, R.M. The relationship between peak height velocity and physical performance in youth soccer players. *J. Sports Sci.* 2006, 24, 221–230. [CrossRef]
- Edwards, T.; Weakley, J.; Banyard, H.G.; Cripps, A.; Piggott, B.; Haff, G.G.; Joyce, C. Influence of age and maturation status on sprint acceleration characteristics in junior Australian football. J. Sports Sci. 2021, 39, 1585–1593. [CrossRef]
- 99. Meyers, R.W.; Oliver, J.L.; Hughes, M.G.; Cronin, J.B.; Lloyd, R.S. Maximal sprint speed in boys of increasing maturity. *Pediatr. Exerc. Sci.* 2015, 27, 85–94. [CrossRef]
- Meyers, R.W.; Oliver, J.L.; Hughes, M.G.; Lloyd, R.S.; Cronin, J.B. New insights into the development of maximal sprint speed in male youth. *Strength Cond. J.* 2017, 39, 2–10. [CrossRef]
- 101. McManus, A.M.; Armstrong, N. Physiology of elite young female athletes. Elite Young Athl. 2011, 56, 23-46.
- Sommi, C.; Gill, F.; Trojan, J.D.; Mulcahey, M.K. Strength and conditioning in adolescent female athletes. *Physician Sportsmed.* 2018, 46, 420–426. [CrossRef]
- 103. Armstrong, N.; McManus, A.M. Physiology of elite young male athletes. Elite Young Athl. 2011, 56, 1–22.
- Rice, P.E.; Goodman, C.L.; Capps, C.R.; Triplett, N.T.; Erickson, T.M.; McBride, J.M. Force–and power–time curve comparison during jumping between strength-matched male and female basketball players. *Eur. J. Sport Sci.* 2017, 17, 286–293. [CrossRef]
- Haizlip, K.; Harrison, B.; Leinwand, L. Sex-based differences in skeletal muscle kinetics and fiber-type composition. *Physiology* 2015, 30, 30–39. [CrossRef]
- 106. Bottinelli, R.; Canepari, M.; Pellegrino, M.; Reggiani, C. Force-velocity properties of human skeletal muscle fibres: Myosin heavy chain isoform and temperature dependence. *J. Physiol.* **1996**, *495*, 573–586. [CrossRef] [PubMed]
- 107. Laffaye, G.; Wagner, P.P.; Tombleson, T.I. Countermovement jump height: Gender and sport-specific differences in the force-time variables. *J. Strength Cond. Res.* 2014, *28*, 1096–1105. [CrossRef]
- Radnor, J.M.; Oliver, J.L.; Waugh, C.M.; Myer, G.D.; Moore, I.S.; Lloyd, R.S. The influence of growth and maturation on stretch-shortening cycle function in youth. *Sports Med.* 2018, 48, 57–71. [CrossRef] [PubMed]
- Ramos, S.; Volossovitch, A.; Ferreira, A.P.; Fragoso, I.; Massuça, L.M. Training Experience and Maturational, Morphological, and Fitness Attributes as Individual Performance Predictors in Male and Female under-14 Portuguese Elite Basketball Players. J. Strength Cond. Res. 2021, 35, 2025–2032. [CrossRef] [PubMed]
- 110. Sekulic, D.; Spasic, M.; Mirkov, D.; Cavar, M.; Sattler, T. Gender-specific influences of balance, speed, and power on agility performance. *J. Strength Cond. Res.* 2013, 27, 802–811. [CrossRef]
- 111. Torres-Unda, J.; Zarrazquin, I.; Gil, J.; Ruiz, F.; Irazusta, A.; Kortajarena, M.; Seco, J.; Irazusta, J. Anthropometric, physiological and maturational characteristics in selected elite and non-elite male adolescent basketball players. J. Sports Sci. 2013, 31, 196–203. [CrossRef]
- 112. Erculj, F.; Blas, M.; Bracic, M. Physical demands on young elite European female basketball players with special reference to speed, agility, explosive strength, and take-off power. J. Strength Cond. Res. 2010, 24, 2970–2978. [CrossRef]
- 113. Slimani, M.; Paravlić, A.; Bragazzi, N.L. Data concerning the effect of plyometric training on jump performance in soccer players: A meta-analysis. *Data Brief* **2017**, *15*, 324–334. [CrossRef]
- Thapa, R.K.; Lum, D.; Moran, J.; Ramirez-Campillo, R. Effects of Complex Training on Sprint, Jump, and Change of Direction Ability of Soccer Players: A Systematic Review and Meta-Analysis. *Front. Psychol.* 2020, 11, 627869. [CrossRef]
- 115. Perez-Gomez, J.; Calbet, J. Training methods to improve vertical jump performance. J. Sports Med. Phys. Fit. 2013, 53, 339–357.
- 116. De Villarreal, E.S.-S.; Kellis, E.; Kraemer, W.J.; Izquierdo, M. Determining variables of plyometric training for improving vertical jump height performance: A meta-analysis. *J. Strength Cond. Res.* **2009**, *23*, 495–506. [CrossRef]
- 117. Darmiento, A.; Galpin, A.J.; Brown, L.E. Vertical jump and power. Strength Cond. J. 2012, 34, 34–43. [CrossRef]

- Zghal, F.; Colson, S.S.; Blain, G.; Behm, D.G.; Granacher, U.; Chaouachi, A. Combined resistance and plyometric training is more effective than plyometric training alone for improving physical fitness of pubertal soccer players. *Front. Physiol.* 2019, 10, 1026. [CrossRef]
- 119. Davies, G.; Riemann, B.L.; Manske, R. Current concepts of plyometric exercise. Int. J. Sports Phys. Ther. 2015, 10, 760.
- Ramírez-Campillo, R.; Gallardo, F.; Henriquez-Olguín, C.; Meylan, C.M.; Martínez, C.; Álvarez, C.; Caniuqueo, A.; Cadore, E.L.; Izquierdo, M. Effect of vertical, horizontal, and combined plyometric training on explosive, balance, and endurance performance of young soccer players. J. Strength Cond. Res. 2015, 29, 1784–1795. [CrossRef]
- 121. Ramírez-Campillo, R.; Vergara-Pedreros, M.; Henríquez-Olguín, C.; Martínez-Salazar, C.; Alvarez, C.; Nakamura, F.Y.; De La Fuente, C.I.; Caniuqueo, A.; Alonso-Martinez, A.M.; Izquierdo, M. Effects of plyometric training on maximal-intensity exercise and endurance in male and female soccer players. *J. Sports Sci.* **2016**, *34*, 687–693. [CrossRef]
- 122. Young, W.; Mc Lean, B.; Ardagna, J. Relationship between strength qualities and sprinting performance. *J. Sports Med. Phys. Fit.* **1995**, *35*, 13–19.
- 123. Young, L.; O'Connor, J.; Alfrey, L. Physical literacy: A concept analysis. Sport Educ. Soc. 2020, 25, 946–959. [CrossRef]
- 124. Faigenbaum, A.D.; Myer, G.D. Resistance training among young athletes: Safety, efficacy and injury prevention effects. *Br. J. Sports Med.* **2010**, *44*, 56–63. [CrossRef]
- 125. Malina, R.M. Weight training in youth-growth, maturation, and safety: An evidence-based review. *Clin. J. Sport Med.* 2006, 16, 478–487. [CrossRef]
- 126. Riley, R.D.; Higgins, J.P.; Deeks, J.J. Interpretation of random effects meta-analyses. BMJ 2011, 342, d549. [CrossRef] [PubMed]